REFERENCE ONLY

UNIVERSITY OF LONDON THESIS

Degree PhD Year 2008 Name of Author COGRAM, Patricia

COPYRIGHT
This is a thesis accepted for a Higher Degree of the University of London. It is an unpublished typescript and the copyright is held by the author. All persons consulting this thesis must read and abide by the Copyright Declaration below.

COPYRIGHT DECLARATION
I recognise that the copyright of the above-described thesis rests with the author and that no quotation from it or information derived from it may be published without the prior written consent of the author.

LOANS
Theses may not be lent to individuals, but the Senate House Library may lend a copy to approved libraries within the United Kingdom, for consultation solely on the premises of those libraries. Application should be made to: Inter-Library Loans, Senate House Library, Senate House, Malet Street, London WC1E 7HU.

REPRODUCTION
University of London theses may not be reproduced without explicit written permission from the Senate House Library. Enquiries should be addressed to the Theses Section of the Library. Regulations concerning reproduction vary according to the date of acceptance of the thesis and are listed below as guidelines.

A. Before 1962. Permission granted only upon the prior written consent of the author. (The Senate House Library will provide addresses where possible).

B. 1962-1974. In many cases the author has agreed to permit copying upon completion of a Copyright Declaration.

C. 1975-1988. Most theses may be copied upon completion of a Copyright Declaration.

D. 1989 onwards. Most theses may be copied.

This thesis comes within category D.

☑ This copy has been deposited in the Library of ________ LCM

☐ This copy has been deposited in the Senate House Library, Senate House, Malet Street, London WC1E 7HU.
Inositol and Protein Kinase C in the prevention of Neural Tube Defects

Patricia Cogram

A thesis submitted for the degree of Doctor of Philosophy in the University of London

July 2007

Neural Development Unit
Institute of Child Health
University College London
30 Guilford Street
London
WC1N 1EH
DEDICATION

To mom and dad,

I would like to dedicate this thesis to my son Blas,
Juan Manuel Perez de Cogran

Nieves Barros Salvarria

To my brothers,

Juan Eduardo Perez de Cogran

Facundo Perez de Cogran

Lucas Perez de Cogran

And to five good friends,

Daniel Giancarlo, Eduardo Weber, Lucy Widman
Jose Palachea and Pablo Arnedo
To mum and dad,

Juan Manuel Perez de Cogram

Norna Behm Silverman

To my brothers,

Juan Eduardo Perez de Cogram

Facundo Perez de Cogram

Lucas Perez de Cogram

And to five good friends,

Daniel Gluschankof, Eduardo Weisz, Lucy Widman

Joe Pelluchi and Pablo Armelin
ABSTRACT

A number of mouse genetic mutants develop neural tube defects (NTDs). In some cases, defects can be prevented by administration of folic acid during pregnancy, whereas in other mutants there is no response. This parallels the human situation in which a proportion of NTDs appear resistant to folic acid therapy. Curly tail is the best characterised mouse model of folic acid-resistant NTDs. Previously it was shown that the incidence of spina bifida in curly tail mice can be reduced by administration of inositol during embryonic development. In this thesis, I compared the effectiveness of two isomers, myo- and D-chiro-inositol, with administration either directly to embryos in vitro, or to pregnant females by subcutaneous or oral routes. Although both inositols exerted a preventive effect on spina bifida, by all routes of administration, D-chiro-inositol consistently exhibited greater potency than myo-inositol. The protective effect of inositol has been shown previously to be mediated through the activity of the inositol/lipid cycle and to depend on downstream activation of protein kinase C (PKC). In the studies described in this thesis, I examined the role of PKC in more detail. The expression of PKC isoforms was first examined by immunohistochemistry. Broad spectrum chemical inhibitors were then used in whole embryo culture to confirm that one or more PKC isoforms are indispensable for normalisation of neural tube closure by inositol. Specific peptide inhibitors were then applied, and revealed that PKC beta I, gamma and zeta are most important in the protective pathway. Finally, I demonstrated that inositol stimulates cell proliferation in the hindgut of curly tail embryos, reversing the imbalance of cell proliferation that is known to lead, via enhanced ventral curvature of the caudal region, to delay or failure of neural tube closure.
ACKNOWLEDGEMENTS

I would like to thank all members of the Copp lab, past and present, for their support and friendships all these years.

Special gratitude goes to my mentor, Professor Andrew Copp for the chance to work in such a stimulating environment with his continual support and infectious optimism, for his guidance and invaluable advice. I have always cherished his constant promotion of new ideas and fruitful scientific discussions. In summary, he has given me an invaluable example and preparation to one day become an independent scientist.

In particular I would like to thank my second supervisor Dr Nicholas Greene for his time and patience, encouragement and valuable supervision. For being a friend as well as an excellent guide all these years, for his tenacious optimism for inositol; without his help and inspiration this thesis would not be written.

Also for their supervision I would like to thank Dr. Jennifer Murdoch and Dr. Deborah Henderson, they have always been there to answer my questions and introduced me to the techniques used throughout this thesis.

A very special thank you go to Dr Carlos Gaston for his inspiring scientific discussions during our coffee breaks, for his contagious enthusiasm and passion for science, for teaching me how to ski and the brainstorming we shared at the Protein Phosphorylation meeting in New Mexico. Above all for being that good friend I will always remember.
To all the adventurers in the Copp group for including me in the team which madly tried to row across the English Channel, more than once!

A big thank you to Dr Patricia Ybot-Gonzalez, for her supervision, advice and companionship all these years.

Thank you to Drs Adam Rutherford, Iain Mc Kinnan and John Chilton for babysitting Blas while I was implanting osmotic mini pumps on curly tail mice.

A warm and special thanks goes to Mrs Katie Gardener for teaching me the masteries of gavaging mice and surgically implanting osmotic mini pumps, and also for sharing with me her experience on how to combine good parenting with having a career.

Thanks also to John and Sheila Tesh for analysing the curly tail embryos. To Dr Angie Wade, for doing and explaining so well all the statistical tests used in this thesis.

To Brenda Gilliver for her capacity for multitasking has allowed me to be able to finish writing up this thesis providing me with a working computer and the office space, for her support, good humour and companionship all these months. To Stella Fusco and Lynne Mason for making me feel part of the office team with their every day smiles, lattes and cappuccinos. A big thank you to every one in the ICH 6th floor office who integrated me with huge kindness; special thank you goes to Naomi Leatham for her courtesy and support when I have to stay late hours.

Thanks to the Developmental Biology Unit for sharing reagents and advice especially to Dr Fang Zhang for her ‘deluxe’ immunohistochemistry protocols, and expert advice.
Out of the laboratory I would like to mention my friends, Fluffy, Tommy and Darren who have genuinely supported me during my thesis, believing in what I do and making the writing up a realisable possibility.

Wellbeing and the Wellcome Trust funded the work in this thesis, which has allowed me a very privileged entry into scientific research, and last, I thank the Institute of Child Health for this opportunity.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>4</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>5</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>8</td>
</tr>
<tr>
<td>List of Figures</td>
<td>15</td>
</tr>
<tr>
<td>List of Tables</td>
<td>17</td>
</tr>
<tr>
<td>Abbreviations</td>
<td>18</td>
</tr>
</tbody>
</table>

## Chapter 1: Introduction

1.1 Introduction

1.2 The normal process of neurulation

1.2.1 Primary neurulation occurs in a cranio-caudal sequence

1.2.2 The spectrum of NTDs depends on which of the events of neurulation fail to be completed

1.3 NTDs in humans

1.3.1 Types of NTDs in humans

1.3.2 Multifactorial aetiology of human NTDs

1.4 The embryonic process of spinal neurulation

1.4.1 Intrinsic forces control morphogenesis of the neural plate

1.4.1.1 Constriction of apical microfilaments

1.4.1.2 Cell wedging mediated through changes in the cell cycle

1.4.2 Extrinsic forces drive spinal neurulation

1.4.3 Fusion of the neural folds

1.5 Mouse genetic models of neural tube defects

1.5.1 Use of mouse models to investigate NTDs

1.5.2 Genes in the planar cell polarity pathway regulate closure

1.5.3 Sonic hedgehog pathway and neural tube closure

1.5.4 Wnt signalling pathway

1.5.5 MARCKS signalling pathway
1.6 Dietary deficiency and NTDs

1.7 The curly tail mutant mouse

1.7.1 The curly tail mutant as a model for NTDs in humans
1.7.2 The curly tail defect at the genetic level

1.7.2.1 The grainyhead

1.7.3 The curly tail defect at the morphological level
1.7.4 The curly tail defect at the cellular level
1.7.5 Molecular abnormalities in curly tail embryos
1.7.6 Curly tail, a mouse model of folate insensitive NTDs

1.8 Inositol

1.8.1 Mechanisms of inositol signalling
1.8.2 Phosphatidylinositol 3-kinase

1.9 Protein Kinase C

1.9.1 Members of the PKC family of enzymes
1.9.2 PKC structure and regulation
1.9.3 Importance of PKC interaction with scaffolding proteins
1.9.4 How PKC peptide inhibitors work
1.9.5 Function of PKC

1.10 Experimental approach

Chapter 2: Material and Methods

2.1 Mice

2.1.1 Generation of experimental litters
2.1.2 Curly tail mice
2.1.3 CD1 mice

2.2 Embryo culture
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.2.1</td>
<td>Embryo dissection</td>
<td>80</td>
</tr>
<tr>
<td>2.2.2</td>
<td>Embryo culture</td>
<td>80</td>
</tr>
<tr>
<td>2.2.3</td>
<td>Preparation of rat serum</td>
<td>81</td>
</tr>
<tr>
<td>2.2.4</td>
<td>Analysis of embryo cultures</td>
<td>81</td>
</tr>
</tbody>
</table>

2.3  
**In vitro treatment of embryos**

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3.1</td>
<td>Administration of inositol</td>
<td>84</td>
</tr>
<tr>
<td>2.3.2</td>
<td><em>In vitro</em> treatment of embryos with chemical PKC inhibitors</td>
<td>85</td>
</tr>
<tr>
<td>2.3.3</td>
<td><em>In vitro</em> treatment of embryos with peptide PKC inhibitors</td>
<td>86</td>
</tr>
</tbody>
</table>

2.4  
**Administration of inositol *in utero***

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.4.1</td>
<td>Methods for <em>in utero</em> administration</td>
<td>87</td>
</tr>
<tr>
<td>2.4.2</td>
<td>Analysis of fetuses following inositol treatment <em>in utero</em></td>
<td>88</td>
</tr>
</tbody>
</table>

2.5  
**Immunohistochemistry**

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.5.1</td>
<td>Preparation of routine histological sections</td>
<td>88</td>
</tr>
<tr>
<td>2.5.1.1</td>
<td><em>Dehydration and embedding</em></td>
<td>88</td>
</tr>
<tr>
<td>2.5.1.2</td>
<td><em>Sectioning</em></td>
<td>89</td>
</tr>
<tr>
<td>2.5.2</td>
<td>Immunodetection of PKC isoforms</td>
<td>89</td>
</tr>
<tr>
<td>2.5.3</td>
<td>Immunochemical Reagents</td>
<td>91</td>
</tr>
<tr>
<td>2.5.4</td>
<td>PCNA</td>
<td>91</td>
</tr>
<tr>
<td>2.5.5</td>
<td>H3</td>
<td>91</td>
</tr>
<tr>
<td>2.5.6</td>
<td>Hoechst Dye</td>
<td>92</td>
</tr>
</tbody>
</table>

2.6  
**Mouse cell culture**

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.6.1</td>
<td>Generation of <em>curly tail</em> primary cell lines</td>
<td>92</td>
</tr>
<tr>
<td>2.6.2</td>
<td>Culture methods</td>
<td>93</td>
</tr>
<tr>
<td>2.6.2.1</td>
<td><em>Culture splitting</em></td>
<td>93</td>
</tr>
<tr>
<td>2.6.2.2</td>
<td><em>Immortalised cells used in control cultures</em></td>
<td>94</td>
</tr>
</tbody>
</table>
2.6.3 Treatment of cells with TPA and PKC peptide inhibitors 94
2.6.4 Immunocytochemical analysis 94

Chapter 3: Prevention of folate-resistant NTDs 96

3.1 Introduction 97
3.1.1 Inositol as a preventive therapy for folic acid-resistant NTDs in mice 98

3.2 Results 99
3.2.1 D-chiro-inositol has greater potency than myo-inositol in normalising neural tube closure 99
3.2.2 Neither myo- nor D-chiro-inositol affects the rate of embryonic growth in embryo culture 100
3.2.3 D-chiro-inositol reduces the frequency of spinal neural tube defects to a greater extent that myo-inositol following in utero administration 102
3.2.4 No evidence of an adverse effect of inositol on pregnancy success or fetal outcome 104

2.6.5 Labelling indices 114

3.3 Discussion 114
3.3.1 Possible reasons for the greater potency of D-chiro-inositol in preventing NTDs 114
3.3.2 Relevance of the findings for clinical application of inositol therapy 115
### Chapter 4: PKC involvement in neural tube closure

#### 4.1 Introduction

4.1.1 Possible requirement for PKC isoforms in mediating the preventive effect of inositol

4.1.2 PKC chemical inhibitors

4.1.3 PKC peptide inhibitors

4.1.3.1 *Molecular basis of PKC isoform inhibition by the peptides*

4.1.3.2 *Use of antennapedia peptide to carry peptides into the cell*

#### 4.2 Results

4.2.1 Specificity of PKC antibodies

4.2.2 PKC isoform expression during mouse embryogenesis

4.2.3 Evaluation of possible effects of chemical inhibitors on growth and development of cultured embryos

4.2.3.1 *Chemical inhibitors of PKC do not affect growth or developmental progression of embryos in vitro*

4.2.4 Investigating the effect of chemical PKC inhibitors on PNP closure

4.2.5 Use of peptide inhibitors to identify the specific PKC isoforms required for protection of PNP closure by inositol.

4.2.6 Evaluation of peptide inhibitors of PKC in cultured cells

4.2.7 Specificity of inhibitors for PKC βI and βII
4.3 Discussion

4.3.1 Distribution of PKC isoforms

4.3.2 Differential requirement for PKC βI and βII

4.3.3 Requirement for conventional and atypical PKCs

4.3.4 Requirement for PKC isoforms during neural tube closure

4.3.5 Which proteins are downstream of PKC activation?

Chapter 5: Inositol and cell proliferation

5.1 Introduction

5.1.1 Analysis of proliferation in the developing curly tail PNP

5.1.2 The Protein Kinase C: a possible role in regulation of cell proliferation

5.2 Results

5.2.1 PCNA analysis

5.2.2 Phospho-histone 3 analysis

5.3 Discussion

Chapter 6: General Discussion

6 General Discussion

6.1 Inositol and folate-unresponsive NTDs in the curly tail mutant

6.2 Grhl3, ct and inositol prevention

6.3 Chiro- vs Myo-inositol in preventing curly tail NTDs

6.4 Inositol action in NTD is mediated via PKC

171
LIST OF FIGURES

Figure 1.1 Initiation sites of neural tube closure 25
Figure 1.2 The three main subtypes of NTDs 27
Figure 1.3 Morphological changes during primary neurulation: convergent-extension, elevation, bending and apposition 28
Figure 1.4 Diagram to illustrate the morphology of the neural plate during progressive closure of the posterior neuropore 31
Figure 1.5 Constriction of apical filaments and bending of neural plate 36
Figure 1.6 Diagram to illustrate the cell cycle-dependent position of the nucleus in formation of bending regions in a transverse section through the PNP 39
Figure 1.7 Diagram to illustrate the proposed regulation of DLHPs in three progressive stages of mouse neurulation 49
Figure 1.8 Curly tail mutant mouse 53
Figure 1.9 Diagrams of tail bud regions of curly tail embryos to illustrate the five PNP categories and subsequent spinal development 56
Figure 1.10 Neural tube malformations in curly tail embryos 60
Figure 1.11 Diagram representing what was known prior to this thesis about possible inositol mechanism in normalising PNP closure in curly tail embryos 63
Figure 1.12 Diagram illustrating myo-inositol and D-chiro-inositol 65
Figure 1.13 The inositol phosphate signalling pathway 67
Figure 1.14 Protein kinase c isoforms 70
Figure 1.15 Signal transduction PKC cascade 73
Figure 1.16 Translocation inhibitors 74
Figure 2.1 Yolk sac circulation 82
Figure 2.2 Assessment of development after embryo culture 84
Figure 2.3 Osmotic mini pumps 87
Figure 3.1 PNP closure in curly tail mouse embryo 100
Figure 3.2 Skeletal preparations of E18.5 curly tail fetuses 108
Figure 4.1 Distribution of protein kinase c isoforms in cerebellum 127
Figure 4.2 Expression of PKC isoforms during mouse spinal neurulation 129
Figure 4.3  Normalization of spinal neural tube closure by inositol in *curly tail* embryos is abrogated by inhibition of specific PKC isoform

Figure 4.4  Inhibition of specific PKC isoforms in cultured *curly tail* embryos - effect on PNP length

Figure 4.5  Inhibition of PKC isoform translocation

Figure 4.6  Inhibitors of PKCβI and βII exhibit isoform-specificity

Figure 5.1  PCNA immunostaining in *curly tail* embryos after 24 hours culture from E8.5 to E9.5

Figure 5.2  Inositol stimulates hindgut cell proliferation during NTD prevention

Figure 5.3  Phospho-histone H3-labelling in the PNP region of the *curly tail* embryos after 24 hours culture from E8.5 to E9.5

Figure 5.4  Cell proliferation was measured in tissues of the PNP region of cultured *curly tail* embryos using phospho-histone H3 as a measure of the proportion of cells in metaphase
### LIST OF TABLES

<p>| Table 2.1 | Concentration information for chemical PKC inhibitors | 82 |
| Table 2.2 | Peptide translocation inhibitors of PKC | 83 |
| Table 2.3 | Concentration information for chemical PKC inhibitors | 85 |
| Table 2.4 | Peptide translocation-inhibitors of PKC isoforms coupled to an <em>Antennapedia</em> carrier peptide. | 86 |
| Table 2.5 | Immunochemical reagents | 92 |
| Table 3.1 | Comparison of growth and developmental parameters in <em>curly tail</em> embryos cultured in the presence of myo- and D-chiro-inositol | 101 |
| Table 3.2 | Frequency of neural tube and tail defects among <em>curly tail</em> fetuses treated <em>in utero</em> with myo- and D-chiro-inositol | 106 |
| Table 3.3 | Survival of embryos and fetuses among <em>curly tail</em> litters treated <em>in utero</em> with myo- and D-chiro-inositol | 109 |
| Table 3.4 | Internal pathological analysis by freehand serial sectioning of <em>curly tail</em> fetuses treated <em>in utero</em> with myo- and D-chiro-inositol | 111 |
| Table 3.5 | Skeletal analysis of <em>curly tail</em> fetuses treated <em>in utero</em> with myo- and D-chiro-inositol | 113 |
| Table 4.1 | CD1 embryos cultured for 24 hours from E9.5 to E10.5 in the presence of the PKC chemical inhibitor | 132 |
| Table 4.2 | <em>Curly tail</em> embryos cultured for 24 hours from E9.5 to E10.5 in the presence of the PKC chemical inhibitor | 134 |
| Table 4.3 | Development of <em>curly tail</em> embryos following culture from E9.5 to E10.5 in the presence of inositol and /or PKC peptide inhibitors | 140 |</p>
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>3AT</td>
<td>3-amino-1,2,4-triazole</td>
</tr>
<tr>
<td>AA</td>
<td>Amino acid</td>
</tr>
<tr>
<td>Bis I</td>
<td>Bisindolylmaleimide I</td>
</tr>
<tr>
<td>Bis V</td>
<td>Bisindolylmaleimide V</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>C1/C2</td>
<td>Catalytic domain</td>
</tr>
<tr>
<td>CI</td>
<td>Cubitus Interruptus</td>
</tr>
<tr>
<td>CT</td>
<td>Curly tail</td>
</tr>
<tr>
<td>DAG</td>
<td>Diacylglycerol</td>
</tr>
<tr>
<td>DAPI</td>
<td>4'-'6-diamidino-2-phenylindole</td>
</tr>
<tr>
<td>ddH20</td>
<td>distilled deionised water</td>
</tr>
<tr>
<td>DEPC</td>
<td>Diethyl pyrocarbonate</td>
</tr>
<tr>
<td>DIC</td>
<td>Differential interference contrast (Nomarski)</td>
</tr>
<tr>
<td>DLHP</td>
<td>Dorsolateral hinge point</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s Modified Eagle’s Medium</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>dNTP</td>
<td>deoxynucleoside triphosphate</td>
</tr>
<tr>
<td>E</td>
<td>Embryonic day</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>EMSA</td>
<td>Electrophoresis mobility shift assay</td>
</tr>
<tr>
<td>ENU</td>
<td>Ethylnitrosourea mutagenesis</td>
</tr>
</tbody>
</table>
EST  Expressed sequence tag
Ex  Excencephaly
FCS  Fetal calf serum
GAG  Glycosaminoglycan
gL  Granular layer
H  Hindgut
Go6976  Godecke 6976
GPI  Glycosylphosphatidylinositol
GST  Glutathione-S-transferase
HBDDE  2,2',3,3',4,4'-hexahydroxy-1,1'-biphenyl-6,6'-dimethanol dimethyl ether
HH  Hedgehog
H3  Phospho histone 3
IP-3K  Phosphatidylinositol-3-kinase
Kb  Kilo base
LB  L-broth
LMP  Low melting point
Lp  Loop-tail
M  Mitosis
M  Presomitic mesoderm
MHP  Median hinge point
N  Notochord
NLS  Nuclear localisation signal
Np  Neural plate
NTD  Neural tube defects
NTMT  Sodium chloride/Tris/magnesium chloride/Tween buffer
OD  Optic density
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PCD</td>
<td>Programmed cell death</td>
</tr>
<tr>
<td>PCP</td>
<td>Planar cell polarity</td>
</tr>
<tr>
<td>PI</td>
<td>Phosphoinositol monophosphate</td>
</tr>
<tr>
<td>PIP2</td>
<td>Phosphoinositol diphosphate</td>
</tr>
<tr>
<td>PKC</td>
<td>Protein kinase C</td>
</tr>
<tr>
<td>PKCα</td>
<td>Protein kinase C alpha</td>
</tr>
<tr>
<td>PKCβI</td>
<td>Protein kinase C beta I</td>
</tr>
<tr>
<td>PKCβII</td>
<td>Protein kinase C beta II</td>
</tr>
<tr>
<td>PKCγ</td>
<td>Protein kinase C gamma</td>
</tr>
<tr>
<td>PKCζ</td>
<td>Protein kinase C zeta</td>
</tr>
<tr>
<td>PCNA</td>
<td>Proliferating Cellular Nuclear Antigen</td>
</tr>
<tr>
<td>PFA</td>
<td>Paraformaldehyde</td>
</tr>
<tr>
<td>pcL</td>
<td>Purkinje cell layer</td>
</tr>
<tr>
<td>PLC</td>
<td>Phospholipase C</td>
</tr>
<tr>
<td>PMA</td>
<td>Phorbol myristate acetate</td>
</tr>
<tr>
<td>PNP</td>
<td>Posterior neuropore</td>
</tr>
<tr>
<td>RACK</td>
<td>Receptor for activated C-kinase</td>
</tr>
<tr>
<td>RPM</td>
<td>rotation per minute</td>
</tr>
<tr>
<td>RT</td>
<td>Reverse transcription</td>
</tr>
<tr>
<td>S</td>
<td>S-phase</td>
</tr>
<tr>
<td>Sb</td>
<td>Spina bifida</td>
</tr>
<tr>
<td>SBA</td>
<td>Spina bifida aperta</td>
</tr>
<tr>
<td>SBO</td>
<td>Spina bifida oculta</td>
</tr>
<tr>
<td>SD</td>
<td>Synthetic defined medium</td>
</tr>
<tr>
<td>SDS</td>
<td>Sodium dodecyl sulphate</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td>Sodium dodecyl sulfate polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>SF</td>
<td>Split face</td>
</tr>
<tr>
<td>Shh</td>
<td>Sonic hedgehog</td>
</tr>
<tr>
<td>Smo</td>
<td>Smoothened</td>
</tr>
<tr>
<td>SSC</td>
<td>Sodium chloride</td>
</tr>
<tr>
<td>TPA</td>
<td>Phorbol ester 12-O-tetradecanoylphorbol-13-acetate</td>
</tr>
</tbody>
</table>
CHAPTER 1
GENERAL INTRODUCTION
1.1 INTRODUCTION

The formation of the vertebrate nervous system begins at gastrulation when, during neural induction, a subset of ectodermal cells segregates and thickens to form the neural plate. Soon afterwards, the neural plate undergoes a series of morphogenetic events that ends with the formation of a hollow neural tube characteristic of the chordate phylum, this process being known as neurulation. Impairment of neurulation leads to a range of anomalies known as neural tube defects (NTDs) that are among the commonest congenital malformations in humans.

The embryonic process of neurulation has been well characterised morphologically in different animal systems (Schoenwolf, 1985; Shum and Copp, 1996; Colas and Schoenwolf, 2001). Some of the genetic pathways controlling this programme have been identified from the large number of mouse mutants that display NTDs (Juriloff and Harris, 2000; Copp et al., 2003). However, the underlying molecular mechanisms are still largely unknown.

1.2 THE NORMAL PROCESS OF NEURULATION

Neurulation is divided into two parts: primary and secondary neurulation. Primary neurulation results in the formation of the cranial neural tube and the upper spinal cord rostral to the mid-sacral region, through a process that involves the specification and shaping of the neural plate, followed by the elevation and fusion of the neural folds (Criley, 1969). Initially, the neural plate becomes specified by the underlying mesoderm and is transformed into a pseudo-stratified columnar epithelium that thickens apicobasally. The edges of the columnar epithelium elevate to form the neural folds that
converge in the dorsal midline and fuse, forming the neural tube. Once primary neurulation has occurred and the neural tube has closed, secondary neurulation takes place caudally to the mid-sacral region. At this axial level, the neural tube forms by condensation of mesenchymal cells within the tail bud region which forms an epithelium that subsequently cavitates, forming the secondary neural tube (Schoenwolf, 1984; Copp and Brook, 1989). Secondary neurulation is a separate autonomous process in relation to primary neurulation, at least in the chick embryo, where if primary neurulation is disrupted experimentally secondary neurulation still occurs normally (Costanzo et al., 1982).

1.2.1 Primary neurulation occurs in a cranio-caudal sequence

During primary neurulation in the mouse embryo, closure of the neural tube starts at three different initiation sites, in a cranio-caudal sequence along the body axis (Fig 1.1) (MacDonald et al., 1989; Copp et al., 1990; Golden and Chernoff, 1993). The first initiation site, Closure 1, occurs in the mouse embryo at the 4-6 somite stage with closure occurring at the cervical/hindbrain region and continuing in a zippering-like fashion caudally along the future spine and rostrally into the hindbrain. By the 12 somite stage, a second site of closure, Closure 2, occurs at the forebrain/midbrain boundary and proceeds caudally into the midbrain and rostrally into the forebrain. At about the same somite stage, a third site of closure, Closure 3, occurs at the rostral extremity of the prosencephalon, and proceeds caudally towards the midbrain. As a result of these three de novo sites of closure, three neuropores become apparent. The anterior neuropore (within the forebrain, formed by closure progression from Closures 2 and 3) closes at approximately the 17 somite stage. Soon afterwards, the hindbrain neuropore (formed by progression from Closures 1 and 2) closes, and the zippering mechanism initiated at
Closure 1 spreads caudally, resulting in the closure of the posterior neuropore at the 29 somite stage.

The developmental stage and exact position in which the events of neurulation take place vary between mouse strains (Juriloff et al., 1991). Hence, the site of Closure 2 is polymorphic between mouse strains and its position confers susceptibility to cranial neural tube defects (Fleming and Copp, 2000).
1.2.2 The spectrum of NTDs depends on which of the events of neurulation fail to be completed

The spectrum of NTDs depends on which of the de novo closure sites or neuropore closures fail to be completed (Fig. 1.2)(Copp and Bernfield, 1994). Hence, failure of initiation of Closures 2 and 3 or incomplete closure of the anterior or hindbrain neuropores leads to an open cranial neural tube termed exencephaly. The second type of NTD, lumbosacral spina bifida results from failure of the posterior neuropore to complete closure. The size and severity of the lesion depends upon the axial level where closure failed. Hence if closure stops at a more rostral level these results in a more severe phenotype. Cranial NTDs and spina bifida can occur independently or in combination, in humans and in mouse. Failure of initiation of Closure 1 causes craniorachischisis, the most severe form of NTD, in which the hindbrain and spinal neural tube remain open (Fig. 1.2). In the mouse models that display craniorachischisis, Closures 2 and 3 occur, and development of the forebrain and rostral midbrain appear normal (Greene et al., 1998; Murdoch et al., 2001). These observations indicate that the genetic regulation of Closure 1 differs from that of Closures 2 and 3.
Figure 1.2 The three main subtypes of NTDs

Diagram to illustrate exencephaly, craniorachischisis and lumbosacral spina bifida, which result from failure of closure initiation events or from failure of each neuropore to complete closure (arrows). The embryo on the left shows exencephaly (E) and lumbosacral spina bifida (S) whilst the embryo on the right shows craniorachischisis (diagram modified from A. (Copp and Bernfield, 1994)).

The neural folds form by elevation and bending of the lateral edges of the neural plate at either side of the midline. The morphology that the neural plate acquires during closure differs in the cranial and spinal neural tube. In the midbrain region of the cranial neural tube, the neural folds initially adopt a biconvex shape as they elevate. Subsequently, the lateral edges bend inwards to form the dorsolateral hinge points (DLHPs), which bring the apices of the neural folds into apposition at the dorsal midline (Morriss-Kay, 1981; Morriss-Kay et al., 1994).
1.3 Morphological changes during primary neurulation: convergent-extension, elevation, bending and apposition

(A-B) Oblique and dorsal images of a 6-8-somite-stage embryo showing the initiation neural tube closure (Closure 1) at the level of the future hindbrain-cervical junction (arrows). (C-E) Three views of the head of a 12 to 16-somite-stage embryo showing the second point of closure (Closure 2) at the level of the forebrain-midbrain junction (arrow) and a third point of closure (Closure 3) at the rostral end of the neural tube (arrowhead). (F) The posterior neuropore at the caudal extremity of the neural tube. Closure of the spinal neural tube proceeds from the hindbrain-cervical junction caudally and eventually closes the posterior neuropore at the 29 somite-pair stage. (h) heart. (Photography by Dr K Tosney)

As the wave of spinal neural tube closure spreads down the body axis, the morphology of the neural plate at the spinal cord region changes in a stereotypic fashion (Shum and Copp, 1996). Three distinct morphologies (named Modes of neurulation) have been
reported, from the cross-sectional appearance of the neural plate at different axial levels (Fig. 1.3; 1.4). In Mode 1 spinal neurulation, which is seen in the closing posterior neuropore at the 7-15 somite stage, the neural plate bends medially forming the median hinge point (MHP), whilst the lateral edges elevate with straight sides and the neural folds approach each other in the dorsal midline, closing the neural tube to form a slit-like lumen.

At the 16-24 somite stage, when Mode 2 spinal neurulation occurs, the neural plate bends not only at the midline, forming the MHP, as in Mode 1, but the dorsal region of each neural fold also bends forming the dorso-lateral hinge points (DLHPs). DLHPs cause the tips of the neural folds to appose in the dorsal midline yielding a closed neural tube with a diamond shaped lumen. At the 25-30 somite stage, in Mode 3 of spinal neurulation, the neural plate does not form a MHP, whereas DLHPs are prominent, closing the neural tube to form a circular shaped lumen. These stereotypical changes in morphology of the spinal neuroepithelium as it closes to form the neural tube have been observed in mouse neurulation. In other systems, such as the chick, DLHP formation occurs in the hindbrain region, but apparently not in the caudal neural tube, demonstrating differences between these species (Schoenwolf, 1985)

1.3 NTDS IN HUMANS

1.3.1 Types of NTDS in humans

NTDs are among the commonest congenital malformation in humans with an average prevalence of 1:1000 live births worldwide (Edmonds and James, 1993). Human NTDs can be divided into open and closed defects. Open NTDs result from failure of the neural tube to close during primary neurulation, whilst closed NTDs result from aberrant
secondary neurulation and abnormal axial skeleton development (Lemire, 1988). As in mouse, open NTDs can be grouped depending on which event of closure fails to occur (Van Allen et al., 1993). Exencephaly, open neural tube in the cranial region, can be subgrouped into three classes. Rostrally, failure of closure 3 at the forebrain region with facial clefting leads to anencephaly. Failure of Closure 2, results in an open midbrain-hindbrain and is named holocrania, whilst failure of closure of the hindbrain neuropore results in merocrania.

As in mouse, spina bifida results from failure of closure of the PNP resulting in an open caudal neural tube that can be exposed (myelocele) or covered by meninges (myelomeningocele). Craniorachischisis is the most severe NTD, and the neural tube remains open along almost the entire rostro-caudal axis.

Neurulation in humans starts at 17-18 days post fertilisation and ends by 26-28 days after fertilisation with closure of the PNP (Campbell et al., 1986). In humans, as in mouse, the initiation of neural tube closure is discontinuous (Van Allen et al., 1993), and sites of initiation equivalent to Closure 1 and Closure 3 have been described (Golden and Chernoff, 1995; Juriloff and Harris, 2000), although some studies do not identify Closure 2 (O'Rahilly and Müller, 2002). Humans undergo secondary neurulation in the low sacral and coccygeal regions. Despite failure in neural tube closure, neural differentiation and nerve connections can occur (Campbell et al., 1986). However tissue exposure to the amniotic fluid results in degeneration of the open neural tube leading to musculoskeletal, gastrointestinal and urinary dysfunction often associated with NTDs in patients (Stark, 1977).
Figure 1.4 Diagram to illustrate the morphology of the neural plate during progressive closure of the posterior neuropore

Mode 1 is characterised by formation of a MHP with straight neural folds apposing each other. In Mode 2 of neurulation the neural plate bends medially to form the MHP and, dorsally, the neural folds bend bilaterally to form the DLHPs. In Mode 3 of neurulation, closure is solely dependent on DLHPs. Diagram modified from Ybot-Gonzalez (2001)

As in mouse, spina bifida results from failure of closure of the PNP resulting in an open caudal neural tube that can be exposed (myelocele) or covered by meninges
(myelomeningocele). Craniorachischisis is the most severe NTD, and the neural tube remains open along almost the entire rostro-caudal axis.

1.3.2 Multifactorial aetiology of human NTDs

Human NTDs have multifactorial aetiology, involving genetic and environmental factors (Campbell et al., 1986; Copp and Bernfield, 1994; Juriloff et al., 2001). The most important environmental factors are geography, maternal age, socio-economic class, maternal diet and illness (Campbell et al., 1986).

The relationship between prevalence of NTDs and geography is noticeable. For instance, prevalence of NTDs is higher in the north west of England than in the south east (Carter, 1974). A correlation has also been found between the month of conception and prevalence of NTDs. Maternal age is also important in prevalence of NTDs since the majority of affected children are born to mothers under 20 years or over 35 years of age. Several studies have shown an association between socio-economic class and the prevalence of NTDs, the prevalence being higher in poor socio-economic backgrounds. This observation prompted investigations of the effects of diet in relation to the prevalence of NTDs. Indeed, supplementing mothers with folic acid or multivitamins has been shown to lead to a reduction in the prevalence of NTDs (Wald et al., 1991; Czeizel and Dudás, 1992). A correlation has also been found between maternal illness, including higher fever, during the first month of pregnancy and an increase in the risk of NTDs.

The genetic component of NTDs is supported by family studies showing that siblings of affected individuals have a ten times greater risk of NTDs than the background prevalence (Campbell et al., 1986). In addition, an increased risk is observed in offspring of affected parents (Blatter et al., 1997). However, the inheritance of NTDs does not
follow a pattern of single-gene inheritance, but rather suggests multigenic inheritance with strong environmental influence (Campbell et al., 1984; Juriloff and Harris, 2000). These factors have made the identification of genes for human NTDs difficult. In some cases a mutation in a gene that could be responsible for the NTD phenotype has been found in a patient but also in unaffected relatives, indicating that the mutation may confer susceptibility but is not causative for NTDs. Moreover some of the genetic studies do not take into consideration the phenotypical spectrum of NTDs, and look for linkage or causative mutations within a group of heterogeneous NTDs: spina bifida, exencephaly and craniorachischisis, without considering that specific genes may regulate just one aspect of neural tube closure. For instance, targeted disruption of \textit{Msx2} has been shown to cause exencephaly in mice (Liu \textit{et al.}, 1995) and this prompted an investigation to determine whether mutations in \textit{MSX2} in humans could also cause NTDs (Stegmann \textit{et al.}, 2001). The study concluded that, despite identifying one deletion in one patient from 204 NTD cases, there was no statistical significance for the implication of \textit{MSX2} in human NTDs. However from the 204 patients with NTD analysed, only 13 displayed cranial NTDs (also including craniorachischisis). Hence, this study included only a very small cranial NTD sample (Stegmann \textit{et al.}, 2001), despite this phenotype being most likely \textit{Msx2}-related based on the mouse studies.

Mutations in the \textit{PAX3} gene have been found in patients with NTDs (Hol \textit{et al.}, 1995). However, a second population study using 194 people including 50 NTD cases failed to find an association between the \textit{PAX3} and NTDs (Chatkupt \textit{et al.}, 1995). A mutation in \textit{SLUG}, a zinc finger transcription factor involved in neural crest development, was found in a patient with NTD. Moreover, the mutation was not present in unaffected individuals raising the possibility that \textit{SLUG} could be causative of the NTD observed in this patient.
(Stegmann *et al.*, 1999). A mutation in *PAX1* was detected in a single patient with spina bifida, suggesting that this gene can also act as a susceptibility factor (Joosten *et al.*, 1998).

Further genetic studies have centred on identifying mutations in enzymes that act in the folic acid pathway. The importance of folic acid in NTDs comes from studies indicating a protective effect of folic acid administration during the periconceptional period (Wald *et al.*, 1991). This prompted studies to identify mutations in genes that participate in the biochemical pathways involving folic acid, which may confer susceptibility to NTDs. A polymorphism in the 5,10-methylene-tetrahydrofolate reductase gene (*MTHFR*) has been found to confer a two-fold increased risk of NTDs in some populations (Van der Put *et al.*, 1995) (Botto and Mastroiacovo, 1998), although there is no association with NTDs in other populations. *MTHFR* encodes an enzyme that catalyses the conversion of 5,10-methyl-tetrahydrofolate to 5-methylene-tetrahydrofolate. Homozygous individuals for the C677T polymorphism are predisposed to mild hyperhomocysteinemia when their folate status is low. The precise mechanism that confers susceptibility to NTDs in individuals homozygous for C677T is unknown.

### 1.4 THE EMBRYONIC PROCESS OF SPINAL NEURULATION

After Closure 1 has occurred at the cervical-hindbrain region, closure of the spinal neural tube continues caudally forming the posterior neuropore. Failure of the posterior neuropore to complete closure leads to spina bifida. The embryonic mechanism that controls closure of the posterior neuropore can be autonomous to the neural plate (intrinsic forces) or non-autonomous to the neural plate (extrinsic forces) (Smith and Schoenwolf, 1997; Colas and Schoenwolf, 2001; Copp *et al.*, 2003).
1.4.1 Intrinsic forces control morphogenesis of the neural plate

As spinal neurulation progresses along the body axis the neural plate bends at specific dorsoventral locations (Fig. 1.4). The MHP forms in contact with the notochord and the DLHPs form bilaterally in contact with the surface ectoderm (Shum and Copp, 1996; Ybot-Gonzalez et al., 2002). Bending in these regions has been suggested to be mediated by intrinsic forces so that the behaviour of neuroepithelial cells changes compared to those in the non-bending regions. Indeed, morphological studies in the chick revealed that the neuroepithelial cells can adopt one of three types of morphology: spindle-shape, wedge-shape and inverted wedge-shape (Smith et al., 1994). In the MHP and DLHP, the majority of cells acquire a wedge-shape morphology which results from an expansion of the basal surface of the cell compared to its apical surface. In contrast, in the non-bending regions, spindle-shape cells and inverse-wedge (apically expanded) cells are in the majority (Smith et al., 1994). Two different mechanisms have been proposed that result in cell wedging: constriction of apical microfilaments and changes in the cell cycle.

1.4.1.1 Constriction of apical microfilaments

A pseudostratified epithelium will bend if its apical surface area is reduced with respect to its basal surface area. The reduction in apical surface area has been proposed to be mediated through the constriction of apical containing microfilaments in a purse-string fashion (see Fig. 1.5) (Karfunkel, 1974; Nagele and Lee, 1980; Sadler et al., 1982). Indeed, microfilaments and cytoskeleton-associated proteins, such as actin, MARCKS, vinculin, spectrin and Shroom are localised apically during neural plate morphogenesis (Nagele and Lee, 1980; Sadler et al., 1982; Stumpo et al., 1995b; Xu et al., 1998; Ybot-Gonzalez and Copp, 1999; Hildebrand and Soriano, 1999; Haigo et al., 2003).
To test experimentally the function of the cytoskeleton in neurulation, actin microfilament polymerisation was disrupted in embryo culture using cytochalasins and calcium chelating agents (Morriss-Kay and Tuckett, 1985; Ybot-Gonzalez and Copp, 1999). In these experiments cranial neural tube closure was inhibited, whilst spinal neural tube closure occurred relatively normally, indicating that cytoskeletal integrity is required for cranial neurulation whilst its loss is not prohibitive for spinal neural tube closure (Ybot-Gonzalez and Copp, 1999). However treatment of embryos with cytochalasin D prior to Closure 1 inhibited this closure site, resulting in a craniorachischisis-like phenotype (Ybot-Gonzalez and Copp, 1999). It appears then that initiation of closure is dependent on the actin cytoskeleton but once Closure 1 has occurred, disruption of the actin cytoskeleton does not affect the continuation and completion of spinal neural tube closure.

Figure 1.5 Constriction of apical filaments and bending of neural plate
Diagram to illustrate how constriction of apical microfilaments could generate bending of the neuroepithelium by constricting the apical surface area with respect to the basal surface area.
This observation is partially supported by the finding that mouse mutants for cytoskeletal or putative cytoskeletal dynamics proteins exhibit exencephaly but generally not spina bifida (Copp et al., 2003). For instance, null embryos for MARCKS, the actin-binding protein vinculin, compound mutants for the Abl and Arg tyrosine kinases or for the protein kinase a subunits CalCfil all display exencephaly but not spina bifida (Stumpo et al., 1995b;Koleske et al., 1998;Xu et al., 1998;Huang et al., 2002). This supports the idea that cytoskeletal integrity is more important for cranial neurulation than spinal neurulation. However, it could also indicate that these genes are not expressed in the lower spinal regions, which would explain the lack of spina bifida in these mutants. Indeed, two mutants for cytoskeleton-related proteins, Shroom and MARKS-related (also called MacMARCKS) protein, develop spina bifida at low frequency (Wu et al., 1996;Hildebrand and Soriano, 1999). Interestingly, Shroom has been shown to be required for apical microfilament constriction in polarised epithelial cells and to regulate hinge point formation in Xenopus (Haigo et al., 2003). More studies are required to rule out a critical role for the actin cytoskeleton during mouse spinal neurulation and to establish whether the cytoskeleton functions simply to stabilise the neural plate once bending has occurred.

1.4.1.2 Cell wedging mediated through changes in the cell cycle

The neuroepithelium consist of a single pseudostratified cell layer in which the nucleus of each cell migrates from the basal surface to the apical surface and back to the basal surface, a phenomenon known as interkinetic nuclear cell migration (Langman et al., 1967). Studies in chick embryos have shown that the positioning of the nucleus, from basal to apical, is linked to the cell cycle (Smith and Schoenwolf, 1987). Hence, during mitosis, nuclei are localised at the apical surface generating inverse wedge-shape cells,
during G1 and G2 phases they are located between the apical and basal surfaces, creating a spindle-shape, and in S phase, they are located basally, generating wedge-shape cells. If a sizeable subset of cells have their nuclei in a basal position, this can potentially generate a neuroepithelial bend, by increasing the basal surface area respective to the apical surface area. Indeed, cells that form the MHP are mostly wedge-shaped and have a longer cell cycle S phase and a shorter M phase than cells outside the MHP (Smith and Schoenwolf, 1987; Smith and Schoenwolf, 1988). Hence, localised changes in the neuroepithelial cell cycle can generate specific sites of bending of the neural plate (see Fig. 1.6). These observations have been shown for the MHP in chick and mouse embryos. A similar mechanism could account for bending at the DLHP, although this has not been proven yet.

1.4.2 Extrinsic forces drive spinal neurulation

During neurulation the neuroepithelium is in contact with the surface ectoderm, the endoderm and the mesoderm. Changes in cell shape and/or cell number in these tissues could provide extrinsic forces that might assist neural plate folding (Schoenwolf, 1985). To test this hypothesis tissue isolation experiments in chick and mouse embryos, where the lateral mesoderm and endoderm tissues are removed, have been performed and result in normal folding of the spinal neural plate (Alvarez and Schoenwolf, 1992; Van Straaten et al., 1993; Ybot-Gonzalez et al., 2002). However, if the surface ectoderm is removed, the neural plate fails to bend dorsolaterally in both chick and mouse resulting in an open neural tube (Alvarez and Schoenwolf, 1992; Ybot-Gonzalez et al., 2002). This indicates that, of all the lateral tissues, only the surface ectoderm is necessary for formation of DLHPS. One hypothesis to explain the extrinsic role of the surface ectoderm has been formulated from experiments in chick embryos, which suggested that medial expansion of
the surface ectoderm through convergent extension movements could potentially provide the force that brings the paired neural folds together (Alvarez and Schoenwolf, 1992).

However, if the neural folds are dissected from the mesoderm and endoderm and only a small fragment of the surface ectoderm is left intact in contact with the neural fold, closure of the neural tube still occurs with the presence of DLHPs (Ybot-Gonzalez et al., 2002). Therefore, whilst the surface ectoderm could mediate a pushing force at early stages, it seems unlikely that this process functions during Mode 2 and Mode 3 of neurulation, and rather the surface ectoderm may be required to signal to the underlying neural folds to form the DLHPs.

**Figure 1.6. Diagram to illustrate the cell cycle-dependent position of the nucleus in formation of bending regions in a transverse section through the PNP**

In the neural plate, cells undergo interkinetic nuclear migration, such that the nucleus is located apically during mitosis (M) and basally during S-phase (S). When the nucleus is in a basal or apical position the cell acquires a wedge or inverted wedge shape respectively. In the median hinge point (MHP), an increased proportion of cells is in S-phase with basally located nuclei. The increase in number of wedge shaped cells in the
ventral midline of the neural plate appears to create the MHP. Cell cycle variations resulting in cell wedging could also regulate DLHPs, although this has not studied in detail.

Whilst the mesoderm and endoderm are not required for DLHP formation, these tissues are nevertheless important for neurulation, since an imbalance of cell proliferation within these tissues can affect spinal neural tube closure. For example, an increase in axial curvature is seen in affected curly tail mutant embryos due to an imbalance in cell proliferation in the hindgut endoderm and notochord, which results in increased axial curvature and delay or failure of posterior neuropore closure (Brook et al., 1991c; Van Straaten et al., 1993). In curly tail, bending at the DLHPs and MHP occurs normally, whereas the increase in axial curvature results in strain on the neural folds that impedes meeting at the dorsal midline. This has also been observed in the chick, where delay in closure was achieved by culturing embryos on a convex surface which led to an increase in axial curvature (Van Straaten et al., 1993).

1.4.3 Fusion of the neural folds

After apposition, the neural folds fuse in the dorsal midline to form the neural tube. The surface ectoderm of each neural fold loses its continuity with the neuroepithelium, and closes over the top of the neural tube to form the epidermis. Fusion of the neural folds has been proposed to be mediated by cell protrusions, lamelipodia, extending from the apposing cells (Geelen and Langman, 1979). Lamelipodia structures have been observed by scanning electron microscopy on the luminal surface of the neural plate and at the edges of the surface ectoderm (Geelen and Langman, 1979). However, the molecules involved in cell to cell recognition have not been studied during closure of the spinal neural tube. Carbohydrate-rich material localised at the tips of the neural folds has been
suggested to assist fusion by increasing the adhesiveness of the neural folds (Moran and Rice, 1975) (Sadler, 1978). Indeed, embryos cultured with phospholipase C to remove carbohydrate material exhibit delayed neural tube closure (O'Shea and Kaufman, 1980). However, the observed phenotype could be due to enzymatic removal of glycosylphosphatidylinositol-anchored (GPI) proteins, including cell adhesion molecules. More studies are needed to understand the role of adhesion molecules in spinal neurulation.

1.5 MOUSE GENETIC MODELS OF NEURAL TUBE DEFECTS

To date more than 80 genes that cause NTDs in mice have been identified by positional cloning, gene targeting or gene trap screens (Juriloff and Harris, 2000; Copp et al., 2003; Harris and Juriloff, 2007a). Despite the identification of a large number of genes required for neurulation, in most cases the embryonic mechanisms leading to NTDs in each individual mutant are not well characterised. The number of mouse mutants that display exencephaly is greater than the number with spina bifida, perhaps indicating greater complexity of genetic regulation of cranial neural tube closure. The identification of these “NTDs genes” provides a tool to determine the molecular pathways that regulate neurulation. For instance, the planar cell polarity pathway is now known to regulate Closure 1 (review). In this section I will explain the importance of using mouse models for the study of NTDs and I will concentrate on some pathways for which information is available from mouse mutants that display spina bifida. The wide range of defects seen in the NTD mutants is also found in humans; it is possible, therefore, that each phenotypic category of mutants mimics a subtype of human NTDs. Today a large number of mouse mutants that produce NTDs have been identified (Juriloff and Harris, 2000; Harris and Juriloff, 2007b).
1.5.1 Use of mouse models to investigate NTDs

Mouse models offer an alternative to direct study of human NTDs, which is hampered by several factors. Human NTDs appear to have a multigenic complex aetiology, with strong influence of environmental factors, such as lifestyle and diet (Campbell et al., 1986; Copp and Bernfield, 1994). Moreover, the identification of causative genes for NTDs by linkage analysis requires large families, and this represents a difficulty since families with large numbers of NTDs are rare. In addition to this, embryological studies using human embryos can raise serious ethical issues.

The use of the mouse represents an excellent model to elucidate the genetic programmes controlling NTDs. With the sequence of the mouse genome completed and the availability of microsatellite markers for genetic mapping, the identification of the mutated genes responsible for NTD phenotypes has become quicker. Moreover, several mutagenesis strategies, particularly using chemical mutagenesis, gene trap strategies or gene targeting, have begun to make a major contribution to the list of known NTDs genes. Phenotype-driven mutagenesis programmes using chemical mutagens such as ethylnitrosourea (ENU) or chlorambucil are available to the scientific community (Justice et al., 1999; Nolan et al., 2000; Justice, 2000). This approach, allows the identification of new mouse mutations that have a particular phenotype, for instance NTDs. The mutated gene must then be identified by positional cloning.

Another type of mutagenesis is the “gene-trap” strategy, where genes are disrupted by vector insertion in ES cells, generating ES-cell clones containing a disrupted gene. This strategy has the advantages that large numbers of genes can be disrupted and then identified by a forward-genetic strategy, prior to implantation of ES cells to generate the
mouse mutant (Skarnes et al., 1992; Mitchell et al., 2001). The disadvantages of this technique include the unpredictable nature of the phenotype caused by the gene trap and the necessity for germ-line transmission of the mutated gene in order to generate a mouse mutant line.

A further mutagenesis approach is gene targeting that allows precision design of the type of mutation. Hence, deletions, point mutations or insertions can all be achieved. The advantage of gene targeting is that mapping of the mutated gene is not required. However the resulting phenotype is unpredictable and knowledge of the gene structure is required to generate the targeted mutant mouse.

The mouse also represents a good experimental tool to investigate the cellular and embryological bases of neurulation. Mouse embryos are easily accessible and can be cultured for up to 48 hours in vitro (Copp et al., 1999). Neurulation in mouse takes place from the 5 to 29 somite stage during a 48 hour period. Therefore, mouse embryos can be cultured throughout the entire neurulation process, allowing experimental manipulation. This is important in the study of the effects of teratogenic substances on closure of the neural tube as well as the analysis of vitamin supplementation to prevent NTDs.

1.5.2 Genes in the planar cell polarity pathway regulate Closure 1

Recently, mutations in the planar cell polarity (PCP) pathway genes have been found to be responsible for the craniorachischisis phenotype observed in three different mouse mutants, loop tail, circletail and crash (Kibar et al., 2001; Murdoch et al., 2001; Curtin et al., 2003; Murdoch et al., 2003). Embryos that are homozygous for mutation in Vangl2 (loop-tail), Scribble (circletail) and Celsr1 (crash) display failure of Closure 1 leading to craniorachischisis. The other mouse mutants known to display craniorachischisis is the
Dishevelled 1/2 double knockout (Dsh1/2) (Hamblet et al., 2002) and the frizzled 3,6 double knockout. Embryonic examination shows that at least three of these mutants, loop-tail, circletail and Dsh1/2 have a similar phenotype to that of Xenopus embryos where convergent-extension has been disrupted (Wallingford et al., 2000; Wallingford and Harland, 2002). Embryos display shorter body axis, with a broad floor plate and failure of the neural tube to close.

Convergent extension movements occur during gastrulation and consist of the migration of cells from a lateral position towards the midline, where they intercalate, resulting in lengthening of the anterior-posterior axis and extension of midline cells anteriorly (Keller et al., 1992; Davidson and Keller, 1999). Disruption of convergent-extension movements has not yet been reported in mouse mutants with craniorachischisis but initial studies using Dil labelling suggest that convergent extension is disrupted in homozygous loop-tail (Lp) embryos ((Ybot-Gonzalez et al., 2007b)). The embryonic mechanism of convergent-extension has been studied in Xenopus, where disruption in the PCP pathway in the midline results in a broader floor plate or MHP, with formation of the neural folds far apart that prevent fusion (Wallingford and Harland, 2002).

Genes that control the PCP pathway, a non canonical-Wnt pathway, have been identified in Drosophila to control the polarisation of cells in the plane of the epithelium. This is required for example, for the unidirectional array of bristles on the wing and for the arrangement of ommatidia in the compound eye (Kühl et al., 2000; Mlodzik, 2002). The PCP pathway shares components of the Wnt pathway, such as the transmembrane receptor Frizzled and the downstream effector Dishevelled. However, unlike the Wnt pathway, the PCP pathway does not result in stabilisation and nuclear translocation of β-
catenin by Dishevelled to control cell proliferation and cell fate decisions. Rather, Dishevelled is thought to signal through small GTPases such as RhoA and Rac to regulate cytoskeleton assembly and cell motility (Mlodzik, 2002) (Keller, 2002). In support of this idea are the experiments in which mouse embryos treated with cytochalasin D before the onset of Closure 1 resulted in failure of this closure site, indicating that cell rearrangements that control Closure 1 are cytoskeleton-dependent. It is unknown how Vangl2, Scribble and Celsr1 are related to each other within the PCP pathway.

1.5.3 Sonic hedgehog (Shh) pathway and neural tube closure
The Shh pathway has been implicated in neural tube closure, specifically in regulating the formation of DLHPs (Ybot-Gonzalez et al., 2002). Shh is an extracellular signalling protein that regulates a number of embryological processes, such as patterning of the neural tube and limbs, cell proliferation and cell-fate determination. Postnatally, aberrant Shh signalling pathway has been linked to basal cell carcinomas and medulloblastoma tumours (Chiang et al., 1996;Goodrich et al., 1997;Fan et al., 1997;Wechsler-Reya and Scott, 1999). The molecular mechanisms underlying the Shh signalling pathway have been principally determined by studies in Drosophila (Ruiz i Altaba, 1999). The preliminary pathway involves binding of HH to its transmembrane receptor Patched (Ptc), which prevents the inhibition of Smoothened (Smo), a transmembrane protein that forms part of the HH receptor complex. De-inhibition of Smo allows signalling to a cytoplasmatic protein complex formed by Fused, Costal-2 and Cubitus Interruptus (CI) (Tabin and McMahon, 1997). When Shh is not present, proteolytic processing of CI results in the generation of the shorter CI N-terminal form that functions as a transcriptional repressor of HH downstream genes. Binding of HH to its receptor inhibits the CI proteolysis resulting in the stable full length CI that functions as a transcriptional activator of HH downstream genes. In mouse, Shh, Patched and Gli are the vertebrate
homologues of *Drosophila* HH, Patched and CI. In mouse three Gli proteins have been identified, Gli1, Gli2 and Gli3 that code for zinc finger domain (ZFD) transcription factors. In mouse Gli1 and Gli2 displays a similar function to the full length CI, and acts as a transcriptional activator of Shh downstream genes. However, Gli3 has a repressive function similar to that of the N-terminal CI (Marigo *et al.*, 1996).

During neurulation, Shh emanating from the notochord functions as a morphogen, to pattern the neural tube so that progenitor cells in the ventral region acquire ventral fates and become ventral neural types including motor neurons. Mice that are null for Shh display a dorsalised neural tube, and dorsal markers such as *Pax3* become expressed in ventral regions (Chiang *et al.*, 1996). In contrast over-expression of Shh results in loss of dorsal fates and a ventralised neural tube.

Several mice that carry mutations in Shh pathway genes display NTDs, for example two mutant alleles of *Open brain (opb)*, one spontaneous and the second ENU-induced. Embryos homozygous for either mutant allele display exencepahly, spina bifida, polydactyly and poorly developed eyes (Sporle *et al.*, 1996). Analysis of *opb*<sup>−/−</sup> mutant embryos shows a lack of dorsal neuronal cell types, a phenotype that resembles mice with partial loss of function of Patched or over-expression of Shh (Milenkovic *et al.*, 1999). The gene mutated in *opb* was identified as *Rab23*, encoding a member of the Rab family of GTPases, which controls vesicle transport. How this protein participates in Shh signalling remains unknown but, since *opb* phenocopies *Gli3* and *Patched1* mutant embryos, Rab23 may antagonistically regulate the Shh pathway.
Interestingly, null embryos for Patched1 (Ptc1l) and double homozygotes for protein kinase a subunit Ca/Cβ1 (Prkaca, Prkacb), display cranial NTDs that may also be caused by excessive Shh signalling. In Drosophila, protein kinase A phosphorylates CI, a process that is required for protein cleavage to yield the N-terminal transcriptional repressor form of CI (Chen et al., 1999). In vertebrates, a similar mechanism has been proposed (Ruiz i Altaba, 1999). Double homozygote embryos for Prkaca and Prkacb have excess Shh signalling, possibly because pKA cannot phosphorylate Gli proteins (Huang et al., 2002).

Further evidence for the importance of regulation of the Shh pathway in neurulation comes from the Extra-toes1 mouse (Xt1), that carries a deletion in Gli3, and also displays cranial NTDs (Hui and Joyner, 1993). Lack of Gli3, which acts as a repressor of Shh downstream targets, results in excessive Shh signalling and exencephaly.

The information obtained from mouse mutants indicates that the Shh pathway is necessary for cranial and spinal neurulation. However, the embryonic mechanisms leading to NTDs in these mutants have not been characterised. One hypothesis to explain the exencephalic phenotype could be the loss of dorsal structures due to excessive Shh signalling resulting in a ventralised neural tube. In the spinal neural tube, the role of Shh has been studied in more detail (Ybot-Gonzalez et al., 2002). Shh signalling was found to inhibit DLHP formation. Indeed, homozygous null embryos for Shh develop DLHPs at an earlier stage of neurulation, during Mode 1, compared to the wild type embryos. DLHP formation can also be inhibited by local release of Shh peptide using implanted beads next to the neural folds, resulting in straight neural folds. In normal development, the inhibitory action of Shh on DLHPs formation declines at more caudal levels. Shh is expressed in the notochord at progressively lower intensity as spinal neurulation
progresses, allowing DLHPs to appear and so enabling the transition to Mode 2 and Mode 3. Therefore, Shh controls the timing of DLHP development by inhibiting its formation.

A hypothetical model of DLHP regulation has been postulated (see Fig. 1.6)(Ybot-Gonzalez et al., 2002). In this model, the balance between positive (inducing) and negative (inhibiting) signals regulates DLHP formation. An unknown inducing signal from the surface ectoderm stimulates bending of the neural plate, perhaps through regulation of the cell cycle of the adjacent tissue. Early in neurulation, at Mode 1, Shh is expressed at high levels in the notochord and antagonises the positive signal from the surface ectoderm resulting in straight neural folds. However, as neurulation progresses (Mode 2 and Mode 3 of neurulation) the expression of Shh decreases, reducing the inhibitory effect and resulting in bending of the neural folds that are under the influence of the inducing signal.

This model is supported by experimental observations and the analysis of mouse mutants. Once Closure 1 has occurred, the MHP is not required for closure of the neural tube. Thus, mouse mutants for HNF3β, Gli2, Shh and Gli1/Gli2 double mutants do not form a floor plate (MHP) and yet close their neural tube successfully in a Mode 3 morphology (Ang and Rossant, 1994;Chiang et al., 1996;Motoyama et al., 1998;Matise et al., 1998;Park et al., 2000).

Removal of the surface ectoderm abolishes DLHPs formation (Ybot-Gonzalez et al., 2002) showing that the surface ectoderm must signal to the underlying neural folds to induce the formation of DLHPs. Initially, BMP2 expressed from the surface ectoderm, was thought to be a good candidate molecule to induce DLHP. However recent
examination of embryos that lack BMP2 revealed that DLHP are actually formed prematurely in these embryos, as in Shh\textsuperscript{−/−} embryos ((Ybot-Gonzalez et al., 2007a)). Recently, it was found that BMP2 from the surface ectoderm induces noggin expression in the dorsal neural fold.

Figure 1.7 Diagram to illustrate the proposed regulation of DLHPs in three progressive stages of mouse neurulation

Strong expression of Shh from the notochord in Mode 1 of neurulation inhibits DLHPs, whilst an unknown signal from the notochord induces the MHP (blue arrow). In Mode 2, Shh expression declines and its inhibitory action is lost. An unknown inducing signal from the surface ectoderm (red arrows) induces bending of the underlying neural fold (green arrows). In Mode 3, the MHP inducing signal is lost and closure of the neural tube depends only on DLHPs. Diagram modified from Ybot-Gonzales (2002).

Bending of the neural plate at the DLHPs regions ensures apposition of the neural folds prior to their fusion in the dorsal midline. However, determining how DLHPs are regulated has been hampered by the lack of mouse mutants that fail to develop DLHPs. A mouse mutant that lacked DLHPs would provide an opportunity to understand the
molecular mechanisms required for DLPHs formation and neural tube closure in the low spinal region (Ybot-Gonzalez et al., 2007a).

1.5.4 Wnt signalling pathway

The Wnts are a family of secreted proteins that regulate many biological processes (Cadigan and Nusse, 1997). Functional analyses in *Xenopus* suggest that the Wnt family can be divided into two functionally distinct groups. The first group of Wnts induces a secondary axis when ectopically expressed in embryos. They activate the canonical Wnt/β-catenin pathway and induce the transcription of target genes such as *siamois* and *Xnr3* ((Brannon and Kimelman, 1996); (Camac et al., 1996); McKendry et al. 1997). The second group of Wnts, which includes *Xwnt5a* and *Xwnt11*, activates the noncanonical Wnt signaling pathway that controls morphogenetic cell movements (Kuhl 2002; Tada et al. 2002). It was shown in zebrafish that mutations in *Wntl1/silberblick* and *Wnt5a/pipetail* inhibit normal gastrulation movements (Rauch et al., 1997); (Heisenberg et al., 2000). The noncanonical Wnt pathway branches into two cascades. One is the Wnt/JNK pathway, which involves c-Jun N-terminal kinase (JNK); (Boutros et al., 1998); (Yamanaka et al., 2002). The other is the Wnt/Ca\(^{2+}\) pathway (Kuhl et al. 2000). In *Drosophila*, the Wnt/JNK pathway is called the planer cell polarity (PCP) pathway, and it specifies cell polarities in epithelial cells and other types of cells (Adler, 2002).

The Wnt signaling pathway is mediated by a seven-transmembrane Wnt receptor, Frizzled, and the signal is transmitted through a cytoplasmic protein, Dishevelled (Dsh), which plays pivotal roles in both the canonical and noncanonical Wnt pathways (Boutros and Mlodzik, 1999); (Rousset et al., 2002). In *Drosophila*, Dsh localizes to the membrane, and this localization is required for Dsh function (Axelrod, 2001). *Xenopus* Dsh (Xdsh) is also translocated from the cytoplasm to the plasma membrane in response to a signal
generated by Frizzled receptors (Yang-Snyder et al., 1996); (Axelrod et al., 1998). One such receptor is *Xenopus* Frizzled7 (Xfz7), which is involved in the noncanonical Wnt pathway (Djiane et al., 2000); (Medina and Steinbeisser, 2000); (Medina et al., 2000). However, the mechanism of this translocation and the activation of Dishevelled are not known. The signal transduction of the canonical pathway seems to be different from that of the noncanonical pathway, because the membrane translocation of Xdsh is not required for the activation of the canonical Wnt pathway (Rothbacher et al. 2000).

Protein kinase C (PKC) is thought to be involved in the noncanonical Wnt signaling pathway, particularly in the Wnt/Ca\(^{2+}\) pathway, for several reasons. Xwnt5a and rat Frizzled2 activate the phosphatidylinositol pathway and increase the intracellular Ca\(^{2+}\) levels in zebrafish embryos (Slusarski et al., 1997). The phosphatidylinositol pathway and Ca\(^{2+}\) levels are closely related to PKC activation. In fact, overexpression of *Frizzled* causes the translocation of epitope-tagged PKC\(\alpha\) from the cytoplasm to the plasma membrane in *Xenopus* embryos (Sheldahl et al., 1999); (Medina et al., 2000). Kuhl et al., (2001) showed that PKC\(\alpha\) phosphorylated Dsh in vitro. In addition, the loss of Xfz7 function leads to a defect in tissue separation during *Xenopus* gastrulation, which is rescued by the overexpression of PKC\(\alpha\) (Winkbauer et al., 2001). PKC is also implicated in the Xwnt11 signaling pathway for *Xenopus* cardiogenesis (Pandur et al., 2002) and in the Dwnt4 pathway for *Drosophila* ovarian morphogenesis (Cohen, Jr. and Shiota, 2002).

Although much evidence suggests that PKC is involved in the Wnt signaling pathway, the molecular roles of PKC in this pathway are not well understood.
1.5.5 MARCKS signalling pathway

As previously described the neural tube is formed by morphogenetic movements largely dependent on cytoskeletal dynamics. Actin and many of its associated proteins have been proposed as important mediators of neurulation. For instance, mice deficient in Myristoylated Alanine-Rich C Kinase Substrate (MARCKS), an actin cross-linking membrane-associated protein that is regulated by PKC and other kinases, present severe developmental defects, including failure of cranial neural tube closure. MARCKS is a ubiquitous protein substrate for different PKC family kinases and proline directed kinases such as MAPK and Cdk5 (Aderem, 1992b). Its PKC-phosphorylation domain or PSD (Phosphorylation Site Domain) is highly conserved and it is also the site for interaction with other molecules, such as calcium-calmodulin, negatively charged membrane phospholipids and F-actin (Aderem, 1992a). Binding to calcium-calmodulin and the plasma membrane, as well as actin filament cross-linking activity, are antagonized by PSD phosphorylation (Laux, 2000). Conversely, calcium-calmodulin binding inhibits PSD phosphorylation and actin crosslinking. In addition to neural tube closure, MARCKS and MacMARCKS have been implicated in several other events related to the actin cytoskeleton, such as cell motility, cell spreading, membrane ruffling, phagocytosis, exocytosis and neurite outgrowth (Laux, 2000).

1.6 DIETARY DEFICIENCY AND NTDs

The role of dietary deficiency during pregnancy has been studied in various animal models including the hamster (Mooij et al., 1993), rat (Miller et al., 1994) and mouse (Heid et al., 1992). No association has been found in any of these models between folate deficiency and increased incidence of offspring affected by NTDs. The question of dietary deficiency has also been addressed using the in vitro whole embryo culture system. Cockcroft (1988)
showed that specifically omitting folate from dialysed serum cultures reduces embryonic growth but does not yield NTDs, in contrast to myo-inositol whose omission leads to the development of cranial NTDs. In other studies, embryos have been cultured under sub-optimal conditions to produce NTDs in non-mutant strains. Such conditions produce a range of defects that can be ameliorated by various supplements. Rat embryos cultured in cow serum (Coelho et al., 1989) or canine serum (Flynn et al., 1987) develop cranial NTDs which can be prevented by supplementation with methionine. Culturing rodent embryos in human serum produces NTDs which can be prevented by supplementation with L-homocysteine (VanAerts et al., 1994). However, these studies do not provide a satisfactory model for the human condition for a number of reasons. Firstly, the original culture conditions are sub-optimal since embryos exhibited growth retardation as well as NTDs, which does not appear to mirror the human situation where pregnancies resulting in NTDs have not been shown to be sub-optimal. Secondly, the administration of methionine or homocysteine, but not folic acid, prevents NTDs whereas homocysteine is a risk factor for human NTDs. Moreover, although these agents are related to folate metabolism, a model for the human condition would have to be preventable by folic acid itself.

1.7 THE curly tail MUTANT MOUSE

Figure 1.8 curly tail mouse. (Photograph from (Catherine Chalmers, 2007)
1.7.1 The *curly tail* mutant as a model for NTDs in humans

Although no animal model has been convincingly established as the equivalent of human NTDs, many aspects of the *curly tail* mouse mutant appear to parallel the malformations in humans (Embury et al., 1979). Lesions occur at both ends of the central nervous system, resulting in exencephaly and spina bifida. Exencephaly occurs in 1-2 % of embryos, spina bifida in around 15 % and tail flexion defects in around 50 % (Anatomy and Embryology review). There is a marked female excess both in exencephalic mice and anencephalic humans where the female:male ratios are 4:1 and 3:1 respectively (Carter, 1974); (Embury et al., 1979). Polyhydramnios, which usually occurs in human anencephalic pregnancies, is also found in association with *curly tail* mouse fetuses with open lesions and is especially significant in the exencephalics. Large numbers of rapidly adherent cells, with distinctive morphology, in the amniotic fluid is another common characteristic in humans (Wald et al., 1977); (Brock and Sutcliffe, 1972), and *curly tail* (Embury et al., 1979) NTD pregnancies. Hydrocephaly sometimes occurs in conjunction with NTDs in both the *curly tail* mouse and humans. Furthermore, raised alphafetoprotein levels in the amniotic fluid can be detected in affected fetuses of both mouse and human (Adinolfi et al., 1976); (Brock and Sutcliffe, 1972).

1.7.2 The *curly tail* defect at the genetic level

The *curly tail* mouse arose as a spontaneous mutation in 1950 in the inbred GFF stock at the Glaxo Laboratories. The founder female was subsequently mated to a CBA/Gr male and then the mice were bred as a closed colony (Grünberg, 1954). As described above, around 60 % of *curly tail* mice exhibit NTDs which have variable expression: exencephaly, lumbo-sacral spina bifida, a coiled or kinked tail. These mice are referred to as ‘affected’ and symbolized by CT. The rest of the mice are morphologically normal and
are referred to as ‘unaffected’, symbolized by ST. Whatever their phenotype, it is believed that all curly tail mice are homozygous for a recessive genetic mutation (ct/ct), the expression of which is modified by the genetic background (Grüneberg 1954); (Seller et al., 1979); (Estibeiro and Copp, 1990). Evidence for recessivity came from out-crossing CT mice to BALB/c, A/Strong, C57BL/6 and DBA/2 strains which produced no offspring with neurovertebral abnormalities in the F1 generation; NTDs reappeared in the backcross generation. However, there was a significant deviation from the expected 50 % CT in the backcross offspring, and the actual expression differed according to the inbred strain used: 24 % of offspring were CT in the BALB/c cross, 8 % in the A/Strong cross, 22.5 % in the C57BL/6 cross and 0.4 % in the DBA/2 cross, suggesting that genetic background has a modifying effect on the expression of the gene (Embury et al., 1979). Selective breeding experiments provided further evidence that all mice, irrespective of their phenotype, are homozygous recessive with the gene having variable penetrance and expressivity (Embury et al., 1979).

1.7.2.1 Grainyhead (Grhl-3)

The Grainyhead, drosophila, Homolog of, or 3 sister of mammalian grainyhead (sister of MGR); SOM or Grainyhead like 3 (Grhl3) belongs to a family of transcription factors related to the Drosophila grainyhead (grh) protein. The Drosophila gene grainyhead is the founding member of a large family of genes that are highly conserved from fly to human. The family consists of two main branches, with grainyhead as the ancestral gene for one branch and the recently cloned Drosophila CP2 (Gemini) as the ancestral gene for the other. Functionally, Grainyhead, the best-studied protein in its subfamily, is mainly a regulator of developmental control genes in D.melanogaster, such as Ultrabithorax, dopa decarboxylase, tailless and decapentaplegic (Ting et al., 2003). Fruit flies carrying
grainyhead mutations display an embryonic lethal phenotype. Like grainyhead, the human Grhl3 gene produces several distinct isoforms with differing functional properties through alternative splicing.

<table>
<thead>
<tr>
<th>Tail Bud Region</th>
<th>PNP Category</th>
<th>Subsequent Spinal Development</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>Normal</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Normal</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Tail Flexion Defects</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Tail Flexion Defects and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spina Bifida</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1.9 Diagrams of tail bud regions of curly tail embryos. The diagram illustrates the five PNP categories and subsequent spinal development. Modified from Copp, 1985

The tissue distributions of these isoforms differ and all display highly restricted expression patterns. These findings indicate that Grhl3, like its family members, may play important roles in mammalian development. By database analysis, Ting et al. (2003) mapped the mouse Grhl3 gene to chromosome 4 and, by in situ hybridization, they detected Grhl3 expression at mouse embryonic day (E) 8.5 in the non neural ectoderm immediately adjacent to the neural plate, which was undergoing folding to form the neural tube. At later
time points, more widespread expression was observed in the surface ectoderm, as well as in other tissues lined by squamous epithelium, including the oral cavity, urogenital sinus, and anal canal. Expression progressively increased until E15.5.

The *curly tail* gene has recently been claimed to be *Grhl-3*. Ting et al., (2003) found that targeted *Grhl3* null mouse embryos displayed neural tube defects, including thoracolumbosacral spina bifida and curled tail, as well as spinal skeletal abnormalities such as kyphosis, splayed spinal processes, and lack of vertebral arch formation. Spina bifida was caused by a primary failure of neural tube closure. They noted that the phenotype of the *Grhl3*-null mice is similar to that of *curly tail* mice (*ct/ct*). The authors found that the mouse *Ghrl3* locus maps to the same 13-Mb contiguous sequence on chromosome 4 as the *ct* locus but failed to find a coding region mutation in *ct* mice. *Ghrl3* mRNA expression in *curly tail* mice is decreased to about 30% of normal. However, there were some phenotypic differences; most notably, inositol treatment had no effect on the severity and incidence of spina bifida in *Grhl3*-null embryos. Ting et al. (2003) concluded that *Grhl3* and *ct* may regulate one another, be allelic, or be involved in the same pathway, and suggested that *Grhl3* is a good candidate for the gene underlying the *curly tail* phenotype.

Mace and colleagues found that *grainyhead* activates wound repair genes in cells surrounding injuries in the outer layer of fly embryos (Mace et al., 2005). They created wounds in flies and analyzed that *grainyhead* initiates repair. They also found that in flies lacking *grainyhead*, wounds failed to heal. Moreover, mice lacking *grainyhead* proved to have more permeable skin than normal mice and had deficient wound repair (Ting et al., 2005). Such a conserved genetic mechanism for wound repair is considered an important finding, given that little is known about how wound repair is halted when injuries are
healed. Nor is it understood how cancer cells evade this stop program. The discovery that grainyhead-like factors are required for the response to injury opens up new avenues of research in the field of wound healing as well as cancer research and development, since many cancer cells and developmental processes activate genes normally involved in wound healing in order to kick start processes such as cell division and cell migration.

1.7.3 The curly tail defect at the morphological level

In 1954, Grüneberg suggested, from morphological observations, that spinal neural tube malformations in curly tail embryos were the result of delayed closure of the posterior neuropore (PNP). Further evidence was provided by Copp (1985) who followed the in vitro development of individual curly tail embryos that exhibited varying extents of delay in PNP closure. He classified the axial length of the PNP, at the stage of 25-29 somites, into five categories (Fig. 1.9). In categories 1 and 2, the PNP is restricted to the expanded distal region of the tail bud. In category 3, the PNP extends beyond the distal region of the tail bud, but does not reach the level of the hindlimb bud rudiment. In category 4, the PNP extends into the region of the hindlimb bud but does not encroach upon the rows of somites. In category 5, the PNP overlaps, in its cranial extent, with the somite rows. It was found that when the PNP was restricted to the expanded distal region of the tail bud the majority of curly tail embryos (63%) were unaffected and developed a straight tail in vitro while the rest of the embryos had tail flexion defects. When the PNP extends beyond the distal expansion, but does not reach the level of the hindlimb bud rudiment, significantly more embryos (71%) developed tail flexion defects with a few (8%) having spina bifida as well. On the other hand when the PNP extends into the region of the hindlimb bud or when the PNP overlaps, in its cranial extent, with the somite rows, only 8% of the embryos were normal, and the proportion of embryos that developed spina bifida...
increased to 34% (Copp, 1985). This understanding of different development of embryos according to the length of unclosed neural folds at the PNP allows comparison between prospective normal and affected *curly tail* embryos at a stage that precedes the development of fully formed spinal NTDs (Copp, 1985).

During the course of other experiments with *curly tail* mice, it was noticed that embryos which have a large PNP often exhibit excessive ventral curvature of the caudal region (Copp et al., 1988a). To determine whether there is a true relationship between the size of the PNP and the angle of curvature, these two parameters were measured in individual embryos. The angle of ventral curvature of the caudal region was found to vary significantly with neuropore size, such that the curvature is greatest in embryos with a large PNP and least in embryos with a small neuropore (Brook et al., 1991a). This was an interesting observation in view of previous suggestions that curvature of the body axis can affect the rate of neurulation in the cranial region of the mouse embryo (Jacobson and Tam, 1982); (van Straaten et al., 1992). Moreover, splitting of the caudal region to prevent development of curvature was effective in reducing PNP length in *curly tail* embryos, strongly supporting the idea that ventral curvature is the cause of delayed PNP closure (Brook et al., 1991a), (van Straaten and Copp, 2001)

1.7.4 The *curly tail* defect at the cellular level

Regional variations in the rate of cell proliferation have been suggested to be an important factor determining the success or failure of normal neurulation in higher vertebrates (Kauffman, 1968); Wilson, 1982). In studies of mouse mutants with neural tube defects, a prolonged neuroepithelial cell cycle was found in regions of open cranial neural tube of homozygous *splotch* mutant mouse embryos (Wilson, 1974); (Wilson and Center, 1974). The increased ventral curvature in *curly tail* embryos appears to result from a growth
imbalance in the caudal tissues of the embryos. When the different cell types in the PNP region of normal and affected *curly tail* embryos were compared, a reduced proliferation rate, equivalent to a 25% increase in cell cycle time, was found in gut endoderm and notochord. Other cell types, including neuroepithelium, surface ectoderm and mesoderm, showed no difference between normal and abnormal embryos (Copp et al., 1988c).

Figure 1.10 Neural tube malformations in *curly tail* embryos. (ST) straight tail; (CT) curly tail; (EX) excencephaly; (SB) spina bifida. Arrow points to the open PNP. (E) embryonic day.
This imbalance of growth between the dorsally situated neuroepithelium and the ventrally situated notochord and gut endoderm, in the PNP region, has been shown to be responsible for the development of spinal NTDs in affected curly tail embryos. Evidence comes from experiments in which NTDs were prevented by re-establishing a balance of proliferation between the slowly growing notochord/gut endoderm and the unaffected neuroepithelium. This was achieved by retarding the growth of the embryo in two ways (Copp et al., 1988c): *In utero*, by depriving pregnant females of food for 48 hours and, *in vitro*, by elevating the culture temperature from the optimal 38 °C to 40 °C for 15-23 hours, prior to PNP closure. Both treatments resulted in normalization of PNP closure and prevented the development of spinal NTDs. $^3$H-thymidine labelling of *in vitro* growth retarded embryos showed that while the proliferation rate of all tissues was reduced, the more rapidly growing neuroepithelium suffered a greater reduction in proliferation rate than other cell types. Thus, the absolute magnitude of the cell proliferation imbalance was diminished by *in vitro* growth retardation of the embryo.

1.7.5 Molecular abnormalities in curly tail embryos

Extracellular matrix molecules, particularly glycosaminoglycans, have been suggested to play a role in neurulation because they show specific patterns of deposition that correlate spatially and temporally with neurulation (Solursh and Morriss, 1977); (Morriss and Solursh, 1978); (Morris-Wiman and Brinkley, 1990). Comparisons of glycoconjugates were made prior to the completion of neurulation, between normally developing curly tail embryos and those developing spinal NTDs. Newly synthesized hyaluronan, which accumulates in large quantities in the posterior neuropore of normal embryos, was found to be significantly reduced in amount in the developing basement membranes beneath the medial aspect of the neuroepithelium and around the notochord in the PNP region of
affected *curly tail* embryos (Copp and Bernfield, 1988b). Other embryonic regions and other glycoconjugates showed no differences between normal and affected *curly tail* embryos, and their accumulation pattern was similar to non-mutant embryos (Copp and Bernfield, 1988a).

Affected *curly tail* embryos also exhibit abnormal binding of the iron-binding growth factor, transferrin, which is taken up and localised in the hindgut of neurulation stage mouse embryos (Copp et al., 1992). Reduced binding was observed in the hindgut of affected *curly tail* embryos compared with their unaffected littermates, although the level and sites of expression of the transferrin receptor are not altered (Hoyle et al., 1996).

Several studies have demonstrated an interaction between retinoic acid and the frequency of NTDs in *curly tail* embryos (Chen et al., 1994) and this has been correlated at the molecular level with altered expression of nuclear retinoic acid receptors (Greene and Copp, 1997a).

### 1.7.6 *Curly tail*, a mouse model of folate-insensitive NTDs

Although some cases of human NTDs can be prevented by folic acid, there is increasing evidence that many cases do not respond. For instance, there was no reduction in NTD frequency in the U.K. during the first ten years after folic acid supplementation was introduced (Abramsky et al., 1999). In 1994 Seller provided preliminary evidence that exogenous *myo-inositol* reduces NTD frequency in *curly tail* mice. Greene and Copp (1997) repeated and extended this study using the curly tail mouse as a model of folate-resistant NTDs. They found that intraperitoneal injection of pregnant female mice with *myo-inositol* at various times during the critical phase of neural tube closure significantly
decreased the frequency of spina bifida in developing embryos. A single injection on embryonic day 9.5 reduced NTDs frequency by 70% in $ct$ embryos.

**Figure 1.11** Diagram representing what was known prior to this thesis about the possible inositol mechanism in normalising PNP closure in *curly tail* embryos.

Greene and Copp (1997) demonstrated further that inositol prevents spinal NTDs *in vitro* and showed that inositol increases the flux through the inositol/lipid cycle, stimulates protein kinase C activity, and up-regulates the expression of retinoic acid receptor beta. They concluded that their findings in the *curly tail* mutant reveal a molecular pathway of NTD prevention and suggest possible efficacy of combined treatment with folate and...
inositol in overcoming the majority of human NTDs (Greene and Copp, 1997a). This hypothesis is currently being tested in a clinical trial.

1.8 INOSITOL

Inositols are cyclic carbohydrates with a basic 6-carbon ring structure. There are actually several isomers of inositol, of which *myo-inositol* is the most abundant in the central nervous system of mammals (Baker et al., 1990). *Myo-inositol* is distinct in that it has a single axial hydroxyl group at the number 2 carbon. Inositol metabolism is extremely complex with multiple isomers (over a hundred) of inositol phosphates and inositol phospholipids present in the cell (Bansal and Majerus, 1990). Several preparations of phosphoglycan molecules that appear to mediate insulin action as second messengers contain *D-chiro-inositol*, an epimer of *myo-inositol* that was unknown in mammals until recently (Asplin et al., 1993). *D-chiro-inositol* has an axial hydroxyl group at the number 2 carbon in an inverted position to *myo-inositol* (Fig. 1.12). It has been shown (Insmed Incorporated, unpublished data) that diabetic subjects excrete 5-40 times as much *D-chiro-inositol* in the urine as normal subjects and that the rate of excretion depends critically on the degree of diabetic control. Plasma *D-chiro-inositol* levels are influenced by insulin treatment and are a strong predictor of hypertriglyceridemia, the most common lipid abnormality in diabetic patients (Larner, 2001). *D-chiro-inositol* can be obtained from the diet in the form of pinitol, a methyl inositol found in legumes. The effects of *D-chiro-inositol* on diabetic subjects are being studied (Insmed Incorporated, unpublished data). The exact structure of the *D-chiro-inositol*-containing molecules thought to be responsible for these effects at the biochemical level has not been reported (Larner, 2001).
1.8.1 Mechanisms of inositol signalling

The inositol/lipid cycle plays a central role in inositol metabolism and is involved in signal transduction leading to the regulation of many cellular functions (Berridge, 1995). Cellular uptake of inositol occurs via a sodium-coupled transporter, which is a member of the sugar transporter superfamily (Nikawa et al., 1991). Inositol is utilised in synthesis of the membrane lipid, phosphatidylinositol (PI), in which it constitutes the polar head group. Subsequent phosphorylation steps lead to generation of phosphatidylinositol diphosphate (PIP$_2$) which is the major substrate for receptor activated phospholipase C (Figure 1.13). The major two pathways for activation of isoforms of PLC involve G-protein linked receptors which activate PLC$\beta$ via GTP-binding proteins and receptor tyrosine kinases which activate PLC$\gamma$ (Berridge, 1993). Hydrolysis of PIP$_2$ generates inositol 1,4,5-triphosphate (IP$_3$) and diacylglycerol (DAG) which are major downstream effectors of the cycle. DAG is physiological activator of protein kinase C (PKC), an important family of regulatory enzymes (Hinchliffe and Irvine, 1997). The potential function of PKC in prevention of NTDs is one focus of this study and is, therefore,
reviewed in more detail in Section 1.9. Binding of IP₃ to its receptor leads to mobilisation of calcium from intracellular stores which may regulate cellular processes such as fertilisation, growth control, regulation of actin assembly and neuronal signalling (Martin et al., 1994). The end product of each pathway is inositol, which is recycled back as a component of the original PI precursor. In addition, this parent compound, phosphatidylinositol, can modulate the activity of numerous membrane enzymes.

1.8.2 Phosphatidylinositol 3-kinase

Aside from the inositol/lipid cycle, phosphoinositides have an additional role in signal transduction involving the enzyme, phosphatidylinositol 3-kinase (PI 3-Kinase) which is recruited and concomitantly activated following stimulation of various receptor tyrosine kinases (Divecha and Irvine, 1995). Following auto-phosphorylation and dimerisation, the activated receptors for ligands such as platelet-derived growth factor α and β, colony stimulating factor-1, c-kit and hepatocyte growth factor, are able to interact directly with PI 3-Kinase (Rodgers and Theibert, 2002). An alternative mechanism is also utilised in which the activated receptor interacts with PI 3-Kinase via an adapter molecule such as insulin receptor substrate-1 and erb/B3 in the case of the insulin and epidermal growth factor receptors respectively (Banker, 2003).
Figure 1.13 The inositol phosphate signalling pathway. When the G-protein coupled receptor B is activated, it activates a 'G protein' which in turn stimulates phospholipase C (PLC). PLC cleaves phosphoinositol diphosphate (PIP$_2$) into inositol 1,4,5 triphosphate (IP$_3$) and diacylglycerol (DAG). DAG is a physiological activator of PKC. The second messenger, IP$_3$ releases Ca$^{2+}$ from the endoplasmic reticulum into the cytoplasm which triggers further biochemical reactions. Diagram from Martin, 2001.

The active PI3-Kinase enzyme, a heterodimer of regulatory (85 kDa) and catalytic (110 kDa) subunits, phosphorylates the D-3 position of PI, PIP and PIP$_2$, the later probably being the major substrate in vivo (Chou et al., 1998). Functions for the lipid products of PI 3-Kinase have been proposed in activation of Ca$^{2+}$-atypical PKC (PKC $\zeta$), vesicular trafficking, organisation of actin and planar cell polarity (reviewed by (Cantley, 2002).

The downstream function appears to be mediated through Rac, a member of the Rho class GTP-binding proteins, which is activated by exchange of bound GDP for GTP (Parker, 1995).
1.9 PROTEIN KINASE C

1.9.1 Members of the PKC family of enzymes

The PKC (protein kinase C) family comprises a multigene family of related serine/threonine kinases that play key roles in growth regulation and programmed cell death. My particular interest has been in the PKC-activated signalling mechanisms during neurulation using the *curly tail* mouse mutant as a model.

Traditional models of PKC activation have focused on the role of physiological second messengers (such as calcium and diacylglycerol (DAG)) or tumour-promoting phorbol esters (such as PMA) to anchor PKCs in their active conformations on membranes (Berridge, 1987). However, most cells co-express multiple PKC isoforms that have distinct (and occasionally functionally opposing) cellular responses. PKC isoform specificity has been attributed to distinctive compartmentalization patterns for individual PKC isoforms (Abeliovich et al., 1993a; Bareggi et al., 1995). The prevailing model holds that protein–protein interactions between a particular PKC isoform and its unique membrane-associated anchoring protein (itself localized to a specific membrane sub-domain) serve to recruit the PKC isoform to a distinct sub-cellular compartment, in close proximity with its unique target substrates (Dekker and Parker, 1994; Nakhost et al., 2002).

1.9.2 PKC structure and regulation

PKC isoforms are single polypeptide chains with N-terminal regulatory domains that contain an autoinhibitory pseudosubstrate domain, two membrane-targeting modules (termed C1 and C2) and a highly conserved C-terminal catalytic domain (that contains the
C3 and C4 motifs required for ATP/substrate binding and catalytic activity) (Figure 1.14) (Parker and Murray-Rust, 2004). PKC isoforms are broadly subdivided into three subfamilies based upon their structurally distinct N-terminal regulatory domains. The conventional PKCs are α, βI, βII and γ (cPKCs), all of which contain two membrane-targeting modules, designated C1 and C2 (Parker and Murray-Rust, 2004). The C1 domain consists of tandem ~50-residue DAG/PMA-binding sequences termed C1A and C1B; each adopts a globular conformation and co-ordinates Zn$^{2+}$ at a metal ion-binding site formed by three cysteines and one histidine. X-ray crystallographic studies identify C1 domains as hydrophobic switches (Parker and Parkinson, 2001). Each C1 domain consists of two β-sheets and a short C-terminal α-helix. PMA (or endogenously generated DAG) binds to a hydrophilic cleft situated in an otherwise hydrophobic surface at the tip of the C1 domain (between two ‘unzipped’ β-strands) (Mochly-Rosen and Kauvar, 2000). By capping this polar groove, PMA (or DAG) forms a contiguous hydrophobic surface that promotes PKC binding to membranes (Balogh et al., 1995). The second cPKC membrane targeting motif is the C2 domain, a motif that is found in many proteins that participate in membrane trafficking and signal transduction. C2 domains characteristically consist of eight β-strands connected by loops of variable lengths. C2 domains of cPKC isoforms bind anionic phospholipids in a calcium-dependent manner due to the presence of several invariant calcium-binding residues in three loops at one end of the structure (Asaoka et al., 1992).

Novel PKCs (nPKCs: δ, ε, η and θ) also have twin C1 domains and a C2 domain. However, C2 domain-like sequences of nPKCs lack calcium-co-ordinating acidic residue side chains. Hence nPKCs are maximally activated by DAG/PMA, without requiring
calcium (Parker and Murray-Rust, 2004); (Dekker and Parker, 1994); (Mochly-Rosen and Kauvar, 2000)).

**Figure 1.14 Protein Kinase C Isoforms.** Scheme depicting the sequence homology between PKC isoforms and their subfamilies. (Diagram adapted from (Disatnik et al., 2002). c: classical; n: novel; a: atypical.

Atypical PKCs (aPKCs: ζ and ν/λ) are the third PKC isoform subfamily. aPKCs lack a calcium-sensitive C2 domain and contain only a single cysteine-rich zinc finger structure that does not bind DAG or PMA. As a result, aPKC isoforms are not allosterically regulated by calcium or DAG/PMA (Parker and Murray-Rust, 2004). Rather, aPKCs are activated by a distinct set of phospholipid cofactors, as well as by stimulus-induced
phosphorylation events (a topic that is beyond the scope of this thesis (see (Hirai and Chida, 2003); (Standaert et al., 1997).

Current models of PKC activation are based largely on studies of cPKC isoforms which, in the absence of calcium or DAG, interact only weakly/transiently with membranes. Agonists that promote phosphoinositide hydrolysis and Ins(1,4,5)P3 generation lead to the mobilization of intracellular calcium, which binds to the C2 domain and increases its affinity for membranes (Blobe et al., 1996). This initial association of cPKC with membranes facilitates the interaction of the C1 domain with DAG (the other product of phosphoinositide hydrolysis) (Fig.1.14) (Parker and Murray-Rust, 2004). C1/C2 domain engagement with membranes promotes a conformational change that expels the autoinhibitory pseudosubstrate domain from the substrate-binding pocket and facilitates the PKC-mediated phosphorylation of membrane substrates (Parker and Murray-Rust, 2004). With the exception of the C2 domain-mediated effects of calcium, nPKC isoform activation for the most part follows a similar mechanism. For both cPKC and nPKC isoforms, translocation to membranes generally is considered an indication of activation (Mochly-Rosen and Kauvar, 2000).

1.9.3 Importance of PKC interaction with scaffolding proteins

Most cells co-express multiple PKC isoforms that display only limited substrate specificity in vitro and yet elicit distinct cellular responses in intact cells. PKC isoform specificity in vivo has been attributed to isoform-specific interactions with various anchoring proteins that localize individual PKC isoforms to specific membrane microdomains (in close proximity with their allosteric activators and/or substrates) (Mochly-Rosen and Kauvar, 2000). To date, a relatively large number of PKC-binding partners have been identified, including STICKs (substrates that interact with C-kinase),
various cytoskeletal proteins (such as actin or tubulin), true scaffolding proteins such as caveolin isoforms and AKAPs (A-kinase anchoring proteins), and RACKs (receptors for activated C-kinase) (Jaken and Parker, 2000). The RACK family of membrane-associated PKC-anchoring proteins has figured particularly prominently in the recent literature, since peptides designed to block or promote PKC isoform-selective interactions with their cognate RACKs are currently being evaluated for various cardiovascular indications in humans (Buensuceso et al., 2001). RACK proteins consist of a seven-WD40-motif repeat structure. The current model holds that cells express a unique RACK, with a distinct subcellular localization, for each PKC isoform (Stebbins and Mochly-Rosen, 2001). By selectively/saturably binding only the activated conformation of a PKC, each RACK protein recruits its cognate PKC isoform (in an active conformation) to a specific membrane compartment (Mackay and Mochly-Rosen, 2001) (Fig. 1.15). To date, proteins with characteristics of RACKs for PKCβ (RACK1), PKCe (RACK2 or b-COP) and PKCδ (p32/gC1qBP) have been identified (Chen et al., 2001). However, it is important to note that RACK proteins can also fulfil functions unrelated to PKC. For example, RACK1 is reported to act as a scaffold to organize signalling complexes containing SFKs, heterotrimeric G-protein βγ subunits, STAT1 (signal transducer and activator of transcription 1) and the receptor protein tyrosine phosphatase PTPm (Chen et al., 2001). RACK2 (or β-COP, a coated-vesicle protein that participates in intracellular transport and vesicular release) was identified as a binding partner for certain RGS (regulators of G-protein signalling) proteins (Mackay and Mochly-Rosen, 2001).
Figure 1.15 Signal transduction PKC cascades: the interaction of calcium-dependent PKCs with selective activators diacylglycerol (DAG), phosphatidylserine (PS) and calcium (Ca^{2+}) reduces the affinity of the pseudosubstrate domain for the catalytic site, thus opening the folded conformation and allowing the activation of the enzyme. The activated PKC can be directed to specific cellular compartments via anchoring proteins such as RACKs. (Diagram adapted from Amadio, 2006).
1.9.4 How PKC peptide inhibitors work

As described above, following activation, each activated isoform is localized to a unique subcellular site due to its binding to the corresponding RACK (Mochly-Rosen and Kauvar, 2000). The activated isoform is thus anchored next to a subset of substrates and away from others. Therefore, isoform-selective functions are determined by their cellular localization. Based on that idea, Professor Mochly Rosen (Aley et al., 2000) identified the interaction site for each RACK on the corresponding PKC isoform and identified isoform-selective inhibitory peptides for all the PKC isoforms. The translocation inhibitors are 6-8 amino acids long and they selectively inhibit translocation and function of their corresponding isoforms (Fig. 1.16) (Mochly-Rosen and Kauvar, 2000)

![Diagram showing PKC and RACK interactions](image)

**Figure 1.16 Translocation inhibitors.** On the left, PKC (lilac) binding to its RACK (Orange) results in anchoring of the activated isoform near its substrate (blue). Phosphorylation (P) of that substrate leads to the physiological responses of that isoform. On the right, a peptide corresponding to the RACK-binding site on PKC (green) inhibits the translocation and function of its corresponding isoform. The translocation inhibitor,
derived from the RACK-binding site on the PKC, binds to the RACK and blocks the binding of the activated isoform to that RACK. Hence, the physiological response mediated by that PKC isoform is not observed. (Diagram adapted from (Mochly-Rosen and Kauvar, 2000)

1.9.5 Function of PKC

Roles for PKC have been proposed in regulation of a variety of cellular processes including function of membrane proteins, cell cycle control and transcription of various genes (reviewed by (Nishizuka, 1986); Mochly Rosen 2004). At the molecular level, the effect of PKC is mediated through phosphorylation of protein substrates on serine or threonine residues.

The functions of PKC at the cell membrane include down regulation of target receptors, such as the epidermal growth factor (EGF) receptor and modulation of ion channel targets, such as the Na⁺/H⁺ exchanger (Sardet et al., 1990). PKC activity also affects long-term responses such as cell proliferation and gene expression. For example, induction of expression of the transcription factor, c-fos, by insulin or insulin related growth factor-1 occurs via PKC-dependent pathway (Heidenreich et al., 1993). Phosphorylation by PKC also regulates the activity of the activator protein (AP) transcription factors, AP-1 (through phosphorylation of c-fos) and AP-2 (Nishizuka, 1992). Activation of c-Raf kinase following phosphorylation by PKC may also be involved in regulation of AP-1 (Hug and Sarre, 1993).

The major PKC substrate MARCKS may be of particular interest in relation to neural tube closure as the null mutant mouse displays exencephaly (Stumpo et al., 1995a). Moreover, knockout of the MARCKS family protein, MRP also causes NTD (Chen et al., 1996).
1.10 EXPERIMENTAL APPROACH

This thesis provides a study of both the development and prevention of NTDs in the mouse embryo. The events of posterior neural tube closure are studied using the whole embryo culture system, which allows a detailed analysis of neurulation as a dynamic, ongoing process.

In Chapter 3, the previously demonstrated prevention of spina bifida in the curly tail mutant by inositol (Greene & Copp) is investigated further by analysis of two different isomers of inositol, with comparison of their relative efficacy. Both myo- and D-chiro-inositol, were found to prevent spinal NTDs but with greater potency observed for D-chiro-inositol. The possibility that inositol therapy might cause fetal malformations was carefully analyzed, as a “pre-clinical” evaluation, prior to using inositol as an adjunct therapy to folic acid for prevention of NTDs in a human clinical trial.

The aim of Chapter 4 was to investigate the possible involvement of specific isoforms of PKC in the mechanism of the curly tail defect and/or in the biochemical and molecular basis of the inositol protective effect. In this chapter I examined neurulation-stage embryos for PKC expression and applied chemical and peptide PKC inhibitors to curly tail embryos developing in culture. This study revealed an absolute dependence on the activity of PKCβ1 and γ for prevention of NTDs by inositol, and partial dependence on PKCζ, whereas other PKCs were found dispensable for the protective effect of inositol. Interestingly, inhibition of PKCs does not appear detrimental to normal development during neurulation.
The *curly tail* cell proliferation defect was investigated in *Chapter 5* in order to determine whether the protective effect of inositol may work via stimulating cell proliferation in *curly tail* embryos. Defective proliferation of hindgut cells is a key component of the pathogenic sequence leading to NTDs in *curly tail*. Hindgut cell proliferation was found to be stimulated specifically by inositol, as judged by PCNA and phospho-histone H3 immunohistochemistry, an effect that required activation of PKCβI. This final chapter, reveals the cellular basis by which specific PKC isoforms function during the prevention of mouse spinal NTDs by inositol.
CHAPTER 2

MATERIAL AND METHODS
All the reagents used in this thesis were obtained from Sigma unless otherwise specified. The components of individual solutions are described in the text except for certain general solutions, which are listed in section 2.8.

2.1 MICE

2.1.1 Generation of experimental litters

Experimental litters were generated by timed matings in which females were paired with males overnight and checked for copulation plugs the following morning. The day of finding a plug was designated embryonic day (E) 0.5.

2.1.2 Curly tail mice

The curly tail mutation is maintained in our laboratory as a closed, random-bred stock of homozygous (ct/ct) individuals (Van Straaten and Copp, 2001). The background of the stock, although not inbred, appears homogeneous with respect to genes that influence the incidence of NTDs. The background is probably a mixture of the GFF and CBA/Gr inbred strains that comprised the original breeding pair (Grüneberg, 1954). The mice are fed with R&M Diet (Quest Nutrition) and tap water. They are maintained in a ventilated room at 22°C on a light/dark cycle with the dark period from 1 a.m. to 9 a.m. About two-thirds of the curly tail mice are affected with spinal NTDs (10-15 % spina bifida, 40-50 % curly tails), whereas the rest are unaffected and have no morphological abnormality. To obtain experimental litters, affected males (tail flexion defect) were mated with females that were either unaffected (straight tail) or had tail flexion defects. Both affected and unaffected females were used as a source of experimental embryos, since the incidence of NTDs has been shown to be the same in both types of litter (Copp et al., 1982). In order to allow accurate estimation of gestational age, for certain experiments timed matings
were performed by pairing two females with one male, at approximately 8:30 a.m. and checking for copulation plugs 3-4 hours later.

2.1.3 CD1 mice
The CD1 stock was used as a non-mutant control in all experiments. It is maintained as a random bred colony with males obtained from Charles River U.K. Ltd. (Margate, U.K.).

2.2 EMBRYO CULTURE

2.2.1 Embryo dissection
Pregnant mice were killed by cervical dislocation at the appropriate day of gestation, 9 days 5 hours for curly tail mice. Conceptuses were explanted using watchmaker's forceps into pre-warmed (37°C) Dulbecco's Modified Eagles Medium (Gibco) containing 10% fetal calf serum (Advance Protein Products). Using fine watchmaker's forceps, embryos were dissected free from the decidua, trophoblast and Reichert's membrane leaving the yolk sac and ectoplacental cone intact (Fig. 2.1). Embryos were then either:
1) Cultured intact (Section 2.2.2)
2) Dissected immediately from the yolk sac and amnion and fixed in 4% PFA. The yolk sac in same studies was rinsed in PBS and frozen for PCR genotyping (Section 2.7.1).
3) Dissected and the caudal region dissociated to prepare primary cell cultures (Section 2.6.2)

2.2.2 Embryo culture
Groups of three embryos were cultured in 30 ml disposable plastic tubes (Nunc, Universal) containing 3 ml immediately-centrifuged heat-inactivated rat serum (the culture method was modified from (Cockroft, 1990). In general there was a delay of 2
hours between killing the female mouse and putting the embryos into culture. Cultures started at 9 days 6 hours (curlyl tail) or 9 days 14 hours (CD1) of gestation, were gassed for 1 minute with 20% O₂, 5% CO₂, 75% N₂ (all gases from Cryoservice Ltd.) and incubated at 38°C in a roller bottle incubator (Cockroft, 1990). After approximately 17 hours, the cultures were again gassed for 1 minute with 40% O₂, 5% CO₂, 55% N₂ and incubated for a further 7 hours.

2.2.3 Preparation of rat serum

Rat blood was collected from the abdominal aorta of rats anaesthetized with diethyl ether. The blood was collected in a 20 ml plastic syringe and immediately centrifuged for 5 minutes at 3,500 rpm to pellet the red cells. The fibrin clot that formed in the upper plasma layer was squeezed to release the serum. The blood was re-centrifuged for 5 minutes at 3,500 rpm for 5 minutes and then the clear supernatant serum was drawn off with a Pasteur pipette. The serum was centrifuged again for 5 minutes at 3,500 rpm to pellet any remaining red cells and then the supernatant was drawn off and divided into 5 ml aliquots. The serum was heat inactivated in a water bath at 56 °C for 30 minutes and then stored at -20 °C.

2.2.4 Analysis of embryo cultures

At the end of the culture period, embryos were first assessed for viability: any embryos that did not exhibit a vigorous yolk sac blood circulation (grade 1 or 2) and heart beat were eliminated from subsequent analysis (see Table 2.1). Extraembryonic membranes were then removed and embryos were scored for: (i) posterior neuropore length (the distance between the rostral end of the posterior neuropore and the tip of the tail bud), (ii)
crown-rump length (Figure 2.2.4.2) and (iii) somite number. Length measurements were made using an eyepiece graticule on a Zeiss SV6 stereomicroscope (Table 2.2).

<table>
<thead>
<tr>
<th>Yolk sac circulation</th>
<th>category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very good</td>
<td>+++ (1)</td>
<td>Blood circulation vigorous and affecting whole yolk sac</td>
</tr>
<tr>
<td>Good</td>
<td>++ (2)</td>
<td>Blood circulation slow and /or in only part of the yolk sac</td>
</tr>
<tr>
<td>Bad/no circulation</td>
<td>+ (3)</td>
<td>No blood circulation visible</td>
</tr>
</tbody>
</table>

Table 2.1 Assessment of yolk sac circulation

Figure 2.1 Yolk sac circulation. Yolk sac circulation was here used as a measurement of development. On the left panel the yolk sac vessels were injected with black ink with the sole purpose to enhance the view of the yolk sac circulation on the photograph.
<table>
<thead>
<tr>
<th>Feature assessed</th>
<th>Expected appearance after culture (normal development)</th>
<th>Potential abnormalities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yolk sac circulation</td>
<td>Category 1 or 2 (see Table 2.2.1)</td>
<td>No yolk sac circulation</td>
</tr>
<tr>
<td>Crown rump length</td>
<td>Normal when compared to littermates with all other developmental criteria normal</td>
<td>Significantly reduced size when compared to normal litter mates</td>
</tr>
<tr>
<td>Somites</td>
<td>Clearly defined somite boundaries</td>
<td>Irregular or unaligned somites</td>
</tr>
<tr>
<td></td>
<td>Correct expected somite number = Time of culture/2 + original somite number</td>
<td>Fewer somites than expected for time in culture</td>
</tr>
<tr>
<td>Neural tube</td>
<td>Closed head region and caudal neural tube or small PNP at E10.5 (approx. 30 somites)</td>
<td>Regions of open neural tube Wavy or distorted neural tube</td>
</tr>
<tr>
<td>Heart</td>
<td>Looped heart and beating</td>
<td>No heart beat</td>
</tr>
<tr>
<td>Axial rotation</td>
<td>Embryo fully turned by E9.5 (approx. 20 somites)</td>
<td>Turning incomplete</td>
</tr>
</tbody>
</table>

Table 2.2. Assessment of development after embryo culture
Figure 2.2. Assessment of development after embryo culture. Physiological parameters such as the developing circulatory system (Heart), crown rump length and somite numbers were used as a measurement of development after embryo culture.

2.3 IN VITRO TREATMENT OF EMBRYOS

2.3.1 Administration of inositol

Thirty minutes after the start of culture, myo-inositol (Sigma, UK) or D-chiro-inositol (InsMed, Virginia, USA) was added to the medium (62.5 μl of inositol stock per ml rat serum) to achieve a final concentration of 5, 10, 20 or 50 μg/ml inositol in the cultures. Control cultures received an equal volume of phosphate buffered saline (PBS). In order to avoid variations in outcome as a result of differences in developmental stage among the cultured embryos, cultures were initiated using only embryos with approximately 17-19 somites (assessed by dissection and somite counting of specimen embryos from each litter). Following 24 hours culture, embryos that fell outside the 29-31 somite range (one
somite is added every two hours in mouse development) were discarded from analysis. Embryos within individual litters were allocated randomly to treatment groups in order to minimise the effect of litter-to-litter variations on developmental outcome.

2.3.2 In vitro treatment of embryos with chemical PKC inhibitors

Embryo cultures were supplemented with 1% (v/v) additions of phosphate buffered saline (PBS) or myo-inositol, to a final concentration of 50 µg/ml. Each culture also received chemical or peptide PKC inhibitors as 1% (v/v) additions, as follows. Bisindolylmaleimide (Bis) I and V, Go6976, HBDDE and LY294002 (all from Calbiochem) were each diluted in a minimal volume of dimethyl sulfoxide (DMSO) and further diluted in PBS to give 1 mM stock solutions, which were added to embryo cultures to a final concentration of 10 µM. DMSO diluted in PBS was added to control cultures.

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>Concentration used*</th>
<th>PKC isoform inhibited</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bis I</td>
<td>10 µM</td>
<td>α, βI, βII, γ, ε</td>
</tr>
<tr>
<td>Bis V</td>
<td>10 µM</td>
<td>Inactive form of BisI</td>
</tr>
<tr>
<td>Gö 6976</td>
<td>10 µM</td>
<td>α, βI, βII, γ</td>
</tr>
<tr>
<td>HBDDE</td>
<td>50 µM</td>
<td>α, γ</td>
</tr>
<tr>
<td>LY294002</td>
<td>1.4 µM</td>
<td>PI3K</td>
</tr>
</tbody>
</table>

Table 2.3 Concentration information for chemical PKC inhibitors

* Concentrations chosen to reflect IC₅₀ values for each PKC isoform
2.3.3 *In vitro* treatment of embryos with peptide PKC inhibitors

Peptide PKC inhibitors coupled to carrier peptide were provided by Professor Daria Mochly-Rosen (Stanford University), and 100 μM solutions in PBS were added to embryo cultures to a final concentration of 1 μM.

<table>
<thead>
<tr>
<th>Peptide inhibitor code number</th>
<th>Region against which peptide was designed</th>
<th>Isoform inhibited</th>
</tr>
</thead>
<tbody>
<tr>
<td>pp109</td>
<td>(C2-4)</td>
<td>α</td>
</tr>
<tr>
<td>pp 97</td>
<td>(V5-3)</td>
<td>βI</td>
</tr>
<tr>
<td>pp 96</td>
<td>(V5-3)</td>
<td>βII</td>
</tr>
<tr>
<td>pp 110</td>
<td>(C2-4)</td>
<td>γ</td>
</tr>
<tr>
<td>pp 101</td>
<td>(δV1-1/carrier)</td>
<td>δ</td>
</tr>
<tr>
<td>pp 106</td>
<td>epsilon agonist</td>
<td>ε</td>
</tr>
<tr>
<td>pp 98</td>
<td>Pseudosubstrate inhibitor of zeta</td>
<td>ζ</td>
</tr>
<tr>
<td>pp 94</td>
<td>(carrier-carrier)</td>
<td>Control peptide</td>
</tr>
</tbody>
</table>

Table 2.4 Peptide translocation-inhibitors of PKC isoforms coupled to an *Antennapedia* carrier peptide, as used in this study
2.4 ADMINISTRATION OF INOSITOL IN UTERO

2.4.1 Methods for in utero administration

Inositol was administered to embryos in utero by two methods. Osmotic mini-pumps (capacity 100 µl, delivery rate 1 µl/hour, for 72 hr; Model 1003D, Alzet) were filled with solutions of 30, 75 or 150 mg/ml inositol (which delivered inositol at 29, 72 and 144 µg/g body weight/day respectively, for an average 25 g mouse). Control mice received mini-pumps containing PBS. Mini-pumps were incubated in sterile PBS at 37°C for 4 hours and then implanted subcutaneously on the back of pregnant mice at E8.5 (Fig. 2.3).

General anaesthesia was induced by an intra-peritoneal injection of 0.01 ml/g body weight of a solution comprising 10% Hypnovel® (Midazolam 5 mg/ml) and 25% Hypnorm® (fentanyl citrate 0.315 mg/ml, fluanisone 10 mg/ml) in sterile distilled water. In a separate experiment, pregnant mice were gavaged with 0.5 ml inositol solution in PBS (400 µg inositol/g body weight) at 12 hourly intervals from E8.5 to E10.5 (six doses in total). Hence, the dose of inositol delivered orally was 800 µg/g body weight/day.

Figure 2.3 Osmotic mini pumps were subcutaneously implanted in the upper body of ct mice
2.4.2 Analysis of fetuses following inositol treatment \textit{in utero}

Pregnant females were killed at E18.5, the uterus was opened and the total number of implantations, classified as viable fetuses or resorptions, was recorded. Fetuses were dissected from the uterus and inspected immediately for the presence of open lumbo-sacral spina bifida and tail flexion defects, which are the primary manifestations of the \textit{curly tail} genetic defect (Van Straaten and Copp, 2001). A randomly selected sample of fetuses was fixed in Bouin’s fluid and subjected to detailed internal pathological analysis (performed by Dr Sheila Tesh) by free-hand serial sectioning, using the method of Wilson (1965). A further sample of fetuses was fixed in 95% ethanol and processed for skeletal examination (performed by Dr John Tesh), by the method of Whittaker and Dix (1979). Fetuses and skeletal preparations were photographed using a Zeiss SV11 stereomicroscope.

2.5 IMMUNOHISTOCHEMISTRY

2.5.1 Preparation of routine histological sections

2.5.1.1 Dehydration and embedding

Embryos were fixed in 4% paraformadehyde (PFA) in PBS at 5 °C overnight. Before embedding in paraffin wax, the tissue was dehydrated by passage through a series of ethanol solutions of increasing concentration: 30%, 50%, 70% and 100%. Twenty-minute changes at each step were employed. Since alcohol is not miscible with molten paraffin, the alcohol in the tissue was removed by a 15 minute exposure to a mixture of equal parts of absolute ethanol and Histoclear (National Diagnostics) followed by two 15 minute changes in pure Histoclear. The tissue was transferred using a pipette to a glass-embedding dish containing molten paraffin wax (melting point 56 °C) in an embedding oven. After 30 minutes, the paraffin wax was poured out, and was replaced by fresh wax.
After another 30 minutes, when the tissue was thoroughly infiltrated with paraffin wax, the tissue was embedded as follows. While observing with a dissecting microscope, the dish containing the embryo was allowed to cool until the bottom layer of wax started to solidify. The tissue was properly orientated, in order to yield transverse sections when cut parallel to the bottom surface of the dish, using two pairs of heated blunt forceps. The paraffin wax was left at room temperature for several hours and then the dish was stored at -20 °C overnight. This enabled the paraffin block to be removed from the dish, after which it was then stored at 4 °C until required for sectioning.

2.5.1.2 Sectioning

The paraffin block was roughly trimmed using a razor blade and the base of the block was slightly melted and attached to a wooden block, which was clamped to the microtome chuck. Ribbons of sections were cut at a thickness of 6 μm using a Leitz microtome. The ribbons were cut into short lengths and transferred to TESPA-coated slides (TESPA, 3-aminopropyl-triethoxy-silane glass slides, Sigma). Water, at 40 °C, was pipetted onto the surface of the slides, the sections were placed on top of the water and then the slides were placed on a slide dryer at 37°C in order to allow the sections to float and spread. Excess water was then removed from the slides, which were left to dry overnight. Slides were stored at 4°C until used for staining.

2.5.2 Immunodetection of PKC isoforms

Sections were re-fixed in 4% paraformaldehyde in PBS for 5 minutes at room temperature and subsequently washed twice in PBS, 1% BSA, 0.25% Triton X-100 for 15 minutes. Antibodies were diluted prior to application as determined by prior titration studies. A range of dilutions for each antibody was tested initially, based on information
provided in data sheets from commercial suppliers, or from previous usage by other groups. The dilution providing optimal signal with minimal background was selected for all subsequent experiments. Typically 100 µl of primary antibody was prepared for each section. Antiserum was diluted in the same solution utilised for non-specific protein blocking (10% fetal calf serum in PBS containing 1% TWEEN 20 (PBS-T)). Primary antibodies were diluted as shown in Table 2.5, and applied immediately following blocking, without washing. The blocking solution was carefully poured from the slide onto a folded tissue; and replaced with antibody solution. In the case of negative control tissue sections, the blocking solution was not replaced. Primary antibodies were applied overnight at 4 °C. Next day, any excess antibody was rinsed from the sections by immersion in a Coplin jar containing PBS-T for 10 minutes with gently shaking. This was repeated 3 times to ensure all unbound antibody had been washed off, to minimise background staining. The selection of secondary antibody varied with the species from which the primary was obtained, and with the desired choice of detection method. The secondary antibodies were raised in goat and directed against either rabbit or mouse immunoglobulin, and conjugated to FITC. Secondary antibodies were diluted (1:40) in PBS, 10% FCS, 0.25% Triton X-100, and incubated for 1 hour at room temperature in a humid chamber. The humid chamber was covered with aluminium foil to prevent the fluorescence from becoming ‘bleached’ by exposure to light. Unbound secondary antibody was then rinsed from the sections by three 10 minute washes in PBS-T. Slides were dried and mounted in Citifluor (anti-photobleaching mounting medium for immunofluorescence, Citifluor Ltd.). Controls for immunohistochemistry were: 1) Omission of primary antibody (to test non-specific staining of secondary antibody); 2) Substitution of primary antibody by non-specific IgG; 3) Pre-absorption of primary antibody with the specific peptide against which antibody was raised. Peptide sources are
shown in Table 2.5. In addition, when fluorescence immunodetection was used, Hoechst nuclear dye was also added to the secondary antibody mixture. This resulted in all nuclei staining blue in colour under fluorescent illumination.

2.5.3 Immunochemical Reagents

PKC isotype hyphen-specific affinity purified rabbit IgG primary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) (See Table 2.3 for details). The secondary antibody was a FITC-conjugated goat anti-rabbit IgG (Jackson Immuno Research).

2.5.4 PCNA

The Proliferating Cellular Nuclear Antigen (PCNA) was detected using a mouse monoclonal IgG2a antibody derived by fusion of spleen cells from a BALB/c mouse immunised with recombinant PCNA with Sp2/0-Ag 14 myeloma cells (Santa Cruz Biotechnology). It reacts against the PCNA p36 protein expressed at high levels in proliferating cells of human, murine, insect and yeast origin.

2.5.5 H3

Anti-phospho-Histone H3 (Upstate Biotechnology, Buckingham, UK) specifically recognises the phosphorylated 17 kDa histone H3 that is found only in mitotic cells. The antibody was raised in the rabbit, using amino acids 7-20 of the human H3 as immunogen.
2.5.6 Hoechst Dye

Staining of cell nuclei was performed using Hoechst 33258 at 1.2 mg/ml dilution in water. This stock was further diluted 1 in 500 prior to use.

<table>
<thead>
<tr>
<th>Antigen detected</th>
<th>*Primary antibody code</th>
<th>Concentration used</th>
</tr>
</thead>
<tbody>
<tr>
<td>PKC α</td>
<td>Sc208</td>
<td>1:200</td>
</tr>
<tr>
<td>PKC βI</td>
<td>Sc209</td>
<td>1:100</td>
</tr>
<tr>
<td>PKC βII</td>
<td>Sc210</td>
<td>1:100</td>
</tr>
<tr>
<td>PKC γ</td>
<td>Sc211</td>
<td>1:200</td>
</tr>
<tr>
<td>PKC ε</td>
<td>Sc214</td>
<td>1:200</td>
</tr>
<tr>
<td>PCNA</td>
<td>PC10</td>
<td>1:100</td>
</tr>
<tr>
<td>Phospho Histone</td>
<td>(Upstate Biotech, Buckingham, UK)</td>
<td>1:100</td>
</tr>
<tr>
<td>H3</td>
<td>33258</td>
<td>1:1000</td>
</tr>
</tbody>
</table>

Table 2.5 Immunochemical reagents

*Unless stated, all primary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA)

2.6 MOUSE CELL CULTURE

2.6.1 Generation of curly tail primary cell lines

Embryos at the 27 somite stage were removed from the uterus and placed in PBS in a plastic dish. The posterior neuropore region was excised from around the level of somite
20 and cut into small pieces, minced, and transferred into a 15 ml centrifuge tube containing 10 ml dissociation buffer (GIBCO™ Cell Dissociation Buffer, enzyme free, Hanks'-based) (roughly enough for 15 tails) and incubated for 20 minutes at room temperature with gentle shaking. The large tissue clumps were dissociated by repeated pipetting using a 10 ml serological pipette and by passage through a Nitex filter. The supernatant was transferred into a fresh centrifuge tube and spun for 5 minutes at 1,000 rpm at room temperature. The supernatant was discarded and the cells were resuspended in 5 ml growth medium. Cells were counted using a haemocytometer and the final volume was adjusted to 2x 10^6 cells/ml. The cells were seeded directly on plastic dishes and cultured at 37°C in 5% CO₂ for 5 passages.

2.6.2 Culture methods
Cells were cultured on glass cover slips coated for 30 minutes with poly-L-lysine and 30 minutes with fibronectin (to allow attachment of cells to the glass substrate). The cover slips were transferred to a 24-well culture dish, seeded with approximately 1x10^4 cells and cultured for 5 hours in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% v/v heat inactivated fetal bovine serum and 1% v/v penicillin-streptomycin solution (10,000 units penicillin and 10 mg streptomycin per ml).

2.6.2.1 Culture splitting
All solutions were pre-warmed to 37°C. The cells were briefly washed with PBS (without CaCl₂ and MgCl₂) and then detached by adding a few drops of trypsin-EDTA solution (0.05% porcine trypsin and 0.02% EDTA.4Na) and incubating at room temperature as necessary. Adding 2 ml of growth medium inactivated the trypsin. The cells were centrifuged for 5 minutes at 1,000 rpm, at room temperature, and the supernatant was
discarded. The cells were then resuspended in the desired amount of fresh growth medium and seeded in plastic dishes.

2.6.2.2 Immortalised cells used in control cultures

3T3 mouse cell line used was obtained from the Dunn School Cell Bank (Department of Pathology, University of Oxford). They were grown in DMEM in a humidified 37°C incubator, with 5% CO₂.

2.6.3 Treatment of cells with TPA and PKC peptide inhibitors

In all experiments, cells were serum starved by culture in DMEM containing 1% fetal calf serum for 18 hours. Some samples were then treated with 100 mM TPA for 10 minutes and then for 20 minutes with 100 mM PKC isoform-specific peptide-bound inhibitors.

2.6.4 Immunocytochemical analysis

Cells grown on cover slips were stained with anti-PKC antibodies (Table 2.2.5). All solutions were applied in 100 µl volumes, which were sufficient to entirely coat the coverslip. Coverslips were placed on top of small pedestals (lids from screw-capped eppendorf tubes). This allowed the coverslips to be manipulated easily. Cells were fixed in 4% PFA solution for 8 minutes. After fixation, coverslips were lifted using forceps and excess solution was removed by touching the side of the coverslip on some folded tissue paper. The coverslip was then washed by dipping successively in three 30 ml tubes containing PBS. Each dip lasted around 4 seconds. The primary antibody (diluted 1:200 in 10% fetal calf serum in PBS) was then applied and left for 1 hour at room temperature. Following this, the primary antibody was blotted off, and the coverslip was washed three times in PBS as before. The secondary antibody (diluted 1:40 in 10% fetal calf serum in
PBS) was then applied and left for 1 hour at room temperature. The coverslip was then washed a further 3 times in PBS, followed by a brief wash in distilled water. Finally, Citifluor was used to mount the coverslips on clean glass slides. Translocation of specific PKC isoforms was assessed using PKC isoform-specific antibodies (Santa Cruz Biotechnology) in immunofluorescence studies and the percentage of cells showing translocation was determined by counting labeled cells, in a blinded fashion. Each isoform experiment was performed in triplicate. The slides were visualised using a Zeiss fluorescence microscope fitted with a digital camera, and images were recorded using Northern Eclipse computer software and scanned directly into OpenLab.

2.6.5 Labelling indices

The labelling indices (total number of labelled cells divided by the total cell number, multiplied by hundred) were obtained from alternate transverse sections through the rostral end of the PNP stained for PCNA or histone H3. Experiments were carried out in triplicate by an observer blinded for treatment type.
CHAPTER 3
PREVENTION OF FOLATE-RESISTANT NTDs
3.1 INTRODUCTION

Folic acid supplementation during early pregnancy can prevent a proportion of NTDs, as indicated by several clinical trials and other observational studies (Abramsky et al., 1999); (Wald et al., 2001); (Antony and Hansen, 2000). Nevertheless, NTDs may occur even following maternal folic acid supplementation. For example, in the randomized controlled trial conducted by the Medical Research Council Vitamin Research group, UK (Wald et al., 1991), the recurrence rate of NTDs was reduced by approximately 72%. Thus, NTDs still occurred despite maternal supplementation with 4 mg folic acid per day. Interestingly, the recurrence rate in folic acid-treated pregnancies in this MRC trial (1 %) was ten times higher than the usual occurrence rate in the population (0.1 %, or 1 per 1000). Furthermore, the recent introduction of folic acid fortification of bread flour in the USA has resulted in only a 26% decline in the prevalence of NTDs (Honein et al., 2001). While these findings may indicate the need for increased levels of folic acid supplementation, they are also consistent with a proportion of NTDs exhibiting resistance to prevention by exogenous folic acid.

Mouse genetic models of NTDs provide further evidence for the existence of folate-resistant NTDs types Wald, 2001;(Carmichael et al., 2003). Mutant strains including *Cart1*, *crooked tail* and *splotch* exhibit NTD that can be prevented by folic acid administered during early pregnancy (Zhao et al., 1996), whereas folic acid is ineffective in preventing NTDs in the mutant strains *curly tail*, *Axial defects* and *ephrin-A5* (Glanville and Cook, 1992; Tran et al., 2002). Of these ‘folate-resistant’ strains, *curly tail* provides a particularly useful model for human NTDs both in terms of its etiology and pathogenesis (van Straaten and Copp, 2001).
3.1.1 Inositol as a preventive therapy for folic acid-resistant NTDs in mice

Previous work has shown that a proportion of the folic acid-resistant NTDs in curly tail mice can be prevented by treating pregnant females, or embryos in vitro, with myo-inositol (Greene and Copp, 1997a). This work was prompted by the earlier finding that deficiency of myo-inositol in the culture medium of rat and mouse embryos causes a high incidence of cranial NTDs (Akashi et al., 1991). Moreover, NTDs that develop in rat embryos cultured under hyperglycemic or diabetic conditions are associated with depletion of inositol (Kubow et al., 1993) and can be ameliorated by supplementation with myo-inositol (Baker et al., 1990). These findings raised the possibility that inositol may offer a potential alternative therapeutic option for prevention of folic acid-resistant NTD. Although the effect of inositol on human NTD recurrence, in cases of suspected folic acid-resistance, has not yet been rigorously evaluated, a recent case study has highlighted a possible beneficial effect. Myo-inositol therapy was associated with a normal third pregnancy outcome, in a family with two previous consecutive NTD pregnancies despite full folic acid supplementation (Cavalli and Copp, 2002).

The purpose of this chapter is to evaluate in detail the potential of inositol as a primary therapeutic agent in preventing mouse NTDs using the curly tail mouse as a model. The aims were to test different routes of administration and to investigate any possible harmful effects of inositol on the developing embryo. In addition, I compared the efficacy of two enantiomers of inositol, myo-inositol and chiro-inositol.
3.2 RESULTS

Embryos were exposed to inositol either by direct treatment in whole embryo culture, or by dosing pregnant females via subcutaneous and oral routes.

3.2.1 D-chiro-inositol has greater potency than myo-inositol in normalising neural tube closure

Curly tail embryos were cultured in the presence of inositol for 24 hours from E9.5, the period during which the neural tube is closing in the low spinal region of the mouse embryo. In normal embryos, primary neurulation is completed by closure of the posterior neuropore at E10.5 (at the 29-30 somite stage) (Copp et al., 1999), whereas in curly tail embryos neuropore closure is delayed, or fails to be completed, leading to the development of tail flexion defects and spina bifida, respectively (Copp et al., 1988c). Posterior neuropore length at E10-10.5 (Fig. 3.1) is positively correlated with the likelihood that an embryo will progress to develop a spinal NTD (Copp et al., 1988b).

Both myo- and D-chiro-inositol showed a dose-dependent normalisation of posterior neuropore length in embryo culture, as judged by the statistically significant reduction in neuropore length observed in embryos treated with higher inositol doses (Table 3.1). Strikingly, however, D-chiro-inositol reduced neuropore length significantly at both 20 and 50 μg/ml whereas a comparable effect was seen only with 50 μg/ml myo-inositol. In fact, embryos exposed to 20 μg/ml myo-inositol (and 5-10 μg/ml D-chiro-inositol) exhibited neuropore lengths that were not significantly different from PBS-treated controls (Table 3.1). Therefore, it appears that D-chiro-inositol has increased potency compared with myo-inositol in normalizing neurulation, an effect that is detectable in vitro, outside the maternal environment.
Figure 3.1 PNP closure in curly tail mouse embryo. A. Curly tail embryo after 24 hours culture from E8.5 to E9.5. Box indicates the posterior neuropore region. B, C. Higher magnification views of the caudal end of cultured curly tail embryos showing posterior neuropores of varying length. The region of open neural folds occupies the dorsal part of the caudal region, between the arrows in (B) and (C). Embryos with a large neuropore (C) progress to develop spina bifida and/or a tail flexion defect, whereas embryos with a small neuropore (B) complete neural tube closure normally. Scale bars: A = 0.5 mm; B,C = 0.2 mm.

3.2.2 Neither myo- nor D-chiro-inositol affects the rate of embryonic growth in embryo culture

In the experimental design, embryos in the different treatment groups were matched for somite number, both before and following the culture period (see section 2.3.1). The aim was to avoid differences in developmental outcome (PNP length) that might arise from comparing embryos of different stages. As expected, therefore, mean somite number following culture was closely similar in all the treatment groups (Table 3.1). There was
no significant difference in crown-rump length between embryos treated with either myo- or D-chiro-inositol and PBS-treated controls (Table 3.1), suggesting that the effect of inositol is specific to the closing posterior neuropore, and not mediated via embryonic growth acceleration or retardation. In particular, the greater potency of D-chiro-inositol does not appear to result from a differential effect on embryonic growth.

<table>
<thead>
<tr>
<th>TREATMENT</th>
<th>Conc. (µg/ml)</th>
<th>No. embryos</th>
<th>Somite number ¹</th>
<th>Crown-rump length (mm)</th>
<th>PNP length ¹ (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>0</td>
<td>16</td>
<td>30.3 ±0.15</td>
<td>3.56 ± 0.10</td>
<td>0.59 ± 0.13</td>
</tr>
<tr>
<td>myo</td>
<td>20</td>
<td>16</td>
<td>30.5 ±0.12</td>
<td>3.50 ± 0.12</td>
<td>0.62 ± 0.06</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>16</td>
<td>30.5 ±0.14</td>
<td>3.57 ± 0.07</td>
<td>0.06 ± 0.03*</td>
</tr>
<tr>
<td>D-chiro</td>
<td>5</td>
<td>15</td>
<td>30.6 ±0.13</td>
<td>3.50 ± 0.10</td>
<td>0.62 ± 0.11</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>15</td>
<td>30.5 ±0.13</td>
<td>3.39 ± 0.10</td>
<td>0.55 ± 0.11</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>18</td>
<td>30.6 ±0.16</td>
<td>3.55 ± 0.10</td>
<td>0.09 ± 0.11*</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>15</td>
<td>30.3 ±0.16</td>
<td>3.49 ± 0.08</td>
<td>0.07 ± 0.03*</td>
</tr>
</tbody>
</table>

Table 3.1. Comparison of growth and developmental parameters in curly tail embryos cultured in the presence of myo- and D-chiro-inositol

¹ Values presented are: mean ± SEM. Statistical analysis: somite number and crown-rump length do not differ significantly between treatment groups (Analysis of variance on ranks: p = 0.72 and 0.54 respectively), whereas posterior neuropore (PNP) length varies significantly between treatment groups (p < 0.0001).

Ordinal regression analysis shows that PNP length is significantly reduced (marked with asterisk) in embryos treated with myo-inositol (50 µg/ml) and D-chiro-inositol (20 and 50 µg/ml) compared with those exposed to PBS alone (p < 0.05), whereas PNP length in other inositol-treated groups does not differ significantly from the PBS control group.
3.2.3 D-chiro-inositol reduces the frequency of spinal neural tube defects to a greater extent that myo-inositol following in utero administration

I next evaluated the possibility of using subcutaneous and oral routes of inositol administration to prevent NTDs in the fetuses of pregnant curly tail females. In order to administer inositol at a constant rate over a period of 72 hours of pregnancy, to encompass the stages of neural tube closure, osmotic mini-pumps were surgically implanted. These delivered inositol by subcutaneous infusion at a rate of 1 μl/hour. Using this approach a dose-dependent effect of both myo- and D-chiro-inositol was observed.

At a dose of 29 μg/g body weight/day, neither myo- nor D-chiro-inositol produced a significant reduction in the frequency of fetuses developing spina bifida nor was the distribution of fetuses between the three phenotype categories (spina bifida, tail defect and normal) altered significantly (Table 3.2.). In contrast, dosing levels of 72 and 144 μg/g body weight/day both produced a significant reduction in the frequency of spina bifida compared with PBS-treated pregnancies and caused a significant shift in the distribution of fetuses towards the mild end of the phenotype spectrum (Table 3.2.). D-chiro-inositol appeared most effective at both 72 and 144 μg/g body weight/day, causing a 73-83% decrease in spina bifida frequency relative to PBS controls. Myo-inositol produced a consistent 54-56% reduction in spina bifida frequency, but this did not reach statistical significance (see below).

Statistical comparisons between the PBS, D-chiro- and myo-inositol treatment groups, separately at each dose level (3 x 2 chi-square tests), reveals significant variation in frequency of spina bifida at 72 and 144 μg/g body weight/day ($p = 0.014$ and 0.006 respectively) but not at 29 μg/g body weight/day ($p = 0.494$ respectively). Pairwise
testing reveals a significantly lower frequency of spina bifida among fetuses treated with D-chiro-inositol compared with PBS at 72,144 μg/g body weight/day (p = 0.006, and 0.013 respectively) but not at 29 μg/g body weight/day (p = 0.291). Frequency of spina bifida among fetuses treated with myo-inositol is consistently intermediate between the values for D-chiro-inositol and PBS, and does not differ from either treatment group at any dose level (p > 0.05). Hence, D-chiro-inositol exerts a significantly more potent preventive effect against spina bifida than myo-inositol when delivered sub-cutaneously.

As an alternative route of treatment, inositol was administered to pregnant females by gavage, using a twice-daily dosing regime, from E8.5 to E10.5 that delivered 800 μg/g body weight/day (equivalent to the intraperitoneal dose used in the previous study (Greene and Copp, 1997a). As with sub-cutaneous administration, there was a marked reduction in the frequency of spina bifida among the offspring of mice treated with either myo- or D-chiro-inositol. There was also observed a significant shift in the distribution of fetuses between the three phenotype categories (Table 3.2). D-chiro-inositol was most effective, causing a statistically significant 86% reduction in the frequency of spina bifida (p = 0.032), while the 53% reduction observed for myo-inositol was not statistically significant (p = 0.059).

I investigated whether clustering of fetuses of particular phenotypes within litters may have affected the outcome of the comparison between myo-inositol, D-chiro-inositol and PBS. An ordinal multilevel regression model (which took into account the potential non-independence of fetuses within litters) was fitted to the data. This confirmed that fetuses treated subcutaneously with D-chiro-inositol are significantly more likely to be normal than those treated with PBS (p < 0.0005). The comparison between myo-inositol and PBS
also reached statistical significance in this analysis ($p < 0.002$). In the oral dosing study, fetuses were more likely to be normal when treated with D-chiro-inositol than PBS ($p = 0.0097$), whereas the values for myo-inositol and PBS did not differ significantly ($p = 0.13$).

Importantly, the multilevel analysis indicated that the difference between treatment groups is unaffected when possible litter effects are taken into account. Hence, it appears that the reduction in NTD frequency following treatment with myo- and D-chiro-inositol is unlikely to arise from litter-to-litter variations.

### 3.2.4 No evidence of an adverse effect of inositol on pregnancy success or fetal outcome

One possible explanation for a decrease in spina bifida frequency following maternal inositol administration could be an increase in loss of affected fetuses during pregnancy. Therefore, resorption rate and litter size were examined in pregnancies receiving either subcutaneous mini-pumps or twice-daily gavage. No significant differences were found between pregnancies treated with inositol and those receiving PBS alone (Table 3.3). This strongly suggests that there is no adverse effect of inositol dosing on the overall success of mouse pregnancy. A noticeable reduction was found, however, in the litter size of mice subjected to oral inositol administration, where litters contained fewer fetuses than those receiving inositol subcutaneously (Table 3.3). As litter size did not vary between treatments this difference is thought to reflect the increased maternal stress caused by daily gavage (without anaesthesia) compared to a single surgical operation, under general anaesthesia, to insert a subcutaneous miniosmotic pump. To identify any adverse effects of inositol treatment on fetal outcome, an extensive pathological analysis of treated
Table 3.2 Frequency of neural tube and tail defects among curly tail fetuses treated in utero with myo- and D-chiro-inositol

1 Inositol dose is expressed as: µg inositol/g body weight/day.

2 Phenotype frequencies are expressed as number of fetuses with % of total for treatment group.

3 Statistical analysis: distribution of embryos among the three phenotype categories varies significantly with treatment group at 72, 144 and 800 µg inositol/g body weight/day (Chi-square tests, $p = 0.0005$, 0.0051 and 0.026 respectively) but not at 29 µg inositol/g body weight/day ($p = 0.34$).
<table>
<thead>
<tr>
<th>Route of administration</th>
<th>Treatment</th>
<th>Inositol dose</th>
<th>Spina bifida + curly tail</th>
<th>Curly tail</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcutaneous</td>
<td>PBS</td>
<td>-</td>
<td>6 (24.0)</td>
<td>14 (56.0)</td>
<td>5 (20.0)</td>
</tr>
<tr>
<td></td>
<td>myo</td>
<td>29</td>
<td>6 (20.7)</td>
<td>12 (41.4)</td>
<td>11 (37.9)</td>
</tr>
<tr>
<td></td>
<td>D-chiro</td>
<td>29</td>
<td>3 (11.5)</td>
<td>17 (65.4)</td>
<td>6 (23.1)</td>
</tr>
<tr>
<td></td>
<td>PBS</td>
<td>-</td>
<td>14 (13.5)</td>
<td>63 (60.6)</td>
<td>27 (25.9)</td>
</tr>
<tr>
<td></td>
<td>myo</td>
<td>72</td>
<td>4 (6.0)</td>
<td>37 (55.2)</td>
<td>26 (38.8)</td>
</tr>
<tr>
<td></td>
<td>D-chiro</td>
<td>72</td>
<td>2 (2.3)</td>
<td>39 (45.4)</td>
<td>45 (52.3)</td>
</tr>
<tr>
<td></td>
<td>PBS</td>
<td>-</td>
<td>19 (18.6)</td>
<td>49 (48.0)</td>
<td>34 (33.3)</td>
</tr>
<tr>
<td></td>
<td>myo</td>
<td>144</td>
<td>8 (8.5)</td>
<td>52 (55.3)</td>
<td>34 (36.2)</td>
</tr>
<tr>
<td></td>
<td>D-chiro</td>
<td>144</td>
<td>5 (5.0)</td>
<td>46 (46.5)</td>
<td>48 (48.5)</td>
</tr>
<tr>
<td>Oral</td>
<td>PBS</td>
<td>-</td>
<td>8 (18.2)</td>
<td>21 (47.7)</td>
<td>15 (34.1)</td>
</tr>
<tr>
<td></td>
<td>myo</td>
<td>800</td>
<td>3 (8.6)</td>
<td>15 (42.9)</td>
<td>17 (48.6)</td>
</tr>
<tr>
<td></td>
<td>D-chiro</td>
<td>800</td>
<td>1 (2.6)</td>
<td>12 (30.8)</td>
<td>26 (66.7)</td>
</tr>
</tbody>
</table>
fetuses was performed, using both free-hand serial sectioning and skeletal preparation (carried out by our collaborator, Ms Sheila Tesh). This analysis confirmed the occurrence of spina bifida and tail defects in a proportion of fetuses (Figure 3.3), as also scored by external fetal inspection.

Additionally, exencephaly, a failure of cranial neural tube closure, was observed in a small proportion of fetuses (Tables 3.4 and 3.5). Exencephaly is a recognised defect in curly tail homozygotes (Casey et al., 1997). In the present study, no overall increase or decrease in this defect in inositol-treated fetuses was observed compared with PBS controls, although the low frequency of affected fetuses may have obscured any treatment effect.

Internal and skeletal examination of control and inositol treated fetuses revealed almost no major structural defects, apart from NTDs (Tables 3.4 and 3.5). For instance, no major malformations of the heart, lungs, kidney, gut or limbs were identified. Among the morphological changes observed in the analysis, most were minor (e.g. small additional liver lobe) and the great majority occurred as frequently in PBS controls as in fetuses treated with myo- or D-chiro-inositol (Tables 3.4 and 3.5). D-chiro-inositol (144 µg/g body weight/day) was associated with a somewhat elevated frequency of enlargement of the renal pelvis/ureter (Table 3.4), and occurrence of anomalous cervical vertebrae and rudimentary ribs on the 7th cervical vertebra (Table 3.5). However these associations were not statistically significant.
Figure 3.2 Skeletal preparations of E18.5 curly tail fetuses. The tail flexion defect (A) comprises 360° curl of the tail, compared with the normal fetus which exhibits a straight tail (B). Compared with a normal fetus in (B), the fetus with spina bifida (C) exhibits vertebral pedicles widely spaced apart and absent neural arches in the low lumbar/sacral region (long arrow in C). The tail (short arrow in C) is enclosed in a skin sac and appears reduced in length owing to deformation and fusion of caudal vertebrae. Scale bars = 2 mm.

Interestingly, anomalous cervical vertebrae appear to be especially associated with exencephaly: both defects were found in a fetus treated with myo-inositol (144 µg/g body weight/day) and in a second fetus treated with D-chiro-inositol (144 µg/kg body weight/day), which also exhibited thoracic rib anomalies. A further two fetuses from the same D-chiro-inositol treated litter had cervical vertebral anomalies and a third had thoracic vertebral and rib anomalies, while a single fetus from a different litter had cervical vertebral anomalies. It seems likely that these cervical anomalies may form part of the spectrum of vertebral column defects present in the curly tail mouse, often in association with exencephaly.
<table>
<thead>
<tr>
<th>Route of administration</th>
<th>Treatment</th>
<th>Inositol dose</th>
<th>No. litters</th>
<th>No. viable fetuses</th>
<th>No. uterine resorptions</th>
<th>Mean litter size ± SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sub-cutaneous</td>
<td>PBS</td>
<td>-</td>
<td>4</td>
<td>25</td>
<td>3 (10.7)</td>
<td>6.25 ± 1.03</td>
</tr>
<tr>
<td></td>
<td>myo</td>
<td>29</td>
<td>4</td>
<td>29</td>
<td>2 (6.5)</td>
<td>7.25 ± 1.80</td>
</tr>
<tr>
<td></td>
<td>D-CHIRO</td>
<td>29</td>
<td>3</td>
<td>26</td>
<td>1 (3.7)</td>
<td>8.67 ± 1.76</td>
</tr>
<tr>
<td>PBS</td>
<td>-</td>
<td>12</td>
<td>104</td>
<td>10 (8.8)</td>
<td></td>
<td>8.67 ± 0.50</td>
</tr>
<tr>
<td>myo</td>
<td></td>
<td>72</td>
<td>8</td>
<td>67</td>
<td>7 (9.5)</td>
<td>8.38 ± 0.78</td>
</tr>
<tr>
<td>D-CHIRO</td>
<td></td>
<td>72</td>
<td>12</td>
<td>86</td>
<td>8 (8.5)</td>
<td>7.17 ± 0.89</td>
</tr>
<tr>
<td>PBS</td>
<td>-</td>
<td>12</td>
<td>102</td>
<td>9 (8.1)</td>
<td></td>
<td>8.50 ± 0.79</td>
</tr>
<tr>
<td>myo</td>
<td></td>
<td>144</td>
<td>12</td>
<td>94</td>
<td>9 (8.7)</td>
<td>7.83 ± 0.44</td>
</tr>
<tr>
<td>D-CHIRO</td>
<td></td>
<td>144</td>
<td>14</td>
<td>99</td>
<td>6 (5.7)</td>
<td>7.07 ± 0.75</td>
</tr>
<tr>
<td>Oral</td>
<td>PBS</td>
<td>-</td>
<td>7</td>
<td>44</td>
<td>5 (10.2)</td>
<td>6.29 ± 0.36</td>
</tr>
<tr>
<td>myo</td>
<td></td>
<td>800</td>
<td>6</td>
<td>35</td>
<td>3 (7.9)</td>
<td>5.83 ± 0.48</td>
</tr>
<tr>
<td>D-CHIRO</td>
<td></td>
<td>800</td>
<td>6</td>
<td>39</td>
<td>3 (7.1)</td>
<td>6.50 ± 1.09</td>
</tr>
</tbody>
</table>

Table 3.3 Survival of embryos and fetuses among *curly tail* litters treated *in utero* with myo- and D-chiro-inositol

1 Inositol dose is expressed as: μg inositol/g body weight/day.

2 Values in parentheses indicate resorptions as a % of total number of implantations (i.e. viable fetuses + resorptions). Logistic regression analysis: the proportion of resorptions does not differ significantly between myo-inositol and PBS litters ($p = 0.87$), between D-chiro-inositol and PBS litters ($p = 0.33$), or between inositol dose levels ($p = 0.88$).

3 Litter size (viable fetuses per litter) does not vary significantly with treatment group or inositol dose level (two-way analysis of variance: treatments, $p = 0.987$; inositol dose level, $p = 0.054$).

Litters treated with oral inositol contain an average of 1.6 (95% confidence intervals: 0.4, 2.8) fewer animals than litters treated with sub-cutaneous inositol.
Table 3.4 Internal pathological analysis, by freehand serial sectioning, of curly tail fetuses treated in utero with myo- and D-chiro-inositol

1 A single fetus may have more than one morphological finding.
2 Values are number of fetuses with defect (% of total for treatment group is indicated in parentheses).
3 Proportion of fetuses with renal pelvis/ureter defect does not differ significantly between fetuses treated with D-chiro-inositol (144 μg/g body weight/day) and PBS controls (Fisher's exact test; \( p = 0.231 \)).
4 Calculation of % based on number of male fetuses.
Table 3.4

<table>
<thead>
<tr>
<th>Inositol dose (µg/g body weight/day)</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>72</td>
<td>144</td>
<td>72</td>
<td>144</td>
<td>72</td>
<td>144</td>
</tr>
<tr>
<td>No. fetuses examined</td>
<td>27</td>
<td>17</td>
<td>11</td>
<td>21</td>
<td>24</td>
<td>19</td>
</tr>
<tr>
<td>Head:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exencephaly + open eye ²</td>
<td>1 (3.7)</td>
<td>2 (11.8)</td>
<td>-</td>
<td>2 (9.5)</td>
<td>-</td>
<td>1 (5.3)</td>
</tr>
<tr>
<td>Hydrocephaly</td>
<td>1 (3.7)</td>
<td>-</td>
<td>-</td>
<td>1 (4.8)</td>
<td>-</td>
<td>1 (5.3)</td>
</tr>
<tr>
<td>Haemorrhage in/around brain</td>
<td>-</td>
<td>2 (11.8)</td>
<td>-</td>
<td>2 (9.5)</td>
<td>-</td>
<td>1 (5.3)</td>
</tr>
<tr>
<td>Microphthalmia</td>
<td>-</td>
<td>1 (5.9)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Macrophthalmia</td>
<td>1 (3.7)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Blood in nasopharynx</td>
<td>-</td>
<td>2 (11.8)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1 (5.3)</td>
</tr>
<tr>
<td>Thorax and abdomen:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bleeding in thorax/abdomen</td>
<td>6 (22.2)</td>
<td>4 (23.6)</td>
<td>2 (18.2)</td>
<td>-</td>
<td>2 (8.4)</td>
<td>1 (5.3)</td>
</tr>
<tr>
<td>Thyroid lobe reduction</td>
<td>1 (3.7)</td>
<td>-</td>
<td>-</td>
<td>1 (4.8)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Carotid artery displaced laterally</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1 (5.3)</td>
</tr>
<tr>
<td>Intrahepatic bleeding</td>
<td>-</td>
<td>1 (5.9)</td>
<td>1 (9.1)</td>
<td>1 (4.8)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Small additional liver lobe</td>
<td>9 (33.3)</td>
<td>4 (23.5)</td>
<td>6 (54.5)</td>
<td>4 (19.0)</td>
<td>6 (25.0)</td>
<td>4 (21.1)</td>
</tr>
<tr>
<td>Fissure in liver lobe</td>
<td>-</td>
<td>2 (11.8)</td>
<td>1 (9.1)</td>
<td>-</td>
<td>-</td>
<td>1 (5.3)</td>
</tr>
<tr>
<td>Umbilical hernia</td>
<td>1 (3.7)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Kidney elongated</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1 (4.2)</td>
<td>-</td>
</tr>
<tr>
<td>Renal papilla absent bilaterally</td>
<td>-</td>
<td>1 (5.9)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Renal pelvis/ureter enlarged</td>
<td>1 (3.7)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1 (4.2)</td>
<td>3 (15.8)</td>
</tr>
<tr>
<td>Testis displaced cranially ⁴</td>
<td>1 (7.7)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1 (6.7)</td>
<td>-</td>
</tr>
<tr>
<td>Anal opening reduced in size</td>
<td>2 (7.4)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Subcutaneous oedema</td>
<td>1 (3.7)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Table 3.5 Skeletal analysis of curly tail fetuses treated in utero with myo- and D-chiro-inositol

1 A single fetus may have more than one morphological finding.
2 Values are number of fetuses with defect (% of total for treatment group).
3 Three fetuses were from the same litter, one of which exhibited exencephaly. The proportion of fetuses with anomalous cervical vertebrae does not differ significantly between fetuses treated with D-chiro-inositol (144 μg/g body weight/day) and PBS controls (Fisher exact test; \( p = 0.11 \)).
4 Proportion of fetuses with rudimentary ribs on 7th cervical vertebra does not differ significantly between fetuses treated with D-chiro-inositol (144 μg/g body weight/day) and PBS controls (Fisher exact test; \( p = 0.14 \)).
5 Both affected fetuses are from the same litter, one also exhibited with exencephaly and cervical vertebral anomalies.
A dash (–) indicates that no fetuses exhibited that finding.
Table 3.5

<table>
<thead>
<tr>
<th></th>
<th>PBS control</th>
<th>myo</th>
<th>D-chiro</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inositol dose (μg/g body weight/day)</td>
<td>72 144</td>
<td>72 144</td>
<td>72 144</td>
</tr>
<tr>
<td>No. fetuses examined</td>
<td>29 18</td>
<td>16 18</td>
<td>22 21</td>
</tr>
<tr>
<td>Exencephaly</td>
<td>-</td>
<td>-</td>
<td>2 (11.1)</td>
</tr>
<tr>
<td>Bony plaque in frontonasal suture</td>
<td>1 (3.4)</td>
<td>1 (6.3)</td>
<td>-</td>
</tr>
<tr>
<td>Anomalous cervical vertebra(e)</td>
<td>-</td>
<td>-</td>
<td>1 (5.6)^2</td>
</tr>
<tr>
<td>Rudimentary ribs on 7th cervical vertebra</td>
<td>4 (13.8)</td>
<td>2 (11.1)</td>
<td>1 (6.3)</td>
</tr>
<tr>
<td>Anomalous thoracic vertebrae and/or ribs</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Rudimentary 14th ribs</td>
<td>- 1 (5.6)</td>
<td>-</td>
<td>1 (5.6)</td>
</tr>
<tr>
<td>Sternal fusions</td>
<td>1 (3.4)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

^1: Significance level not provided.

^2: Value corrected for multiple comparisons.

^3: Includes one outlier.

^4: Includes one abnormality not specified.

^5: Includes one abnormality not specified.
3.3 DISCUSSION

This chapter describes studies to evaluate the ability of exogenous inositol to prevent spina bifida in a mouse genetic model of folate-resistant NTDs. Maternal inositol administration significantly reduced the frequency of spina bifida in curly tail mice and normalized closure of the PNP in whole cultured embryos. A striking finding was the increased potency of D-chiro- compared with myo-inositol. At identical dosage levels, subcutaneously administered D-chiro-inositol caused a consistently greater reduction in frequency of spina bifida than myo-inositol. Moreover, in vitro, D-chiro-inositol was effective in normalizing neural tube closure at a concentration at which myo-inositol had no effect.

3.3.1 Possible reasons for the greater potency of D-chiro-inositol in preventing NTDs

Previous work suggested that the protective effect of myo-inositol is mediated via the phosphoinositide cycle (Greene and Copp, 1997a). Briefly, this cycle involves hydrolysis of phosphatidylinositol diphosphate by receptor-activated phospholipase C, to generate the second messengers inositol triphosphate and diacylglycerol (DAG) (Majerus, 1992). Among the downstream events of this signalling pathway, activation of protein kinase C (PKC) by DAG appears to be critical for normalisation of neuropore closure in curly tail embryos. For instance, activation of PKC by phorbol esters mimics the effect of inositol supplementation, whereas PKC inhibitors abrogate the protective effect (Greene and Copp, 1997a).

Although the role of PKC in mediating the effect of D-chiro-inositol has not yet been investigated, one possibility is that both inositol enantiomers act through the same PKC-dependent pathway. In this case, the greater potency of D-chiro-inositol may result from
its differential incorporation and metabolism within the phosphoinositide cycle. Such increased potency of D-chiro- compared to myo-inositol has been demonstrated in other systems. Thus, insulin stimulation of rat fibroblasts expressing the human insulin receptor leads to a significant increase in the incorporation of D-chiro-inositol into phospholipids whereas the effect on myo-inositol incorporation is only marginal (Pak et al., 1993). Moreover, D-chiro-inositol induces a much larger reduction in plasma glucose level in rats rendered diabetic by streptozotocin administration compared with exogenous myo-inositol (Ortmeyer et al., 1993). These findings suggest an inherently greater potency or bioactivity of D-chiro-inositol than myo-inositol, perhaps as a result of incorporation into different phosphatidylinositol species (Pak and Larner, 1992). I suggest that the greater potency of D-chiro-inositol in preventing NTD in curly tail mice, may reflect a relatively greater production of second messengers and/or downstream stimulation of PKC by D-chiro-inositol. It is striking, however, that these differences of in vivo potency are maintained in the face of the demonstrated interconversion of the two inositol isomers. Pak et al. (1992) showed that \[^{3}\text{H}]myo\)-inositol is converted to \[^{3}\text{H}]D-chiro\)-inositol in rat tissues. Perhaps the rate of interconversion is too low to obscure the inherently greater potency of D-chiro-inositol in short-term effects on embryonic development.

### 3.3.2 Relevance of the findings for clinical application of inositol therapy

In order for these experimental findings to be translated into a clinical application, inositol supplementation must be demonstrated to be both effective in preventing NTDs and safe for use during human pregnancy. In terms of efficacy, this study has demonstrated a protective effect of inositol in a mouse NTD model, using subcutaneous
and oral routes of administration, and these findings are supported by previous work in which myo-inositol was injected intraperitoneally (Greene and Copp, 1997a). Oral dosing is most likely to be useful in humans, and further support for the effectiveness of oral supplementation with myo-inositol comes from the finding of a reduction in the incidence of diabetes-induced abnormalities in rats by oral administration of myo-inositol (Khandelwal et al., 1998). The efficacy of inositol in preventing human NTDs has not yet been tested in a clinical trial. However, in a recent case study, inositol supplementation was associated with a normal pregnancy outcome in a woman who had experienced two consecutive NTD pregnancies while taking 4 mg folic acid throughout the periconceptional period (Cavalli and Copp, 2002). The empirical recurrence risk of NTD following two previous affected fetuses is approximately 1 in 9 (Seller, 1981) so, clearly, the association of inositol therapy with normal pregnancy outcome in this case may have been a chance association. A larger study of pregnancies at risk of ‘folate-resistant’ NTDs is needed to test the idea that inositol may be effective in humans, as in mice.

With regard to the safety of inositol therapy during pregnancy, the pathological survey of fetuses from inositol-treated mice revealed no major defects, apart from NTDs, and no increase in the frequency of embryonic or fetal loss in utero. These findings are indicative of the relative safety of inositol usage during pregnancy, although direct information from use in human pregnancy is also urgently needed. In the case of the mother who took inositol in a third pregnancy, following two apparently ‘folate-resistant’ NTD pregnancies, a dose of 0.5 g inositol per day was used, with no apparent side effects for mother or baby (Cavalli and Copp, 2002). In particular, there was no evidence of abnormal uterine contractions, such as have been suggested as a possible adverse effect of inositol therapy (Limpach et al., 2000). The reproductive toxicology of D-chiro-inositol
has been the subject of several studies in both rats and rabbits at doses up to 2000 mg/kg/day. In these studies, there were no adverse effects on mating, fertility or embryo/fetal development (Dr G. Allan, Insmed Inc., personal communication). Other lines of evidence also suggest that inositol supplements may be used clinically without adverse side effects. For instance, myo-inositol has been previously tested in adults for prevention of depression, panic disorder and obsessive compulsive disorder (Belmaker et al., 1996; Atack, 1996) and in children for treatment of autism (Levine et al., 1997). No significant side effects were reported in these studies which employed relatively high inositol doses: up to 18 g per day in adults and 200 mg/kg in children. D-chiro-inositol has recently been demonstrated to increase the action of insulin in patients with polycystic ovary syndrome, thereby improving ovulatory function and decreasing serum androgen concentrations, blood pressure and plasma triglyceride concentrations (Nestler et al., 1999).
CHAPTER 4

PKC INVOLVEMENT IN NEURAL TUBE CLOSURE
4.1 Introduction

In Chapter 3, it was shown that NTDs in the curly tail mouse can be prevented by administration of not only myo-inositol but also D-chiro-inositol. This effect of inositol was previously shown to be mediated through the activity of the inositol/lipid cycle (Greene, 1997). Of particular relevance to the present studies, DAG which is produced during inositol phospholipid signalling binds to and activates PKC, and this process appears essential for the action of inositol in preventing NTDs (Greene and Copp, 1997a).

The purpose of the studies in the present chapter was to further investigate the role of PKC in mediating the protective effect of inositol. I first performed an immunohistochemical analysis to verify the relationship between PKC isoform distribution and posterior neuropore closure in the curly tail mouse. Second, the requirement for the various isoforms of PKC was investigated using chemical and peptide inhibitors of PKC in embryo culture. The specificity of the peptide inhibitors was also verified using primary cell cultures from curly tail mouse embryos.

Embryonic development requires that a wide variety of information be relayed via intracellular signalling pathways. A number of these signals are transduced into a cell through cell surface receptors, which by binding to their ligands, initiate one or more signal transduction cascades and alter the state of phosphorylation of several cellular components through the action of both kinases and phosphatases.

One of these signal transducers is protein kinase C (PKC), which functions during embryo development. The serine/threonine protein kinase C plays a major role in
transmembrane signal transduction (Mochly-Rosen and Kauvar, 2000). It is activated by diacylglycerol originated from membrane phospholipids upon cell stimulation by various ligands, i.e. hormones or growth factors (Dorn et al., 1999). The existence of a wide range of PKC isoenzymes in mammalian tissues has been shown following the first identification of PKC by Nishizuka (Nishizuka, 1988). PKC heterogeneity poses the question as to why so many isoenzymes exist, and suggests that each of them could have a specific relevance in the regulation of various cellular functions (Braun and Mochly-Rosen, 2003). Moreover, a major distinguishing feature of PKC isoforms is their distinct and selective organ and tissue distribution. Several different techniques have been used to examine the expression of PKC isoforms in post-natal and adult tissues (Nishizuka, 1988); (Wetsel et al., 1992); (Bareggi et al., 1995); (Hunter, 1995) Most of the PKC isoenzymes (α, βI, βII, δ, ε and η) have been found to be ubiquitously distributed, e.g. in brain, lung, spleen, thymus and skin, whereas PKC γ has been found in the central nervous system (Wu et al., 2000); (Harris and Juriloff, 2007c). PKC isoforms appear to be expressed at low levels during the late stages of gestation and early in the postnatal period and to increase during the first 2 to 3 weeks after birth. However, expression data for PKC during embryonic development were not available prior to day 15 of gestation, preceding the work described in this thesis.

4.1.1 Possible requirement for PKC isoforms in mediating the preventive effect of inositol

Greene and Copp (1997) found that brief treatment with TPA, a PKC activator that mimics DAG, caused a reduction in PNP length of curly tail embryos following culture. This effect of TPA was comparable to that observed following inositol supplementation. The protective effect of TPA suggested that PKC activation is crucial in preventing spinal
NTDs in *curly tail* embryos and, since only the conventional and novel PKC isoforms are DAG and TPA-responsive, this focussed attention on these classes of PKC isoforms as likely mediators of the inositol effect. Use of the PKC inhibitor Bisindolylmaleimide I (BisI; GF 109203x) provided support for this idea as addition of Bis I prior to, and during, inositol treatment reversed the protective effect of TPA on closure of PNP (Greene and Copp, 1997a). This inhibitor study indicated that the mechanism of action of inositol involves activation of PKC, and suggested, furthermore, that the critical PKC isoforms might include PKC α, β, γ and ε. These isoforms are reportedly to be selectively inhibited by Bis I at 10 μM, the concentration used by Greene and Copp (1997). To extend this analysis, the present study used a series of additional PKC inhibitors, both chemical and peptide, in order to identify the specific PKC isoforms required for the inositol effect.

### 4.1.2 PKC chemical inhibitors

The aminoalkyl bisindolylmaleimide I (Bis I; GF109203x; Go6850) is a staurosporine analogue with selective inhibitory activity against PKC (IC$_{50}$ = 10 nM). Importantly, studies of diverse effects of Bis I in intact cells provide evidence for selective recognition of cellular PKC by the inhibitor and therefore suggest the usefulness of Bis I as a probe of PKC function in cell culture. Bis I is known to inhibit cPKCs (α, βI, βII and γ) and PKC ε ((Parker and Parkinson, 2001)). Another staurosporine analogue used in this study is the indole carbazole, Godecke 6976 (Go6976) [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo (3,4-c)-carbazole] which inhibits PKC α, βI and βII. It has been found that this PKC inhibitor also inhibits DNA synthesis suggesting a pro-proliferative role for the Go6976-inhibited PKC isoforms (Iankov, 2002). Go6976 inhibition of DNA synthesis could be rescued by subsequent incubation with vehicle suggesting that the action of the inhibitor is not irreversibly toxic (Beltman et al., 1996).
Pre-incubation of cells with Go6976 leads to enhancement of IL-6-induced p44/p42 MAPK activity (Martiny-Baron et al., 1993). These findings suggest that in addition to a role in proliferation, PKC is also required for negative regulation of the MAPK pathway. Another selective PKC inhibitor used was 2,2',3,3',4,4',hexahydroxy-1,1'-biphenyl-6,6'-dimethanol dimethyl ether, (HBDDE) which inhibits PKC α and γ but not PKC βII, δ or ε (Mathur and Vallano, 2000). In order to identify a possible involvement of the atypical PKC isoform ζ, LY294002 was used at a concentration of 2 μM. At this concentration, this inhibitor also blocks the phosphatidylinositol-3-kinase pathway (Vlahos et al., 1994), something to be taken into account when analysing these results. Bisindolylmaleimide V (Bis V; an inactive analogue of GF109203X) was used as a negative control compound, as it does not inhibit PKC (Asakai et al., 2002).

4.1.3 PKC peptide inhibitors

Chemical inhibitors may be specific for sub-classes of PKC isoforms, at certain concentrations, but do not allow the role of single PKC isoforms to be evaluated. For example, the cell-permeable, inhibitor HBDDE is reported to be a selective inhibitor of PKC α and γ with IC$_{50}$ values of 43 and 50 mM, respectively, using an in vitro assay. However, data examining the potency and selectivity of HBDDE in intact cells are lacking. Moreover, the concentrations of chemical inhibitors found to block certain groups of PKC isoforms in cultured cell lines, or in cell-free systems, may not apply to biological systems, especially complex multicellular organisms such as mouse embryos. Hence, it is dangerous to assume that use of a chemical inhibitor at a particular concentration in embryo culture will block the same group of PKC isoforms as in cell culture. For this reason, the experiments with chemical inhibitors were extended by the use of peptide PKC inhibitors, which offer isoform-specificity of PKC inhibition.
4.1.3.1 Molecular basis of PKC isoform inhibition by the peptides

Receptor for Activated C-Kinase (RACK) is responsible for the binding of active forms of PKCs. There are different RACKs for different isoforms of PKC (Section 1.3.4), which thus mediate differential subcellular targeting of the isoforms. Inactive forms of PKC occlude the RACK binding site with a pseudo-RACK peptide sequence (Dorn et al., 1999). Peptides that mimic the PKC binding site on RACK proteins are able to inhibit the translocation and thus the activity of PKC. This property results from the fact that anchoring is necessary for the function of individual PKC isoforms, such that inhibition of anchoring inhibits their kinase activity. The peptide sequences bind in a competitive manner to the PKC isoform RACK binding site, blocking its translocation (Dorn et al., 1999). See Chapter 1.

4.1.3.2 Use of antennapedia pepetide to carry peptides into the cell

To facilitate transfer of peptides into the cell, they were coupled to a sequence from the homeodomain protein antennapedia. Homeoproteins are a class of transcription factors that bind DNA through a structure of 60 amino acids length, called the homeodomain. The idea that transcription factors could traverse from cell to cell results from the observed internalisation of the homeodomain of the Drosophila protein antennapedia (Joliot, 1991). The antennapedia third helix (amino acids 43-58) is necessary for translocation (Derossi et al., 1994); (Theodore et al., 1995). Therefore, to ensure penetration into the cell, peptides are bound to the antennapedia third α helix peptide, which will deliver a ‘cargo’ into the cell. Internalisation occurs at both 4°C and 37°C, implying that it does not involve classical receptor-mediated endocytosis. Derossi, 1994 has proposed a model in which the positively charged peptide interacts with negatively charged phospholipids on the outer layer of the plasma membrane. Due to the interactions
between tryptophan residues in the peptide and the lipids, the planar form of the outer phospholipid monolayer is distorted, encouraging the formation of inverted micelles, which will contain the peptide (Derossi et al., 1994).
4.2 Results

4.2.1 Specificity of PKC antibodies

The specificity of anti-PKC antibodies was first tested using sections of adult mouse cerebellum (Figure 4.1) as a positive control in which staining patterns have been previously reported. As expected, anti-PKC α, γ and ε stain only Purkinje cells, whereas anti-PKC βI and βII stain only granule cells (Figure 4.1 and Table 4.1). These results correlate with those previously described for the rat cerebellum (Bareggi et al., 1995).

4.2.2 PKC isoform expression during mouse embryogenesis

In order to identify the isoforms that might play a role in prevention of NTDs, it was imperative to determine which PKC isoforms are expressed in mouse embryos undergoing spinal neurulation (E9.5 to E10.5). A member of our laboratory performed western blot analysis, which detected expression of all PKC isoforms in whole E 9.5 and E 10.5 embryos. However, this approach was insufficiently sensitive to detect PKC isoform expression in specific embryonic regions, such as the posterior neuropore (PNP), the site of spinal neurulation. I thus performed immunohistochemical staining on histological sections throughout the PNP region. Expression of PKCs was detected in the closing neural tube, hindgut, notochord and presomitic mesoderm, at both E9.5 and E10.5 in curly tail embryos (Figure 4.2). A control was run with each experiment to test for non-specific staining of the primary antibody (Figure 4.1). In this control, affinity purified rabbit IgG from pre-immune serum (Sigma) was used instead of isozyme specific primary antibody. Additional controls received only primary antibody or secondary antibody. In all cases, the negative controls gave a complete lack of staining.
Figure 4.1 Distribution of Protein Kinase C isoforms in cerebellum

Immunohistochemistry was used to detect isoforms of protein kinase C within the adult cerebellum. Sagittal sections were immunostained for PKC α (A-B), PKC β (C-D), PKC γ (E-F). Cells in the purkinje cell layer (pcL) are immunoreactive to the antisera to PKC α (A-B) and γ, whereas cells in the granular layer (gL) are negative. In contrast, granule cells are immunoreactive to the antiserum to PKC β, whereas purkinje cells are negative (C-D). A control section that was not incubated in any primary antiserum is also shown (G). B, D and F are high magnifications of A, C and E respectively. For A, C, E and G, scale bar = 20 μm; from B, D and F, scale bar = 250 μm.
Figure 4.2 Expression of PKC isoforms during mouse spinal neurulation

Immunohistochemistry reveals ubiquitous expression of PKC isoforms during mouse spinal neurulation. Transverse sections through the posterior neuropore region of curly tail mouse embryos at E9.5 (A, C, E, G, I) and E10.5 (B, D, F, H, J) were stained with antibodies specific for PKC α, βI, βII, and γ. All PKCs exhibit ubiquitous expression in the neural plate (Np), notochord (N), hindgut (H) and presomitic mesoderm (M) of the posterior neuropore region. Scale bar represents 20 μm.
4.2.3 Evaluation of possible effects of chemical inhibitors on growth and development of cultured embryos

In order to investigate the potential role of different PKC isoforms during closure of the PNP, a series of inhibitors was applied to curly tail embryos in culture. It was important to first identify the most appropriate concentration to use for each inhibitor, so as not to cause generalised toxicity or growth retardation. Growth retardation is known to reduce the delay of closure of the PNP in curly tail embryos (Copp et al., 1988c) and it was important to determine whether PKC inhibitors alone had any effect on growth, prior to using them to investigate the protective effect of inositol. Inhibitors were first tested in a non-mutant strain, CD1, and then in curly tail embryos.

In cellular models of phosphorylation, PKC activity is inhibited with IC\textsubscript{50} values (half maximal inhibitory concentration) of 0.2 to 10 μM. For example, in an assay of vimentin phosphorylation in Swiss 3T3 cells maximal inhibition of PKC was obtained at a concentration of 2.5-5 μM Bis I, with no inhibition of cAMP-dependent PKA even at the highest concentration. Based on cell culture data, each inhibitor was used at two concentrations, as shown in Tables 4.2 and 4.3 in cultures of CD1 and curly tail embryos respectively. For each inhibitor, the lower concentration was typical of that used in cell culture. A higher concentration was also tested, in case it was necessary to overcome any decreased uptake of the inhibitor due to the intact yolk sac surrounding the embryo, as compared with cultured cells which are likely to be more accessible to cell-permeable inhibitors. At the end of the culture period, the crown rump length was measured as an indicator of growth and the number of somites was counted as a measure of developmental progression. In addition, any malformations or abnormalities were noted as these could indicate teratogenic effects of the inhibitors. The yolk sac circulation was recorded as a measure of overall health of the embryo.
4.2.3.1 Chemical inhibitors of PKC do not affect growth or developmental progression of embryos in vitro

In CD1 embryos (Table 4.1), there was no difference in mean somite number or mean CR length between PBS/DMSO controls and either low or high concentrations of BisI, or the inactive BisV. Yolk sac circulation was also unaffected and no teratogenic effects, such as irregular somites, under-developed branchial arches, enlarged pericardium or failure of embryonic turning were observed. In contrast, cultures of curly tail embryos gave a somewhat different result (Table 4.2). In cultures exposed to the lower concentration of each PKC inhibitor, all treatment groups were comparable in terms of developmental progression and growth, with no significantly difference from PBS/DMSO controls. However, at the higher PKC inhibitor concentrations, curly tail embryos showed retardation of developmental progression, as judged by a significant lower somite number at the higher concentration compared to the lower concentration for each inhibitor (p < 0.05). Despite this effect, yolk sac circulation was normal in all embryos and malformations were not observed. Moreover, while crown-rump length varied significantly between treatment groups overall (ANOVA; p< 0.05), pair-wise comparisons failed to detect significant differences between high or low concentrations of each inhibitor (after correction for multiple comparisons; Holm-Sidak method). Hence, this preliminary culture analysis reveals a greater susceptibility of mutant curly tail embryos than wild type CD1 embryos to PKC inhibitor, and indicated the need to use the lower inhibitor concentrations in subsequent curly tail culture studies.

4.2.4 Investigating the effect of chemical PKC inhibitors on PNP closure

PNP length was measured after culture as an indicator of risk of developing spina bifida. In CD1 embryos cultured in the presence of BisI for 24 hours to the 30-32 somite stage,
all the embryos had completed closure of the PNP suggesting that the inhibitors did not have a major deleterious effect.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Conc.</th>
<th>No. embryos</th>
<th>Mean somite no. ± SEM</th>
<th>Mean CR length (mm) ± SEM</th>
<th>Yolk sac circulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS/DMSO</td>
<td>_</td>
<td>10</td>
<td>31.0 ± 0.09</td>
<td>3.02 ± 0.03</td>
<td>3</td>
</tr>
<tr>
<td>Inositol</td>
<td>50 µg/ml</td>
<td>10</td>
<td>31.6 ± 0.20</td>
<td>3.19 ± 0.11</td>
<td>3</td>
</tr>
<tr>
<td>BisI</td>
<td>10 µM</td>
<td>10</td>
<td>30.3 ± 0.11</td>
<td>3.37 ± 0.09</td>
<td>2.9</td>
</tr>
<tr>
<td>BisI</td>
<td>30 µM</td>
<td>10</td>
<td>31.2 ± 0.32</td>
<td>2.97 ± 0.12</td>
<td>3</td>
</tr>
<tr>
<td>BisV³</td>
<td>10 µM</td>
<td>10</td>
<td>31.6 ± 0.10</td>
<td>2.90 ± 0.21</td>
<td>2.8</td>
</tr>
<tr>
<td>BisV</td>
<td>30 µM</td>
<td>10</td>
<td>30.3 ± 0.08</td>
<td>3.42 ± 0.13</td>
<td>2.9</td>
</tr>
</tbody>
</table>

Table 4.1 CD1 embryos cultured for 24 hours from E9.5 to E10.5 in the presence of the PKC chemical inhibitor BisI

PKC inhibitors were diluted in DMSO and further diluted in PBS. A DMSO-PBS solution was used as a control. Inhibitors do not adversely affect developmental progression or growth in CD1 embryos after 24 hr in vitro culture.

1 No significant difference in somite number by analysis of variance between treatments, P > 0.05
2 No significant difference in crown rump (CR) length by analysis of variance between treatments, P > 0.05
3 BisV is an inactive variant of BisI
Table 4.2 Curly tail embryos cultured for 24 hours from E 9.5 to E 10.5 in the presence of PKC chemical inhibitors

One way ANOVA shows significant difference in somite number. Pairwise multiple comparisons by the Holm-Sidak method show that for each inhibitor the higher dose tested caused a significant reduction in somite number compared to the PBS/DMSO control and to the lower dose of the same inhibitor, (p< 0.001). There was no significant difference in somite number between PBS/DMSO control and lower dose of any inhibitor.

One way ANOVA (p<0.017) shows significant variation overall in crown rump length. However, pairwise multiple comparisons by the Holm-Sidak method show that for each inhibitor there is no difference between high and low concentration of each inhibitor, nor between high inhibitor dose and PBS/DMSO control.
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Conc.</th>
<th>No. embryos</th>
<th>Mean somite no. ± SEM</th>
<th>Mean CR length (mm) ± SEM</th>
<th>Yolk sac circulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS/DMSO</td>
<td>_</td>
<td>10</td>
<td>30.09 ± 0.06</td>
<td>3.04 ± 0.07</td>
<td>2.9</td>
</tr>
<tr>
<td>BisI</td>
<td>10 μM</td>
<td>10</td>
<td>30.3 ± 0.15</td>
<td>3.56 ± 0.10</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>30 μM</td>
<td>10</td>
<td>23.2 ± 0.70</td>
<td>2.50 ± 0.50</td>
<td>3</td>
</tr>
<tr>
<td>BisV</td>
<td>10 μM</td>
<td>10</td>
<td>30.6 ± 0.13</td>
<td>3.50 ± 0.10</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>30 μM</td>
<td>10</td>
<td>25.5 ± 0.55</td>
<td>1.80 ± 0.64</td>
<td>2.8</td>
</tr>
<tr>
<td>Go6976</td>
<td>10 μM</td>
<td>10</td>
<td>30.5 ± 0.13</td>
<td>3.39 ± 0.10</td>
<td>2.9</td>
</tr>
<tr>
<td></td>
<td>30 μM</td>
<td>10</td>
<td>22.3 ± 0.82</td>
<td>2.00 ± 0.21</td>
<td>2.7</td>
</tr>
<tr>
<td>HBDDE</td>
<td>50 mM</td>
<td>10</td>
<td>30.6 ± 0.16</td>
<td>3.55 ± 0.10</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>150 mM</td>
<td>10</td>
<td>25.8 ± 0.54</td>
<td>2.70 ± 0.80</td>
<td>2.8</td>
</tr>
<tr>
<td>LY294002</td>
<td>1.4 μM</td>
<td>10</td>
<td>30.3 ± 0.16</td>
<td>3.49 ± 0.08</td>
<td>2.8</td>
</tr>
<tr>
<td></td>
<td>42 μM</td>
<td>10</td>
<td>24.6 ± 0.67</td>
<td>2.60 ± 0.76</td>
<td>3</td>
</tr>
</tbody>
</table>
Curly tail embryos were exposed to each inhibitor alone to determine whether there was an effect on PNP closure. Embryos were also treated with inhibitor and inositol to determine whether suppressing PKC activity reduced the effect of inositol. The mean PNP length of embryos exposed to PBS alone was 0.6 mm (Figure 4.3A), reflecting the in vivo situation in which curly tail embryos exhibit delayed closure of the PNP, leading to development of NTDs or tail flexion defects in 60% of embryos (Van Straaten and Copp, 2001). When added alone, none of the inhibitors significantly altered PNP length in cultured curly tail embryos after twenty four hours (p> 0.05; yellow bars, Figure 4.3). Treatment of curly tail embryos with 50 µg/ml of myo-inositol (first red bar, Figure 4.3) resulted in a significant decrease in PNP length after culture, to a mean value of 0.08 mm, which is characteristic of normally developing embryos. Thus, as demonstrated in Chapter 3, inositol normalises PNP closure in vitro as well as in vivo.

PNP length in the presence of inositol plus inhibitor was 60-90% of that in the presence of inhibitor alone (blue bars, Figure 4.3). Embryos cultured in the presence of inositol and Bis I, exhibit a PNP length that is significantly larger than the PNP length of embryos cultured in the presence of inositol alone, suggesting that the protective effect has been blocked. Similarly when embryos were cultured in the presence of Go6976 and inositol or in HBDDE and inositol, the PNP length of embryos after cultured was significantly larger than the embryos cultured in the presence of inositol alone. In the case of LY294002 the effect of inositol was partially blocked suggesting a role for PKCζ and/or PI3-kinase. In contrast, the inactive analogue BisV did not prevent the reduction in PNP length caused by co-administration of inositol (second red bar in Figure 4.3). Therefore, the use of chemical inhibitors highlights the potential importance of PKCα, β, γ, ε and ζ (i.e. those isoforms acted upon by the chemical inhibitor) in mediating the effect of inositol although
the chemical inhibitors do not give sufficient specificity to narrow down the effect to individual isoforms.

**Figure 4.3 Normalization of spinal neural tube closure by inositol in curly tail embryos is abrogated by inhibition of specific PKC isoforms.**

Chemical inhibitors of PKC were applied to curly tail mouse embryos cultured from E9.5 for 24 h, and the posterior neuropore (PNP) length was measured as an indicator of predisposition to spinal NTD. Yellow bars: PNP length of embryos exposed to PKC inhibitors in the absence of inositol; red bars: PNP length of embryos exposed to PKC inhibitors in the presence of inositol; blue bars: PNP length in the presence of PKC inhibitor plus inositol as a % of the value in the presence of PKC inhibitor alone (right axis). Inositol significantly reduces PNP length in the absence of inhibitor (PBS;
and in the presence of inactive BisV ($P<0.002$), whereas the inositol effect is abrogated in the presence of chemical inhibitors BisI, Go6976, HBDDE and LY294002 ($P>0.05$).

4.2.5 Use of peptide inhibitors to identify the specific PKC isoforms required for protection of PNP closure by inositol.

The use of chemical inhibitors of PKC provided an indication of which PKC isoforms may be required for prevention of NTDs by inositol but did not permit individual isoforms to be implicated. For this reason I decided to make use of peptide inhibitors which prevent translocation, and therefore activation, of specific PKC isoforms (Ron and Mochly-Rosen, 1995), (Johnson et al., 1996). Curly tail embryos were cultured in the presence of the different isoform-specific peptide PKC inhibitors for 24 hours, from E9.5 to E10.5.

A series of isoform-specific peptides were used in addition to a general cPKC peptide inhibitor and a control inactive peptide. No differences in growth or development progression, as indicated by crown-rump length and number of somites, were detected between treatment groups (Table 4.4). Moreover, no teratogenic effects were observed. These data suggest that any effect on PNP closure results from specific inhibition of PKC as opposed to generalised toxicity of inhibitors. As shown in Chapter 3, embryos cultured in the presence of inositol show a significant reduction in PNP length compared with PBS treated controls and this effect of inositol was maintained in the presence of specific inhibitors for PKCα, βII, δ, and ε, as well as the inactive peptide used as a negative control (Figure 4.4). In contrast, when inositol was added in the presence of inhibitors specific for PKCβI, γ or ζ the therapeutic effect of inositol was largely abolished (red bars in Figure 4.6). Mean PNP lengths were 74%, 81% and 56% respectively of the values
observed in the absence of inositol (blue bars in Figure 4.4). These findings correlate well with the results of the chemical inhibitor study, and indicate the need for βI and γ among the conventional PKCs, and additionally PKCζ among the atypical PKCs, in order for inositol to mediate its enhancing effect on PNP closure in curly tail embryos.

4.2.6 Evaluation of peptide inhibitors of PKC in cultured cells

At the outset of this experiment the efficacy of isoform-specific PKC inhibitory peptides had not been verified in embryonic mouse cells. In order to check the effect of the peptide inhibitors on PKC activity, I generated primary fibroblastic cell lines from curly tail embryos and used antibody staining to localise PKC isoforms following addition of the DAG analogue TPA to activate PKC.

After culture of primary fibroblasts in medium containing 1% fetal calf serum, immunohistochemistry showed that PKC α, βI, βII, γ and ε were all localised in a diffuse pattern throughout the cytoplasm (Figure 4.4). A parallel set of cultures was treated with TPA, and in each case PKC was seen to have translocated the nucleus (Figure 4.4). Another set of cultures was treated with TPA and one of the isoform-specific peptide inhibitors. Staining for the corresponding PKC isoform showed that the presence of inhibitor prevented translocation of that isoform to the nucleus (Figure 4.4).
Table 4.3 Development of *curly tail* embryos following culture from E 9.5 to E10.5 in the presence of inositol and/or PKC peptide inhibitors

1No significant difference in somite number by analysis of variance between treatments, $P > 0.05$

2No significant difference in crown rump (CR) length by analysis of variance between treatments, $P > 0.05$
<table>
<thead>
<tr>
<th></th>
<th>Number of embryos</th>
<th>Mean somite number ± SEM&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Mean CR length (mm) ± SEM&lt;sup&gt;2&lt;/sup&gt;</th>
<th>Yolk sac circulation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+ PBS</td>
<td>+ PBS</td>
<td>+ PBS</td>
<td>+ PBS</td>
</tr>
<tr>
<td>No inhibitor</td>
<td>10 10</td>
<td>31.7 ± 0.05 30.5 ± 0.10</td>
<td>3.5 ± 0.21 4.45 ± 0.01</td>
<td>2.8 3</td>
</tr>
<tr>
<td>cPKC</td>
<td>10 10</td>
<td>30.4 ± 0.11 31.2 ± 0.8</td>
<td>3.6 ± 0.09 3.60 ± 0.33</td>
<td>2.7 2.7</td>
</tr>
<tr>
<td>Control-peptide</td>
<td>10 10</td>
<td>31.2 ± 0.49 30.8 ± 0.19</td>
<td>3.5 ± 0.72 3.8 ± 0.22</td>
<td>2.8 3</td>
</tr>
<tr>
<td>PKC α</td>
<td>10 10</td>
<td>31.7 ± 0.05 30.2 ± 0.12</td>
<td>3.8 ± 0.09 3.93 ± 0.10</td>
<td>3 2.8</td>
</tr>
<tr>
<td>PKC βI</td>
<td>10 10</td>
<td>30.5 ± 0.02 31.6 ± 0.81</td>
<td>3.9 ± 0.73 3.44 ± 0.32</td>
<td>2.9 3</td>
</tr>
<tr>
<td>PKC βII</td>
<td>10 10</td>
<td>30.3 ± 0.10 30.2 ± 0.15</td>
<td>3.5 ± 0.09 3.52 ± 0.19</td>
<td>3 2.8</td>
</tr>
<tr>
<td>PKC γ</td>
<td>10 10</td>
<td>30.8 ± 0.21 31.5 ± 0.73</td>
<td>3.9 ± 0.74 3.6 ± 0.41</td>
<td>3 3</td>
</tr>
<tr>
<td>PKC ε</td>
<td>10 10</td>
<td>31.7 ± 0.30 31.1 ± 0.10</td>
<td>3.7 ± 0.68 3.8 ± 0.65</td>
<td>3 2.7</td>
</tr>
<tr>
<td>PKC δ</td>
<td>10 10</td>
<td>30.5 ± 0.08 30.8 ± 0.66</td>
<td>3.7 ± 0.55 3.45 ± 0.34</td>
<td>2.8 2.9</td>
</tr>
<tr>
<td>PKC ζ</td>
<td>10 10</td>
<td>31.1 ± 0.05 31.6 ± 0.25</td>
<td>3.5 ± 0.43 4.3 ± 0.09</td>
<td>2.9 3</td>
</tr>
</tbody>
</table>
Figure 4.4 Inhibition of specific PKC isoforms in cultured curly tail embryos – effect on PNP length

Peptide inhibitors of PKC were applied to curly tail mouse embryos cultured from E9.5 for 24 h, and the posterior neuropore (PNP) length was measured as an indicator of predisposition to spinal NTDs. Yellow bars: PNP length of embryos exposed to PKC inhibitors in the absence of inositol; red bars: PNP length of embryos exposed to PKC inhibitors in the presence of inositol; blue bars: PNP length in the presence of PKC inhibitor plus inositol as a % of the value in the presence of PKC inhibitor alone (right axis). Normalization of spinal neural tube closure by inositol in curly tail embryos is abrogated by inhibition of specific PKC isoforms. Inositol significantly reduces PNP length in the absence of inhibitor (PBS; $P<0.001$) and in the presence of inactive peptide (Pept) or peptide inhibitors to PKC α, βII, δ ($P<0.005$) and ε ($P<0.05$), whereas the inositol effect is abrogated by inhibitors to PKCβI, γ and ζ ($P>0.05$). There is no effect on PNP length of either chemical or peptide inhibitors in the absence of inositol (analysis of variance, $P>0.05$).
Treatment Groups

-- % Control --

-- No Inositol --

-- Plus Inositol --

% PNP length of control (no inositol)

Posterior neuropore length (mm ± SEM)

Figure 4.4
Figure 4.5 Inhibition of PKC isoform translocation

Isoform-specific antibodies were used to detect PKC isoforms (as in Figure 4.1 and 4.2) in *curly tail* primary embryonic cell cultures. Cells cultured for 18 h in growth medium containing 1% FCS were either fixed with no additional treatment ('serum starved'; A, D, G, J, M), exposed to 100 μM TPA for 10 min prior to fixation (+TPA; B, E, H, K, N), or exposed to 1 mM isoform-specific PKC inhibitor for 20 min and to TPA for 10 min prior to fixation (TPA+Inhib; C, F, I, L, O). PKCs are uniformly located in the cytoplasm of serum starved cells whereas a 10 min treatment with TPA induces translocation to the nucleus in all cases. Pre-treatment with isoform-specific PKC inhibitors prevents TPA-induced translocation and all PKC isoforms exhibit cytoplasmic staining. Inset in (O) shows same field stained with DAPI to demonstrate nuclei. Scale bar represents 20 μm.
4.2.7 Specificity of inhibitors for PKC βI and βII

Due to the close relationship between PKC βI and its alternatively spliced variant PKC βII, I decided to test whether abrogation of the inositol effect by the PKC βI inhibitor might have resulted from antagonism of both PKC βI and βII activation. Therefore, cells were exposed to TPA in culture and the effect on both βI and βII inhibitors were determined by immunohistochemistry. PKC βI translocated to the nucleus following TPA stimulation, and this translocation to the nucleus was blocked by the βI inhibitor, but not by the βII inhibitor (Figure 4.5 A–C). Conversely, translocation of PKC βII was blocked by the βII inhibitor but not the βI inhibitor (Figure 4.5 D–F). This finding confirms that the peptide inhibitors of PKC βI and βII are isoform-specific and suggests separate roles for these splice variants in the protective effect of inositol in curly tail PNP closure. This finding strongly suggests that the requirement for specific PKC isoforms is unlikely to reflect differential activity of the peptide inhibitors, but may reflect a difference in participation of PKC isoforms in the action of inositol in preventing mouse NTDs. Figure 4.5 also shows that inositol induces translocation of PKC α to the nucleus, demonstrating that apart from the essential isoforms (βI and γ) other isoforms may be activated following inositol treatment. However, their activity is not essential for the prevention of NTDs.
Figure 4.6 Inhibitors of PKCβI and βII exhibit isoform-specificity

Inositol stimulates PKC translocation, whereas peptide inhibitors to PKCβI and βII exhibit isoform-specificity in blocking translocation. PKC isoforms were localized by immunocytochemistry on primary cell cultures established from curly tail mouse embryos. Serum starved cells exhibit PKCβI and βII immunoreactivity in the cytoplasm. TPA-induced translocation to the nucleus of PKCβI can be blocked by the βI inhibitor (C) but not by the βII inhibitor (B). Conversely, translocation to the nucleus of PKCβII can be blocked by the inhibitor to βII (E) but not by the inhibitor to βI (F). Addition of 50 μg/ml myo-inositol to serum starved cells 6 h prior to fixation induces translocation of PKCα to the nucleus (H) whereas PKCα is cytoplasmic in untreated cells (G). This effect of inositol is not unique to curly tail cells as similar results were obtained in 3T3 cells. Scale bar represents 20 μm.
Figure 4.6

serum +TPA + TPA
starved + βII inhib. + βI inhib.

βI

D
E
F

serum starved + Inositol

βII

G
H

α

147
4.3 Discussion

4.3.1 Distribution of PKC isoforms

This *Chapter* demonstrates that several different isoforms of PKC are present in *curly tail* embryos, during the process of neurulation. The PKC isoforms α, βI, βII and γ were detected by immunohistochemistry and all other known isoforms have been detected by western blot (Cogram et al., 2004a). Together these results show that the neurulation stage mouse embryo contains representatives from all three categories of PKCs, the conventional, atypical and novel forms. These three categories of PKC isoforms have different requirements for activation of the kinase and are enriched in different subcellular localizations in a developmental stage specific fashion (Dorn et al., 1999). This presents the possibility that different isoforms of PKC are differentially activated and involved in different events during embryonic development. The detection of all PKC isoforms from E9.5 to E17.5 is in agreement with previous analysis of PKCs in E15–17 fetuses (Dorn et al., 1999). However, my results contrast with a study of E10.5 embryos that detected PKC α, and γ, but not ζ and βII ((Dorn et al., 1999)). This difference may reflect the previously reported low abundance of cPKCs on western blot (Dorn et al., 1999), whereas in the present study all isoforms were clearly detectable in the PNP region by immunohistochemistry.

The published observations that individual isoforms are found in different sub cellular compartments suggest that they are regulated differently (Courage, 1995); (Dorn et al., 1999). For instance, cPKCs are confined to the cytoplasm, suggesting minimal activation during undisturbed development. This finding is consistent with a role for the cPKCs γ and βI, in mediating the preventive effect of inositol, since activation of these isoforms may be limited in the absence of inositol, providing capacity for activation after treatment.
The results presented in this chapter demonstrate that activation of PKC by inositol treatment of curly tail embryos in vitro has a protective effect on closure of the PNP which like inositol supplementation would in vivo lead to reduction in spinal NTDs. This suggests a possible mechanism for the prevention of spinal NTDs by inositol supplementation in which there is increase in flux through the inositol/lipid cycle leading to activation of PKC.

Abrogation of the protective effect of inositol by Bis I, a broad spectrum chemical inhibitor of PKCs strongly suggests that the activity of one or more of the classical PKC isoforms is indispensable for normalisation of neural tube closure. Moreover, the chemical inhibitors Go 6976 and HBDDE also inhibited the inositol effect arguing for the requirement for specific PKC isoforms. The high degree of specificity of the inhibitor Bis I for PKC (Toullec et al., 1991) shows that the effect of inositol (or TPA) on closure of PNP is due to activation of PKC rather than activation of another enzyme. The inhibitor studies also suggest that the mechanism of action of inositol (or TPA) involves activation of PKC rather than secondary negative feedback caused by depletion of PKC as in conditions of sustained treatment (Heidenreich et al., 1993). In the later case, the inhibitor would be expected to mimic the effect of TPA since both inhibition and depletion resulting from chronic TPA treatment reduces cellular PKC activity. Subsequent exposure of embryos to inhibitors of individual isoforms indicates a requirement for PKC βI, γ and possibly ζ in prevention of spinal NTDs by inositol.

In this study use was made of the fact that phorbol esters such as 12-O-tetradecanoyl-phorbol-13-acetate (TPA) can substitute for DAG in activation of PKC, by binding to the same region of the C1 structural motif (Section 1.5.5). Unlike DAG which is rapidly metabolised, TPA is metabolically stable and can thus cause sustained activation of PKC.
PKC activation is probably responsible for the tumor promoting activity of phorbol esters which disturb both proliferation and differentiation events. Prolonged activation of PKC by TPA causes alterations in enzyme activity, in addition to those elicited by transient generation of DAG. Extended exposure to TPA initiates degradation of activated membrane-associated PKC by proteolytic cleavage which leads to depletion of cellular PKC (Nishizuka, 1988). TPA thus has a dual action on PKC, with transient positive activation followed by negative regulation owing to degradation of the enzyme. This complex regulation must be considered when interpreting the effects of TPA treatment on mouse embryos.

4.3.2 Differential requirement for PKC \( \beta I \) and \( \beta II \)

The two most closely related isoforms, PKC \( \beta I \) and \( \beta II \), are distinct but highly homologous with 96% identity at the amino acid level. They are identical for the first 621 amino acids and differ only in their carboxy-terminal 50-52 amino acids, in which they are 45% homologous (Chapter 1, Figure 1.3). The PKC\( \beta \) gene, and its products \( \beta I \) and \( \beta II \) have well defined structural differences between the two isoforms which presumably account for the isoform specific functions. For example, PKC \( \beta II \) has been found as an actin-binding protein that translocates to the actin cytoskeleton in cells, while antibodies to PKC \( \beta II \), but not to PKC \( \beta I \), co-immunoprecipitate actin, (Blobe et al., 1996)). Thus, \( \beta II \) can be distinguished from \( \beta I \) through its interaction with F-actin, perhaps suggesting that the protective effect of inositol in curly tail embryos is not due to an effect of PKC on actin function.

Another important difference between the two isoforms comes from a difference in carboxy terminal phosphorylation, which has been indicated in regulating their function and sub-cellular localization. Biochemical and immunolocalization studies of
phosphorylation site mutant proteins reveal that negative charge at this position is require for cytosolic localization of PKC and phorbol ester dependent translocation (Mochly-Rosen and Kauvar, 2000). PKC βI is phosphorylated at T642 whereas PKC βII is phosphorylated at T646, which may contribute to difference in function and localization of the two isoforms (Banan et al., 2004).

Interestingly it has been shown previously that βI and βII play a very important role in cell proliferation but at distinct check points during the cell cycle. PKC βI appears to play a role in control of G1-S progression while βII is implicated in the G2/M transition. The differential role of PKC β isoforms in cell cycle regulation is notable as the underlying defect in curly tail embryos involves a cell proliferation defect (see Chapter 6)

4.3.3 Requirement for conventional and atypical PKCs

It was previously reported that treatment of curly tail embryos with phorbol ester, which acts as a DAG analogue, can mimic the effect of inositol (Greene and Copp, 1997a). This action was proposed to be mediated through activation of conventional or novel PKC isoforms as atypical isoforms are not DAG-responsive. Recent evidence suggests that in some cell types phorbol ester treatment also leads to activation of PI3-kinase and PKCζ (Kim et al., 2001). The data in the present study do indeed suggest some requirement for atypical PKCs, as also indicated by the ability of LY294002 and the PKCζ inhibitor to abrogate the effect of inositol in this study.

It is possible that the PKC ζ isoform could augment the effect of PKC βI and PKC γ on neural tube closure, either through activation of PDK-1 or phosphorylation of additional substrates.
The phosphoinositide cycle involving diacylglycerol and PKC\(\zeta\) is activated downstream of PI3-kinase (Standaert et al., 1997); (Kim et al., 2001). PKC\(\zeta\) may phosphorylate substrates that are directly involved in normalisation of neural tube closure or alternatively could play an indirect role through phosphorylation and regulation of other PKC isoforms (Ziegler et al., 1999). Two obvious possibilities could explain the reduction in inositol efficacy following inhibition of PI3-kinase. First, the effect could be simply due to reduced activation of PKC\(\zeta\) as described for the specific PKC\(\zeta\) inhibitor. Second, activity of all groups of PKCs, like other members of the AGC kinase family, depends on phosphorylation of the T-loop in the kinase domain (Parekh et al., 2000). This phosphorylation is catalysed by 3-phosphoinositide-dependent protein kinase-1 (PDK1) (Chou et al., 1998), (Dutil et al., 1998), in a reaction that, as the name suggests, requires activity of PI3-kinase. PDK1 provides a functional link between activity of PI3-kinase and regulation of PKC signalling that could explain how inhibition of PI3-kinase reduces the magnitude of the PKC-dependent response to inositol in curly tail embryos.

4.3.4 Requirement for PKC isoforms during neural tube closure

The results in this chapter show that PKC isoforms are required for prevention of curly tail NTDs by inositol. However, in the absence of inositol, inhibition of PKC either by chemical or peptide inhibitors did not worsen the delay in PNP closure in cultured embryos. Nor did it have any adverse effect on neural tube closure in wild type embryos. Thus, it appears that inositol stimulates a novel action of PKC as opposed to an underlying function of PKC in normal neural tube closure. This hypothesis is supported by the lack of an NTD phenotype in null mutant mice for any of the PKC isoforms that are essential for prevention of NTDs. PKC\(\gamma\) null mice exhibit mild defects in learning tasks associated with function of the hippocampus (Abeliovich et al., 1993b), while PKC
β null mice display low alcohol tolerance but no apparent developmental disturbance (Harris et al., 1995). However, as compound mutant mice for these PKC isoforms have not been generated it remains possible that inhibition of both PKC β and γ in the same embryo might have detrimental effects on neurulation.

4.3.5 Which proteins are downstream of PKC activation?

The link between PKC activity and correction of PNP closure in curly tail embryos presumably involves phosphorylation of one or more target proteins. There are a number of potentially important PKC substrates that are proteins with direct cellular activity or transcription factors that regulate expression of further downstream proteins. Roles for PKC have been proposed in regulation of a variety of cellular processes including function of membrane proteins, cell cycle control and transcription of various genes (reviewed by (Nishizuka, 1986); (Hug and Sarre, 1993).

The major PKC substrate myristoylated alanine-rich C kinase (MARCKS) may be of particular interest in relation to neural tube closure as the null mutant mouse displays excencephaly (Blackshear et al., 1996b); (Chen et al., 1996). Moreover, knockout of a MARCKS family protein, known as MARCKS-related protein (MacMARCKS or F52) also causes NTDs, inducing both spina bifida and excencephaly (Arbuzova et al., 2002). In future work the identification of substrates for specific PKC isoforms might contribute towards understanding the function of PKC in prevention of NTDs by inositol.
CHAPTER 5
INOSITOL AND CELL PROLIFERATION
5.1 INTRODUCTION

5.1.1 Analysis of proliferation in the posterior neuropore region of developing *curly tail* embryos

As described in *Chapter 1*, NTDs in *ct/ct* embryos are associated with delay and failure of posterior neuropore (PNP) closure between the 24- and 32-somite stages (Copp, 1985; van Straaten et al. 1992). Copp et al. (1988) analysed cell proliferation in the developing caudal region of *ct/ct* embryos and observed decreased cell proliferation in the hindgut endoderm and notochord of embryos with severely enlarged PNP compared to those with normal or near-normal phenotypes. In contrast, neuroepithelial cell proliferation was the same in both groups. Recently, Ting et al (2003) also demonstrated reduced proliferation around the hindgut in embryos lacking *Grhl3* expression, a strong candidate for the *ct* gene. It is proposed that the resulting proliferation imbalance between dorsal and ventral tissues causes increased ventral curvature of the caudal region as the normal neuroepithelium is tethered via extracellular matrix to the underlying defective notochord and gut endoderm. Indeed, enhanced axial curvature was observed in affected *ct/ct* embryos in association with delayed PNP closure and spina bifida development (Brook et al., 1991b).

Further support for the general role of axial curvature in regulating neurulation comes from experiments in which the angle of axial curvature of the chick embryo was experimentally altered by culturing the embryo on curved (either concave or convex) substrates in vitro (van Straaten et al., 1992). Either increasing or decreasing the curvature led to delay in PNP closure and there was a direct correlation between the extent of delay and the degree of curvature. Thus, it seems possible to conclude that excessive curvature, both convex and concave, can oppose neurulation movements in vertebrate embryos. Any factor that alters the angle of curvature can be expected, therefore, to affect the rate of progression of neural fold closure.
It has been proposed that the NTDs in *curly tail* result from reduced expression of *Grhl3* (Auden et al., 2006). Thus, if reduced proliferation is indeed responsible for the failure of PNP closure in *curly tail* embryos it would also be predicted to be present in *Grhl3* mutant embryos. Indeed, when *in vivo* bromodeoxyuridine (BrdU) incorporation was used to examine cellular proliferation in the caudal regions of *Grhl3*\(^{+/+}\) and *Grhl3*\(^{+-}\) embryos, Ting et al. (2003) found that *Grhl3*\(^{+-}\) embryos at the 21-25-somite stage exhibited a consistent reduction in the number of proliferating cells in the ventral, but not the dorsal, half of this region, compared to wild-type controls. This reduction in BrdU incorporation was particularly evident around the hindgut endoderm, comparable to the findings in the *ct/ct* mice.

Two additional studies have detected abnormalities that may be related to proliferation defects in a subset of *ct/ct* embryos prior to the phenotypic divergence of embryos with normal and enlarged posterior neuropores (21-25-somite stages). Peeters et al. (Peeters et al., 1998) reported a greater proportion of S-phase nuclei in dorsal compared to ventral tissues of the caudal region, and Gofflot et al. (Gofflot et al., 1998) reported reduced expression of *Wnt5a*, a cell proliferation-related gene (Christian et al., 1991), in ventral mesoderm.

### 5.1.2 Protein Kinase C: a possible role in regulation of cell proliferation

A key outstanding question regarding the mechanism of action of inositol relates to whether the underlying proliferation defect is corrected, or whether inositol enhances closure through an alternative mechanism. Activation of PKC by TPA treatment of *curly tail* embryos *in vitro* has a protective effect on closure of the PNP which, like inositol supplementation, would lead to a reduction in frequency of spinal NTDs (Greene and Copp, 1997b). This suggests a possible mechanism for the prevention of spinal NTDs by inositol supplementation in which there is increased flux through the inositol/lipid cycle.
leading to production of diacylglycerol (DAG) and activation of PKC. Moreover, the influence of PKC inhibitors in reversing the protective effect of inositol on closure of the PNP in curly tail embryos provides support for this idea (Chapter 4).

In several studies, PKC activity has been associated with regulation of cellular proliferation, suggesting that there could be a direct effect of inositol and PKC on the underlying cell proliferation defect in curly tail embryos. Effects of different isoforms on cell growth have been investigated by stable over-expression of individual PKC isoforms or through the use of PKC agonists that differentially activate specific members of the PKC family. Emerging evidence increasingly points to roles for PKCα, δ and ι in negative growth regulation and/or differentiation (Nakashima, 2002), and for PKC β, γ, and ε in positive control of cell growth (Yamamoto et al., 1998). Interestingly, different isoforms may have opposing effects in the same cell type. For example, over-expression of PKC β1 in the R6 rat embryo fibroblast cell line resulted in enhanced growth (Suzuma et al., 2002), while over-expression of PKC α led to a marked inhibition of cell growth (Nakashima, 2002). It should also be emphasized that the actions of individual isoforms appear to be highly dependent on cellular background, and may differ between biological systems. For example, while over-expression of PKC β1 in fibroblasts resulted in enhanced growth (Kuo et al., 1990), increased levels of this isoform in colon adenocarcinoma cells produced growth arrest and reduced tumorigenicity in nude mice (Yamamoto et al., 1998). Taken together, these findings suggest that the varying growth regulatory effects of PKC agonists in different systems may be the result of differential activation of individual members of the PKC family.

A full understanding of the function of PKC isoforms in control of the cell cycle under normal and pathological conditions requires clarification of the specific actions of these
molecules on cell cycle progression and on individual components of the cell cycle machinery. This is an emerging field and our current understanding of the molecular pathways is limited. However, accumulating evidence points to a role for member(s) of the PKC family in control of cell cycle progression at two sites: the G1 to S and the G2 to M transitions (Kampfer et al., 2001);(Thompson and Fields, 1996);(Yamamoto et al., 1998).

The aim of this chapter was to determine whether the protective effect of inositol on PNP closure in ct/cf embryos was mediated through correction of the proliferation defect in the hindgut endoderm.
5.2 RESULTS

*Curly tail* embryos were cultured in the presence of inositol, or PBS as a vehicle control, for 24 hours from E9.5, the period during which the neural tube is closing in the low spinal region of the mouse embryo. After culture, the extra-embryonic membranes were dissected away and each embryo was observed directly under a dissecting microscope. Crown-rump length and PNP length were measured and number of somites was noted. Any embryo which fell outside the 27-29 somite range was excluded. After the measurements were made, the embryo was cut into two parts at the level between somites 13 and 14. The rostral half was discarded and transverse histological sections of the posterior half were used to examine the neuroepithelium, notochord and hindgut endoderm by immunostaining to allow labelling indices to be determined in order to quantitate regional cell proliferation.

The population of dividing cells in the *curly tail* PNP was investigated in two ways: by immunostaining (i) for proliferating cell nuclear antigen (PCNA) and (ii) for phospho-histone H3. PCNA is expressed by proliferating cells and has a longer half-life than phospho-histone H3. Expression of PCNA is maintained through G1 and S phases of the cell cycle, labelling those cells about to enter or within the DNA synthetic phase. In contrast, phospho-histone H3 is detected only in cells that are currently in M-phase of the cell cycle.

5.2.1 PCNA analysis

PCNA-positive and total nuclei (visualised by DAPI staining) were counted within neural tube, notochord and gut endoderm at X 60 magnification (Fig. 5.1). The fraction of proliferating cells, as revealed by the proportion of cells in G1/S-phase, was calculated as the number of PCNA positive cells within a specific domain divided by the total number
of cells within the same domain. PNP length was determined by counting the number of
serial sections between the first section with a clearly differentiated neural plate and the
first section to show contact of the neural folds in the dorsal midline.

Figure 5.1 PCNA immunostaining in curly tail embryos after 24 hours culture from
E8.5 to E9.5. A, B: immunohistochemistry for PCNA on transverse sections of caudal
embryonic regions. Intensively green stained nuclei are those in S to G1 phase of the cell
cycle. Section A is through the caudal part of the PNP, whereas section B is nearer the
point of neural fold fusion C, D: DAPI staining, which labels all nuclei. Scale bar: 250
μm

Cell proliferation, is most rapid in neuroepithelium, less intense in hindgut endoderm and
slowest in notochord (Fig. 5.2), as described previously (Copp et al., 1988c). No
difference in PCNA labelling index, between inositol-treated and PBS-treated embryos
was detected in the neuroepithelium or notochord. However, there was a significant
increase in PCNA labelling index in the hindgut of inositol-treated embryos.
Figure 5.2 Inositol stimulates hindgut cell proliferation during NTD prevention. Cell proliferation was measured by PCNA labelling in tissues of the PNP region of cultured curly tail embryos a measure of cells in S-phase. Inositol significantly increased PCNA labelling index in the hindgut (P<0.005), whereas inositol has no significant effect on PCNA labelling in either neuroepithelium or notochord. Labelling index values are mean ± SEM of at least 10 embryos per treatment.

5.2.2 Phospho-histone 3 analysis

As an independent measure of cell proliferation marker, I also used phospho-histone H3 immunostaining in order to assess the proportion of cells in M-phase in the neuroepithelium, notochord and hindgut endoderm. Only a few cells were found to be labelled on each section (Fig. 5.3), in contrast to PCNA staining, reflecting the smaller proportion of cells in M-phase compared to G1/S phase.
Figure 5.3 Phospho-histone H3-labelling in the PNP region of curly tail embryos after 24 hours culture from E8.5 to E9.5. Transverse section through the PNP, stained for phospho-histone H3 and photographed using epifluorescence plus Nomaski optics. Mitotic (H3-positive) nuclei appear as bright dots on the section. Note mitoses in neuroepithelium (NE) and hindgut (HG) but not in notochord (NC). Scale bar: 150 μm.

Inositol treatment caused a significant increase in the phospho-histone H3 labelling index in the hindgut (Fig. 5.4), suggesting a stimulatory effect on cell proliferation, as found by PCNA staining. In contrast, there was no significant effect of inositol treatment on phospho-histone H3-labelling in the neuroepithelium or notochord (Fig. 5.4). The increase in labeling of both a G1/S-phase and an M-phase marker strongly suggests that proliferation rate is indeed increased following inositol treatment, in association with prevention of PNP closure delay, and that this stimulation of cell proliferation specifically affects the hindgut epithelium.

A parallel set of cultures was performed to determine whether inhibition of a PKC isoform, PKC βI, that is required for prevention of NTDs (Chapter 4), is also essential for the effect of inositol on proliferation. As a control, another set of embryos were cultured in the presence of inositol plus the PKC ε inhibitor, that was found to be dispensable for
the inositol preventive effect (Chapter 4). Co-administration of the peptide inhibitor of PKC βI blocked the stimulatory effect of inositol on hindgut proliferation (Fig. 5.4), whereas the PKCε inhibitor had no effect. In the presence of inositol, neither inhibitor significantly altered proliferation in neuroepithelium or notochord. Hence, inositol overcomes the genetically-determined defect of cell proliferation in curly tail embryos, an effect that specifically requires activation of PKC βI.
Figure 5.4 Cell proliferation was measured in tissues of the PNP region of cultured *curly tail* embryos using phospho-histone H3 as a measure of the proportion of cells in metaphase. Inositol significantly stimulates histone H3 labelling \( (P<0.02) \) in hindgut endoderm (hindgut 4\textsuperscript{th} bar versus 1\textsuperscript{st} bar), whereas inositol has no significant effect on histone H3 labelling in either neuroepithelium or notochord. In hindgut endoderm, inhibition of PKC \( \beta I \) significantly reduces histone H3 labelling compared with inositol alone \( (P<0.05) \), whereas inhibition of PKC\( \varepsilon \) has no significant effect \( (P>0.05) \). Blocking PKC \( \beta I \) or \( \varepsilon \) has no significant effect on histone H3 labelling in neuroepithelium or notochord \( (P>0.05) \). No notochordal cells were positive for histone H3 in the presence of inositol and the PKC \( \beta I \) inhibitor. Labelling indices are mean \( \pm \) SEM of at least 10 embryos per treatment.
In this chapter, we have demonstrated that specific perturbations in the regulation of early cell behavior, involving the redistribution of PKC, can lead to altered cell division, cell death, and cell differentiation. The results of our experiments suggest that PKC activation plays a critical role in the regulation of cell cycle progression and differentiation.

PKC activation has previously been shown to regulate cell cycle progression in a wide variety of cell types, including myoblasts (Richard et al., 2003), neuronal cells (Wang et al., 2007), and fibroblasts (Fernandez, 2002). PKC activation has also been implicated in the regulation of cell death (Friedlander et al., 2007), apoptosis (Suzuki et al., 1999), and differentiation (Kai et al., 1996). In particular, PKC activation has been previously associated with increased cell proliferation.
5.3 DISCUSSION

In this chapter, I have demonstrated that inositol stimulates cell proliferation in the hindgut of curly tail embryos, reversing the imbalance of cell proliferation that is known to lead, via enhanced ventral curvature of the caudal region, to delay or failure of PNP closure (Copp et al., 1988c). Since the prevention of NTDs by inositol in curly tail mice requires specific PKC isoforms, it was predicted that these PKC isoforms would also be required for stimulation of the cell cycle in the embryonic hindgut. Indeed, I found that PKC βI, which is required for correction of PNP closure, is also required for this stimulation of cell proliferation. S-phase entry/progression has been suggested to be defective in hindgut cells of curly tail embryos (Copp et al., 1988c), raising the possibility that activation of PKC βI may reverse this defect, leading to ‘rescue’ of the mutant phenotype. Interestingly, inositol treatment of cells for 6 h resulted in nuclear translocation of PKC βI as also observed for short-term exposure to TPA (see Chapter 4). This nuclear localization suggests that a role of PKC βI in cell cycle regulation is plausible. However, PKC α also exhibits nuclear translocation in inositol-treated cells (both curly tail and non-mutant), but does not play an essential role in the prevention of NTDs, demonstrating that nuclear translocation per se is not sufficient to achieve the cell cycle regulation necessary for normalization of PNP closure.

PKC activation has previously been shown to regulate cell cycle progression in a wide variety of cell types (e.g., vascular endothelial cells (Kinsella et al., 1992), vascular smooth muscle cells (Suzuma et al., 2002), melanoma cells (Szalay et al., 2001), fibroblasts (Nakashima, 2002), keratinocytes (Suzuma et al., 2002), myeloid leukemia cells (Miyamoto et al., 2002), breast carcinoma cells (Kuo et al., 1990), and intestinal epithelial cells (Kuo et al., 1990). In particular, PKC βI, the isoform required in prevention of curly tail defects, has been previously associated with increased cell cycle
entry. Its over-expression leads to increased proliferation of aortic endothelial cells, in contrast to PKC βII which has an inhibitory effect (Yamamoto et al., 1998). Similarly, proliferation of vascular smooth muscle cells is stimulated by PKC βI, through increased S-phase entry, but inhibited by PKC βII, through extension of S-phase (Yamamoto et al., 1998).

Furthermore, Aaltone et al (2006) in the study cell proliferation within transitional cell carcinoma, reported an increased PKC substrate phosphorylation which correlated with increased expression and nuclear localization of PKC βI in tumor samples and in cultures with increased PKC βI immunosignal. Moreover, they found that, in normal epithelium, a significant number of cells were negative for PKC βI nuclear localization, whereas in cancerous tissue, particularly in highly proliferative areas, nearly all nuclei were positive for immunosignal. Interestingly, in transitional cell carcinoma cultures, nuclear PKC βI appeared as a 65-kDa fragment, whereas in the cytoplasm, it was present as a full-size 79-kDa form, as demonstrated by La Porta et al. (La Porta, 1997) in a Western blotting study. There are earlier reports locating PKC-βI in the nucleus (Svensson et al., 2000; Raghunath et al. 2003), and it has been demonstrated that PKC-βI is transported to the nucleus and fragmented (Bastiaens and Jovin 1996). Others have shown a 65-kDa fragment for PKC βI in the membrane fraction of cells (al-Mazidi HA, 1998) and in whole-cell lysates (Pfaff et al. 1999; Redling et al. 2004). It is thus possible that PKC βI is fragmented during activation and that localization of the 65-kDa fragment in membranes (possibly nuclear membrane) is necessary for activation. Taken together, these reports confirm the likely involvement of PKC βI in cell cycle regulation, as also indicated by the findings presented in this thesis. In future work, it would be interesting to determine whether increased PKC substrate phosphorylation is correlated with PKC βI activity during inositol-mediated prevention, and whether there is a requirement for PKC βI
cleavage, in order to allow nuclear tranlocation and nuclear activity of PKC βI in *curly tail* embryos.

The possibility must also be considered that changes in PKC expression, as seen in this thesis, reflect changed activity of other cell signalling pathways affecting cell cycle progression. As an example, oncogenic Ras has been shown to up-regulate PKC α, c-myc oncogene induces increased PKC β expression, and wild-type p53 has been shown to suppress PKC γ expression (Barr et al. 1991; Delage et al. 1993; Zhan et al. 2005). Further studies would be needed to fully evaluate the role of such regulatory interactions during mouse neurulation.

The next step in studying the role of inositol in hindgut cell cycle regulation, would be to determine the effects of inositol treatment on phosphorylation of known PKC targets involved in proliferation, including the nuclear lamins and MARcKS (Aderem, 1992b). Specific isoforms of PKC regulate the transcriptional control of cyclin D1 (CCND1) expression, which plays a critical role in the progression of mammalian cells through the G1 phase of the cell cycle (Kampfer et al., 2001). G1 to S transition is a critical step because abnormalities in this step can enhance cell proliferation, genome instability, and tumor progression. However, the possibility that PKC βI, γ and ζ may stimulate cyclin D1 promoter activity in *curly tail* embryos remains to be investigated. Further studies might include the assessment of knockout mice lacking function of putative PKC targets, to determine whether double mutant combinations with *curly tail* would render the NTDs resistant to inositol-mediated prevention.

An interesting question that remains to be answered is why inositol stimulates PKC βI-dependent cell proliferation only in the hindgut endoderm and not in the neuroepithelium, which is an even more mitotically-active tissue than the hindgut. PKC βI, like all the PKC
isoforms studied, is expressed in all tissues of the caudal embryonic region (Chapter 4). Hence, selective PKC expression cannot explain the specific effect of inositol. It is possible that the sub-normal hindgut proliferation in curly tail embryos might reflect "available" capacity for a PKC βI-dependent response. Whereas non-mutant embryos have "maximal" hindgut proliferation and cannot be further stimulated. The same argument could apply to the neuroepithelium in curly tail embryos in which proliferation appears normal. This idea would predict that inositol would not stimulate enhanced proliferation in the hindgut of wild type embryos, a suggestion that could be addressed in future work.

Sections of curly tail mouse embryos at the stage just prior to PNP closure were recently analyzed by in situ hybridization for Grhl3, a compelling candidate for the ct gene. Specific expression in the hindgut endoderm was observed (Greene, unpublished data), raising the possibility that Grhl3 expression may be required for an embryonic tissue to show a proliferative response to inositol. Grhl3<sup>−/−</sup> embryos do not respond to inositol treatment (Ting et al, 2003) in support of this idea. Currently, there is no information, however, on a possible molecular regulatory link between inositol/PKC βI, Grhl3, and the cell cycle machinery.

Last, Ting et al (2003) showed that Grhl3<sup>−/−</sup> embryos exhibit NTDs and growth retardation, particularly around the hindgut endoderm, results which are comparable to this chapter’s finding in the ct/ct mice.
CHAPTER 6
GENERAL DISCUSSION
6. GENERAL DISCUSSION

Although some cases of human NTDs can be prevented by folic acid, there is increasing evidence that many cases do not respond. For instance, there was no major reduction in NTD frequency in the U.K. during the ten years after folic acid supplementation was introduced (Locksmith, 1998). The objective of this thesis was to investigate inositol as a possible treatment for folate-resistant NTDs, in order to prevent a larger proportion of human NTDs than is currently possible.

The specific aims of this thesis were:

1. To use the *curly tail* mouse as a model of folate-resistant NTDs, in order to find the optimal dose and treatment method for maximal reduction of NTD frequency.

2. Determine the critical PKC isoformes that mediate the preventive effect of inositol in preventing folate-resistant NTDs, and determine the tissue-localisation of these PKC isoformes.

3. Correlate inositol treatment/PKC activation with rates of cell proliferation in the caudal region of *curly tail* embryos, as their NTDs are being prevented.

The overall findings of this thesis are that exogenous inositol is able to prevent NTDs by stimulating specific PKC isoforms, and whose actively impinges upon the hindgut cell cycle in *curly tail* embryos to regulate spinal neurulation.

6.1 INOSITOL AND FOLATE-UNRESPONSIVE NTDS IN THE *CURLY TAIL* MUTANT.

Primary prevention of NTDs in humans became a reality when clinical trials demonstrated that folate-containing multivitamins (Smithells, 1998) and specifically folic acid (Wald, 1995) can reduce recurrence risk (a second NTD pregnancy in a family) and
perhaps reduce first occurrence of NTDs (Czeizel, 1995). Folate supplementation is underway by health advice in the UK, and by 'food fortification' in the USA (Simthells, 1998). Several major issues remain. First, little is known of the molecular basis of folate action in preventing NTDs. A genetic polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is weakly related to NTD risk (Barber et al., 1999), but variants of other folate-related genes are not NTD-related. While several mouse models of NTD are folate-preventable (Barber, 1999), none result from mutation in folate-related genes. A second critical point is that a significant proportion of NTDs: around 30% in the MRC folate trial (Kirke, 1992), appear unresponsive to folic acid supplementation. The poor response to folate supplementation, with barely any decline in NTD frequency in the UK (Locksmith and Duff, 1998), and only a 19% decline in the USA (Kirke et al., 1992); (Honein et al., 2001), suggests adjunct therapies are needed to prevent folate-resistant NTDs.

While the mechanism of folic acid preventive action has not been studied in this thesis, new information has been gathered on the normalisation of neurulation, by inositol, in the folate-unresponsive NTDs of the curly tail mutant (Cogram et al., 2002; 2004). The thesis has shown that: (1) inositol is active in preventing these NTDs, with a greater potency of the D-chiro- than myo-inositol isoform; (2) inositol can prevent NTDs either via maternal administration or by a direct effect on the cultured embryo; (3) inositol stimulates PKC, an effect that is required for NTD prevention; (4) PKC isoforms β1 and γ are required to mediate the inositol effect, whereas α, βII and all novel PKCs are dispensable; (5) inositol reverses the cell proliferation defect that was described previously in the hindgut of curly tail embryos (Copp et al., 1998); (6) the inositol effect is non-toxic during pregnancy, and not associated with an increase in other birth defects. In addition, (7) a case report of inositol usage in humans has been associated with a normal third pregnancy following
two consecutive NTDs while on folate therapy (Cavalli and Copp, 2002). It can be concluded, therefore, that inositol may offer a potential novel method for preventing human NTDs. As a result of these findings a pilot clinical trial is now in progress (Copp, Greene and others, unpublished). Hence this research, which began in a mouse genetic model, is being “translated” into clinical application.

6.2 GRHL3, CT AND INOSITOL PREVENTION

The effect of folate and inositol administration on pregnant Grhl3+/− females mated with Grhl3+/− males was studied by Ting et al (2003). Folate did not rescue spina bifida in Grhl3−/− embryos and, contrary to expectation neither did inositol (Ting et al., 2003). Hence, although the Grhl3 gene seems very likely to be altered in curly tail mice, the Grhl3 knockout appears inositol-resistant. Possible mechanisms for this difference in inositol responsiveness of ct/ct and Grhl3−/− mice could be related to the fact that ct is a hypomorphic allele of Grhl3, and therefore more easily normalised than the null Grhl3 allele, or that the residual Grhl3 function in ct/ct embryos enables inositol to exert its effect on hindgut cell proliferation, whereas complete loss of Grhl3 renders the hindgut responsive to inositol (Chapter 5).

Interestingly, clones of grh mutant cells in the adult Drosophila epidermis have defects in pigmentation, cell polarity, and epidermal hair differentiation (Lee and Adler, 2004). Loss of Grhl3 results in embryos with defective epidermal wound repair (Ting et al., 2005) suggesting that Grhl3 may have other roles in epithelial fusion events. Furthermore, over-expression of grh in Drosophila embryos causes a failure in dorsal closure (Attardi, 1993), a widely studied epithelial fusion event that has many similarities to wound repair (Wood et al., 2002). Recent cellular and molecular studies have substantially increased our understanding of the elegant cascade of signalling events necessary for the wound
healing process (Frank, 2002). For example, several important biochemical mediators of cell migration and growth have been identified that are involved in tissue reformation (Frank, 2002).

Inositol receptor-mediated signal transduction can occur by various pathways to affect downstream targets which are ultimately involved in wound healing, planar cell polarity and cell proliferation. Activation of PKC stimulates the mitogen-activated protein kinase (MAPK) cascade leading to MAPK activation, and modulation of transcription factor activity. This can lead to changes in cell behaviour such as proliferation, as is seen in a variety of growth factor-mediated events of receptor tyrosine kinase stimulation (Liaw, 1995) Hence, stimulation of cell proliferation in curly tail embryos by inositol could act via this pathway. A prediction would be that intermediates in the MAPK pathway (e.g. ERK) would show increased phosphorylation after inositol stimulation. It is currently unknown how Grhl3 might interact with such signalling pathways.

6.3 CHIRO-VS MYO-INOSITOL IN PREVENTING CURLY TAIL NTDs

The data presented in Chapter 3 confirm previous observations supporting a role for inositol in neurulation, since administering inositol to ct/ct embryos reduces the incidence of spina bifida. In a prior study, relatively high doses of myo-inositol were required to give a protective effect (Greene and Copp, 1997a). However, here it has been shown that an alternative isomer, D-chiro-inositol, provides a similar protective effect at lower concentrations, indicating that it is more effective than myo-inositol at lowering the incidence of spinal neural tube defects. This observation has been shown in four independent experiments, involving three different routes of administration to the developing embryo. At present the reason for enhanced efficacy of D-chiro-inositol is
not known. It is important to take into account the fact that myo-inositol converts to D-chiro-inositol in vivo, and since the D-chiro-form seems to be more effective, it would be very interesting to investigate the biosynthesis of D-chiro-inositol from myo-inositol in curly tail mice.

If it is to be used clinically, it is imperative that inositol is a safe treatment during pregnancy. It has been suggested that inositol treatment could stimulate uterine contractions during pregnancy (Colodny and Hoffman, 2000). The idea behind this suggestion is that oxytocin (a uterine stimulator) acts via activation of phospholipase C. However, although oxytocin is activated via the inositol phospholipid signalling pathway and can stimulate uterine contractions, there is no evidence to suggest that inositol supplementation has this effect. In the case report of a woman who took inositol in a third pregnancy, following two NTD pregnancies, there were no abnormal uterine contractions reported (Cavalli and Copp, 2002). Moreover, according to the data presented here (Chapter 3) there was no significant difference in pregnancy loss between the treated and the placebo groups of curly tail mice, suggesting that inositol is an effective and safe treatment, at least during mouse pregnancy.

6.4 INOSITOL ACTION IN NTDs IS MEDIATED VIA PKC

Using specific PKC inhibitors, both chemical and peptide in whole embryo culture, I showed in Chapter 4 that the preventive effect of inositol is mediated via specific PKC isoforms. All PKC isoforms were detected, during mouse development from E9.5 to E17.5, in agreement with previous analysis of PKCs in E15-17 fetuses (Blackshear et al., 1996a). These findings contrast with a study of E10.5 embryos that detected PKCa, but not βI, βIII, and ζ (Wilda et al., 2001). This difference may reflect the low abundance of
cPKCs on western blot, at early stages (E9.5–11.5) in particular (Cogram et al., 2004b), although all isoforms were clearly detectable in the PNP region by immunohistochemistry. Another member of the laboratory, Andrew Hynes, carried out the western blot analysis and found that each isoform exhibited a distinct distribution between sub-cellular fractions, which likely reflects the degree of activation. For instance, cPKCs were confined to the cytoplasmic fraction, suggesting minimal activation during undisturbed development, whereas aPKCs were present in membrane-associated and insoluble fractions throughout development, suggesting constitutive activation (Cogram et al., 2004b). This finding is consistent with a role for the cPKCs, βI and γ, in mediating the preventive effect of inositol, since activation of these isoforms may be limiting in the absence of inositol, providing capacity for activation after treatment.

6.5 MOLECULAR BASIS OF THE REQUIREMENT FOR PKC AND PI3-KINASE

The normalizing effect of inositol on PNP closure was partially blocked by both the chemical inhibitor LY294002 and the peptide inhibitor specific for PKC ζ. LY294002 has activity against both PKC ζ and also the PI 3-kinase pathway, suggesting a possible role for the latter in the mechanism of inositol action. To test this idea, I performed preliminary experiments using the PI 3-kinase inhibitor wortmannin in whole embryo culture. Even at the low concentration of 0.1 μM, wortmannin proved extremely toxic to neurulation stage embryos, with all treated embryos dying during the culture period. Clearly, PI 3-kinase activity is essential for mouse embryonic development at this stage. The fact that LY294002 did not exhibit similar toxicity may indicate a more selective action, and the finding that specific inhibition of PKC ζ produced no general toxicity but a similar partial blockade of inositol-mediated prevention supports the idea that PKC ζ
and not the entire PI 3-kinase pathway was mainly affected in these studies.

6.6 IS PKC IMPLICATED IN THE MECHANISM OF NEURAL TUBE CLOSURE?

Several lines of evidence suggest that spinal neurulation _per se_ does not depend on inositol and PKC activation and that defective closure in _curly tail_ embryos is unlikely to result from an intrinsic deficiency in inositol or specific PKC isoforms. First, exposure of _curly tail_ embryos to PKC inhibitors, in the absence of inositol, did not affect PNP closure. Second, uptake and incorporation of $^3$H-inositol occurs similarly in cultured _curly tail_ and non-mutant embryos, while inositol deficiency _in vitro_ does not increase the penetrance of spinal NTDs in _curly tail_ embryos (Copp et al., 1998) although the frequency of cranial NTDs is increased (Cockroft et al., 1992). Finally, mice with targeted inactivation of the genes encoding PKC, $\beta$, $\gamma$ and $\zeta$ do not exhibit neurulation defects (Erin, 2007).

6.7 CELLULAR ACTION OF INOSITOL

I propose that prevention of NTDs in _curly tail_ mice by exogenous inositol operates via stimulation of the cell cycle in the embryonic hindgut, an effect that requires activation of specific PKC isoforms. I have shown in _Chapter 5_ that cell proliferation, as judged by the percentage of cells positive for the S-phase marker PCNA, and the mitotic marker phospho-H3, is significantly increased in the hindgut endoderm of inositol-treated embryos, whereas proliferation in other tissues is not significantly affected. Hence, I have demonstrated that inositol therapy, via PKC stimulation, corrects the cell behavioral defect that leads to spina bifida in the _curly tail_ mouse (Copp et al., 1988c). Inositol is also reported to prevent NTDs in animal models of diabetes, whereas inositol deficiency causes cranial NTD, even in non-mutant mice (King, 2006). It remains to be determined
whether the protective action of inositol also involves stimulation of cell proliferation in these cases.

6.8 POSSIBLE INVOLVEMENT OF INS-DAG AND PKC IN CELL PROLIFERATION.

It is well known that many growth regulatory signals are directly or indirectly coupled to protein kinases intrinsic to, or associated with, the receptors for a variety of growth factors (Banan et al., 2004). These protein kinases have been subdivided into two major groups according to their ability to phosphorylate either serine or threonine residues of substrate proteins. Binding of growth factors to their surface receptors often leads to the activation of specific phospholipases (either by receptor-activated tyrosine phosphorylation or receptor coupling to GTP-binding proteins), which results in the elevation of intracellular calcium and diacylglycerol (DAG). It would be interesting in our system to measure levels of intracellular DAG in mutant curly tail and non-mutant mice. The purpose would be to understand the role of PKC subtypes in the regulation of cell proliferation in the hindgut endoderm of curly tail embryos, and to identify possible mechanisms by which inositol-DAG and PKC may contribute to the proliferation defect in curly tail mouse mutants.

The role of PKC in normal growth regulation is based on the idea that this enzyme family is the principal transducer for DAG that is generated upon activation of a phospholipase-linked cell surface receptor (Nishizuka, 1992). Intracellular levels of DAG have been considered a marker for the activation condition of PKC, since DAG initiates a broad range of cellular responses by activating PKC isoforms and other proteins (Nishizuka, 1992). One consequence of this regulation may be to modulate cell proliferation. Indeed, (Besson et al., 2004) demonstrated that PKC activity was an important factor regulating
cell proliferation and that a sustained increased in the cellular DAG and, PKC activity was required for cell cycle progression. Consequently, there is a possibility that normal hindgut cells have higher DAG levels and, therefore, a higher rate of proliferation compared with curly tail hindgut cells.

DAG binds to and activates PKC subtypes, together with acid phospholipids and Ca\(^{2+}\) (Nishizuka, 1992); (Dekker and Parker, 1994). Activation of PKC goes together with the tight association of the enzyme with membranes, a process referred to as 'translocation of PKC' (Anderson et al. 1985; Wolf et al. 1985). Ca\(^{2+}\)-chelators promote the cytosolic localization of the cPKCs, whereas elevated Ca\(^{2+}\) levels encourage association of PKC with membranes. It is interesting to speculate that varying levels of Ca\(^{2+}\) may affect PKC translocation in curly tail cells and thus, affect cell proliferation.

6.9 PKC DOWNSTREAM TARGETS

In this thesis I have identified the PKC isoforms that mediate the preventive effect of inositol. The logical next step would be to identify proteins that may be phosphorylated by PKC during inositol action, for instance by comparing treated and untreated embryos. Below, I consider some possible PKC substrates, which are putative candidates to form part of the inositol-PKC preventive effect of inositol in curly tail embryos.

6.9.1 MAPK

Because of the possible link between Grhl3 and MAPK, this would be the first candidate I would analyze. MAPK pathways are evolutionarily conserved kinase modules that link extracellular signals to the machinery that controls fundamental cellular processes such as growth, proliferation, differentiation, migration and apoptosis. There are two isoforms of MAPK, the p44 MAPK (Erk-1) and the p42 MAPK (Erk-2), which are expressed in most
cell types. The substrates of MAPK include nuclear transcription factors and non-nuclear substrates such as the protein, serine/threonine kinase p90sk and cytoskeletal proteins. EGF-induced nuclear transcriptional activation stimulates cell proliferation by initiating progression from G1 to S phase of the cell cycle. Another substrate of MAPK activation is phospholipase A₂ (cPLA₂) (Davis et al., 1994). cPLA₂ catalyzes the release of arachidonic acid from phospholipids in membranes and is one of the rate-limiting steps in the synthesis of prostaglandins. In cultured rabbit corneal endothelial cells, it was shown that the prostaglandin PGE₂ inhibits mitosis (Humblatt, 1994).

6.9.2 Myristoylated alanine-rich C kinase substrate

The major PKC substrate MARCKS may be of particular interest in relation to neural tube closure as the null mutant mouse displays exencephaly (Stumpo et al., 1995). Moreover, knockout of MARCKS family protein, MRP (also known as MARCKS-related protein, MacMARCK or F52) also causes NTDs, both spina bifida and exencephaly (Chen et al., 1996). The potential importance of these proteins is their involvement in cytoskeleton rearrangement and cell cycle.

6.9.3 Cyclins

Specific isoforms of PKC, such as βI and βII regulate the progression of cells through the G1 to S phases of the cell cycle. PKC is a potent activation of the transcriptional activity of the cyclin D1 promoter (Erin, 2007). PKC activation, leads to activation of c-fos and c-jun, which form AP-1 complexes and activate the cyclin D1 promoter. Expression of cyclin D1 then facilitates cell cycle progression from G1 to S phase and enhances proliferation. Activation of PKC also leads to activation of cyclin E expression, through mechanisms not fully understood. It could be interesting to determine if any of these
downstream PKC targets contribute to the enhancement of cell proliferation in inositol-treated *curly tail* mice.

### 6.9.4 Shuttle proteins

A considerable number of PKC substrates are localized in defined membrane compartments (Parker and Parkinson, 2001). It would be interesting, as a continuation of this thesis, to identify how these signals get into the nucleus to regulate gene expression, a mechanism that is unclear at present. The discovery of shuttle proteins capable of carrying information from the cytoplasm into the nucleus has improved the understanding on how growth factors regulate gene expression (Nigg, 1995). In the absence of stimuli, these shuttle proteins remain in the cytoplasm in the form of macromolecular complexes and translocate to the nucleus in response to cell stimulation, either because they are small enough to pass the nuclear membrane or because they carry special nuclear target sequences that facilitate nuclear uptake (Silver, 1990). The NFkappa P shuttle is especially interesting, as it appears to be regulated by PKC. The NFkappa P system is widespread in a variety of cell types and regulates many genes (Gilmore 1990). It consists of a heterotetradimer protein complex capable of interacting with a DNA regulatory sequence (the kβ sequence). NFkappa P is a transcriptional activator that participates in the induction of several genes, in particular those related to cell proliferation. NFkappa P is a possible PKC substrate whose translocation to the nucleus could be a possible rapid signalling pathway. It would be interesting to identify whether NFkappa P may be involved in the inositol-PKC protective effect in *curly tail*.

### 6.9.5 Lamins

Numerous studies indicate that gene transcription is regulated by the action of protein kinases in the nucleus. As described in *Chapter 4*, treatment of cells with TPA induces a
translocation of cytosolic PKC to nuclear fractions raising the possibility of that these isoforms are involved in nuclear function. Lamin B, a nuclear envelope protein, and topoisomerase I (Holaska et al., 2002) have been found to be substrates of PKC in vitro and be phosphorylated on serine or threonine in response of phorbol ester treatment of cells. Phosphorylation of lamin is essential for nuclear envelope disassembly during mitosis (Holaska et al., 2002) while phosphorylation of topoisomerase I relaxes positive DNA supercoiling, a crucial event for efficient gene transcription (Goss et al., 1994). There may be a role for nuclear PKCβI and γ in the regulation of cell growth via activation of nuclear lamins.

6.10 CONCLUSION AND PERSPECTIVES

Although there are still many unanswered questions about inositol lipid signaling, new techniques and tools are now available to study molecular cell physiology that should allow us to gain, in a relatively short time, a better understanding of their roles in the cell during the neurulation process. For example, in order to elucidate further the role of specific forms of PKC in modulating the expression of genes related to cellular growth control during neural development, it would be desirable to generate cell lines that stably produce elevated levels of a specific isoform of this enzyme. These cell lines would then provide a model system for studying cellular events occurring subsequent to activation of PKC γ and βI, by tumor promoters and other agents in an epithelial cell system.

Although there are also many unanswered questions about NTDs, this thesis work has established, a clear link between inositol lipid signaling and specific isoforms of PKC, PKC γ and βI, which together appear to integrate a complex network of signal transduction pathways. This PKC-related mechanism seems likely to control gene
expression and cell proliferation in the caudal region of inositol-treated *curly* embryos during rescue of NTDs.
7. REFERENCES


O'Rahilly, R., Müller, F., 2002. The two sites of fusion of the neural folds and the two neuropores in the human embryo. Teratology. 65, 162-170.


displays altered homocysteine metabolism without folate responsiveness or a defect in Mthfr. Mol.Genet.Metab 76, 297-304.


8. PUBLICATIONS


D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects

Patricia Cogram1, Sheila Tesh2, John Tesh2, Angie Wade3, Geoffrey Allan4, Nicholas D.E.Greene1 and Andrew J.Copp1,5

Neural Development Unit, Institute of Child Health, University College London, 2Tesh Consultants International, Swaffling, Saxmundham, Suffolk, 3Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, UK and 4Insmed Incorporated, Richmond, VA, USA

BACKGROUND: Among mouse genetic mutants that develop neural tube defects (NTDs), some respond to folic acid administration during early pregnancy, whereas NTDs in other mutants are not prevented. This parallels human NTDs, in which up to 30% of cases may be resistant to folic acid. Most spina bifida cases in the folic acid-resistant 'curly tail' mouse can be prevented by treatment with inositol early in embryonic development. Here, the effectiveness and safety during pregnancy of two isomers, myo- and D-chiro-inositol, in preventing mouse NTDs was compared. METHODS AND RESULTS: Inositol was administered either directly to embryos in vitro, or to pregnant females by s.c. or oral routes. Although D-chiro- and myo-inositol both reduced the frequency of spina bifida in curly tail mice by all routes of administration, D-chiro-inositol consistently exhibited the more potent effect, reducing spina bifida by 73–86% in utero compared with a 53–56% reduction with myo-inositol. Pathological analysis revealed no association of either myo- or D-chiro-inositol with reduced litter size or fetal malformation.

CONCLUSIONS: D-chiro-inositol offers a safe and effective method for preventing folic acid-resistant NTDs in the curly tail mouse. This raises the possibility of using inositol as an adjunct therapy to folic acid for prevention of NTDs in humans.

Keywords: embryo culture/malformations/pregnancy/spina bifida/teratogen

Introduction

Folic acid supplementation during early pregnancy can prevent a proportion of neural tube defects (NTDs) (Wald et al., 1991; Czeizel and Dudás, 1992; Berry et al., 1999), whereas other cases of NTDs appear resistant to folic acid. In the randomized controlled trial of the Medical Research Council, UK (Wald et al., 1991), 28% of NTD cases recurred despite supplementation with 4 mg folic acid per day. Moreover, the recent introduction of folic acid fortification of bread flour in the USA resulted in only a 19% decline in the prevalence of NTDs (Honein et al., 2001). While these findings may indicate the need for increased levels of folic acid supplementation, they are also consistent with a proportion of NTDs exhibiting resistance to exogenous folic acid.

Mouse genetic models also indicate the existence of folate-resistant NTDs. Mutant strains including 'splotch', 'crooked tail' and the ‘Cartl’ knockout exhibit NTDs that can be prevented by folic acid treatment during early pregnancy (Fleming and Copp, 1998; Zhao et al., 1996; Carter et al., 1999), whereas folic acid is ineffective in preventing NTDs in the mutant strains 'curly tail', 'axial defects' and the 'ephrin-A5' knockout (Essien and Wannberg, 1993; Seller, 1994; Holmberg et al., 2000).

Previously, it was demonstrated that a proportion of the folate-resistant NTDs in curly tail mice can be prevented by treating pregnant females, or embryos in vitro, with myo-inositol (Greene and Copp, 1997). These findings were consistent with earlier work showing that deficiency of myo-inositol in the culture medium of rat and mouse embryos caused a high incidence of cranial NTDs (Cockroft, 1988; Cockroft et al., 1992), and that NTDs developing in rat embryos cultured under diabetic conditions could be ameliorated by supplementation with myo-inositol (Baker et al., 1990; Hashimoto et al., 1990). Together, these findings suggest inositol as a potential therapeutic option for prevention of folate-resistant NTDs.

Here, the analysis of inositol as a primary therapeutic agent in preventing mouse NTDs has been extended. The study was intended to serve as a preliminary to a human clinical therapeutic trial. It was shown that inositol could prevent NTDs both in vitro and following administration to pregnant curly tail females, either by s.c. or oral routes. A detailed pathological...
SPECIAL NOTE

ITEM SCANNED AS SUPPLIED
PAGINATION IS AS SEEN
D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects

Patricia Cogram¹, Sheila Tesh², John Tesh², Angie Wade³, Geoffrey Allan⁴, Nicholas D.E.Greene¹ and Andrew J.Copp¹,⁵

¹Neural Development Unit, Institute of Child Health, University College London, ²Tesh Consultants International, Sweffling, Saxmundham, Suffolk, ³Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, UK and ⁴Insmed Incorporated, Richmond, VA, USA

BACKGROUND: Among mouse genetic mutants that develop neural tube defects (NTDs), some respond to folic acid administration during early pregnancy, whereas NTDs in other mutants are not prevented. This parallels human NTDs, in which up to 30% of cases may be resistant to folic acid. Most spina bifida cases in the folic acid-resistant ‘curly tail’ mouse can be prevented by treatment with inositol early in embryonic development. Here, the effectiveness and safety during pregnancy of two isomers, myo- and D-chiro-inositol, in preventing mouse NTDs was compared. METHODS AND RESULTS: Inositol was administered either directly to embryos in vitro, or to pregnant females by s.c. or oral routes. Although D-chiro- and myo-inositol both reduced the frequency of spina bifida in curly tail mice by all routes of administration, D-chiro-inositol consistently exhibited the more potent effect, reducing spina bifida by 73-86% in utero compared with a 53-56% reduction with myo-inositol. Pathological analysis revealed no association of either myo- or D-chiro-inositol with reduced litter size or fetal malformation.

CONCLUSIONS: D-chiro-inositol offers a safe and effective method for preventing folic acid-resistant NTDs in the curly tail mouse. This raises the possibility of using inositol as an adjunct therapy to folic acid for prevention of NTDs in humans.

Keywords: embryo culture/malformations/pregnancy/spina bifida/teratogen

Introduction

Folic acid supplementation during early pregnancy can prevent a proportion of neural tube defects (NTDs) (Wald et al., 1991; Czeizel and Dudás, 1992; Berry et al., 1999), whereas other cases of NTD appear resistant to folic acid. In the randomized controlled trial of the Medical Research Council, UK (Wald et al., 1991), 28% of NTD cases occurred despite supplementation with 4 mg folic acid per day. Moreover, the recent introduction of folic acid fortification of bread flour in the USA resulted in only a 19% decline in the prevalence of NTDs (Honein et al., 2001). While these findings may indicate the need for increased levels of folic acid supplementation, they are also consistent with a proportion of NTDs exhibiting resistance to exogenous folic acid.

Mouse genetic models also indicate the existence of folate-resistant NTDs. Mutant strains including ‘splotch’, ‘crooked tail’ and the ‘Cart1’ knockout exhibit NTDs that can be prevented by folic acid treatment during early pregnancy (Fleming and Copp, 1998; Zhao et al., 1996; Carter et al., 1999), whereas folic acid is ineffective in preventing NTDs in the mutant strains ‘curly tail’, ‘axial defects’ and the ‘ephrin-A5’ knockout (Essien and Wannberg, 1993; Seller, 1994; Holmberg et al., 2000).

Previously, it was demonstrated that a proportion of the folate-resistant NTDs in curly tail mice can be prevented by treating pregnant females, or embryos in vitro, with myo-inositol (Greene and Copp, 1997). These findings were consistent with earlier work showing that deficiency of myo-inositol in the culture medium of rat and mouse embryos caused a high incidence of cranial NTDs (Cockroft, 1988; Cockroft et al., 1992), and that NTDs developing in rat embryos cultured under diabetic conditions could be ameliorated by supplementation with myo-inositol (Baker et al., 1990; Hashimoto et al., 1990). Together, these findings suggest inositol as a potential therapeutic option for prevention of folate-resistant NTDs.

Here, the analysis of inositol as a primary therapeutic agent in preventing mouse NTDs has been extended. The study was intended to serve as a preliminary to a human clinical therapeutic trial. It was shown that inositol could prevent NTDs both in vitro and following administration to pregnant curly tail females, either by s.c. or oral routes. A detailed pathological
analysis revealed no significant adverse effects of inositol therapy on mouse fetuses. Moreover, the effectiveness of myo-inositol was compared with that of D-chiro-inositol, a closely related enantiomer that differs in the orientation of the carbon-two hydroxyl group (C2-OH) relative to the plane of the six carbon ring.

Materials and methods

Mice
Curly tail mice are maintained as a homozygous, random-bred stock in which NTDs develop in ~60% of individuals (Van Straaten and Copp, 2001). Experimental litters were generated by timed matings, and the day of finding a copulation plug was designated embryonic day (E) 0.5.

In-vitro inositol treatment
E9.5 embryos (17–19 somite stage) were cultured for 24 h at 38°C in whole rat serum, as described previously (Copp et al., 1999). At 30 min after the start of culture, myo-inositol (Sigma, UK) or D-chiro-inositol (Insmed, VA, USA) was added to the medium (62.5 μl of inositol stock per ml rat serum) to a final concentration of 5, 10, 20 or 50 μg/ml inositol. Control cultures received an equal volume of phosphate-buffered saline (PBS). Following culture, embryos were scored for: (i) posterior neuropore length (the distance from the rostral end of the posterior neuropore to the tip of the tail bud); (ii) crown-rump length; and (iii) somite number.

In-utero inositol treatment
For s.c. administration, osmotic mini-pumps (capacity 100 μl, delivery rate 1 μl/h; model 1003D. Alzet) were filled with solutions of 30, 75 or 150 mg/ml inositol (delivering 29.72 and 144 μg inositol/g body weight per day respectively for a 25 g mouse), or PBS as a control. Mini-pumps were incubated in sterile PBS at 37°C for 4 h and then implanted s.c. on the back of pregnant mice at E8.5. General anaesthesia was induced by an i.p. injection of 0.01 ml/g body weight of a solution comprising 10% Hypnovel® (midazolam 5 mg/ml) and 25% Hypnorm® (fentanyl citrate 0.315 mg/ml, fluanisone 10 mg/ml) in sterile distilled water. For oral administration, pregnant mice were gavaged with 0.5 ml inositol solution in PBS twice daily intervals from E8.5 to E10.5 (six doses in total; 800 μg/g body weight per day).

Analysis of fetuses following inositol treatment in utero
Pregnant females were killed at E18.5, and the total number of implantations, classified as viable fetuses or resorptions, was recorded. Fetuses were dissected from the uterus and inspected immediately for the presence of open lumbo-sacral spina bifida and tail flexion defects; the primary manifestations of the curly tail genetic defect (Gruneberg, 1954; Van Straaten and Copp, 2001). A randomly selected sample of fetuses was fixed in Bouin’s fluid and subjected to detailed internal pathological analysis by free-hand serial sectioning (Wilson, 1965). Other fetuses were fixed in 95% ethanol and processed for skeletal examination (Whittaker and Dix, 1979).

Statistical data analysis
Continuous variables (somite number, crown-rump length, posterior neuropore length, litter size) were compared between treatment groups using analysis of variance or Kruskal-Wallis test. Ordinal regression was used to quantify further the effects of treatment and dosage on posterior neuropore length. Fisher’s exact or χ²-tests were used to compare phenotype frequencies between groups. To evaluate possible litter effects, multilevel ordinal logistic models were fitted to the data in Table III (MLwiN v1.10,006) (Goldstein, 1995). Logistic regression was used to determine whether the number of resorptions in utero was linked to dose and/or treatment.

Results

D-chiro-inositol is more effective than myo-inositol in normalizing neural tube closure in embryo culture
Curly tail embryos were cultured in the presence of inositol for 24 h from E9.5, the period during which the neural tube is closing at the posterior neuropore of the mouse embryo. In curvy tail embryos, neuropore closure is delayed or fails to be completed, leading to the development of tail flexion defects and spina bifida, respectively (Figure 1A–C) (Copp, 1985). Posterior neuropore length at E10–10.5 is positively correlated with the likelihood that an embryo will progress to develop a spinal NTD (Copp, 1985; Van Straaten et al., 1992).

Both myo- and D-chiro-inositol exhibited a dose-dependent normalization of posterior neuropore length in embryo culture, as judged by the reduction in neuropore length observed in embryos treated with higher inositol doses (Table I; Figure 2A). Strikingly, D-chiro-inositol significantly reduced neuropore length at dose levels of both 20 and 50 μg/ml, whereas a comparable effect was seen with myo-inositol only at 50 μg/ml. Embryos exposed to 20 μg/ml myo-inositol (or 5–10 μg/ml D-chiro-inositol) exhibited neuropore lengths that were not different from PBS-treated controls.

Neither myo- nor D-chiro-inositol affect the rate of embryonic growth in embryo culture
In the experimental design, embryos in the different treatment groups were matched for somite number before culture, in order to avoid differences in developmental outcome (neuropore length) that might arise from comparing embryos of different stages. Following culture, all groups exhibited mean somite numbers in the range 30–31, with no difference between treatments (Table I). Moreover, no significant difference was found in crown–rump length of embryos treated with either myo- or D-chiro-inositol compared with PBS-treated controls (Table I), suggesting that the effect of inositol is specific to the closing posterior neuropore, and not mediated via alteration of embryonic growth.

D-chiro-inositol is more effective than myo-inositol in preventing NTDs in utero
Next, the effectiveness of s.c. and oral routes of inositol administration in preventing NTDs in curly tail litters was evaluated. Using surgically implanted osmotic mini-pumps to administer inositol at a constant rate over a period of 72 h of pregnancy, encompassing the stages of neural tube closure, a dose-dependent effect of both myo- and D-chiro-inositol was observed. At 29 μg/g body weight per day, neither myo- nor D-chiro-inositol significantly affected the frequency of fetuses with spina bifida (Figure 2B), whereas at dose levels of 72 and 144 μg/g body weight per day, both inositols reduced the frequency of spina bifida compared with PBS-treated pregnancies (Figure 2B). At these higher dose levels, inositol
Inositol and prevention of neural tube defects

Figure 1. (A) Curly tail embryo after 24 h culture from E9.5 to E10.5. The box indicates the posterior neuropore region. (B,C) Higher magnification of the caudal region of cultured curly tail embryos. The posterior neuropore, a region of open neural folds, occupies the dorsal part of the caudal region, between the arrows in (B) and (C). Embryos with a large neuropore (C) develop spina bifida and/or a tail flexion defect, whereas embryos with a small neuropore (B) complete neural tube closure normally. (D-G) Skeletal preparations of E18.5 curly tail fetuses in dorsal view (D,E: rostral to the top) or right lateral view (F,G: rostral to the right). Compared with the normal fetus in (D), the fetus with spina bifida (E) exhibits vertebral pedicles widely spaced apart and absent neural arches in the low lumbar/sacral region (long arrow in E). The tail (short arrow in E) is enclosed in a skin sac and appears reduced in length owing to deformation and fusion of caudal vertebrae. The tail flexion defect (G) comprises a 360° curl of the tail, compared with the normal fetus which exhibits a straight tail (F).

Scale bars: A = 0.5 mm; B,C = 0.2 mm; D,E = 2 mm; F,G = 2 mm.

caused a significant shift towards the mild end of the NTD phenotype spectrum, with fewer fetuses having spina bifida and more appearing normal (Table II). As with the in-vitro study, D-chiro-inositol appeared most effective, causing a 73–83% decrease in spina bifida frequency relative to PBS controls, at both 72 and 144 μg/g body weight per day.
No evidence of an adverse effect of inositol on pregnancy success or fetal outcome

One possible explanation for a decrease in spina bifida frequency following maternal inositol administration could be an increase in loss of affected fetuses during pregnancy. When both resorption rate and litter size were examined in pregnancies receiving either s.c. or oral inositol, no significant difference was found between pregnancies treated with inositol and those receiving PBS alone (Table III).

To identify any adverse effects of inositol treatment on fetal outcome, fetal crown–rump length was measured, but no significant differences were found between treatment groups (Table III). An extensive pathological analysis of treated fetuses was performed using both free-hand serial sectioning and skeletal preparation. This analysis confirmed the occurrence of spina bifida and tail defects in a proportion of fetuses (Figure 1D–G), as also scored by external fetal inspection. Additionally, exencephaly, a failure of cranial neural tube closure, was observed in a small proportion of fetuses (Table IV). Exencephaly is a recognized, infrequent defect in curly tail homozygotes (Embrey et al., 1979). No overall increase or decrease in this defect was observed in inositol-treated fetuses compared with PBS controls, although the low frequency of affected fetuses may have obscured any treatment effect.

Internal and skeletal examination revealed almost no major structural defects, apart from NTDs (Table IV). For instance, no major malformations of the heart, lungs, kidney, gut, limbs or skeleton were identified. Of the morphological changes observed in the analysis, most were minor (e.g. small additional liver lobe) and the great majority occurred as frequently in PBS controls as in fetuses treated with inositol. D-chiro-inositol-treated fetuses (144 μg/g body weight per day) showed a somewhat elevated frequency of enlargement of the renal pelvis/ureter, rudimentary ribs on the seventh cervical vertebra and occurrence of anomalous cervical vertebrae (Table IV), although these trends were not statistically significant. Anomalous cervical vertebrae was associated with exencephaly in several litters, suggesting that cervical anomalies may form part of the spectrum of vertebral column defects present in the curly tail mouse.

Discussion

In the present study, the ability of exogenous inositol to prevent spinal NTDs in the folate-resistant curly tail mouse genetic

---

Table I. Comparison of growth and developmental parameters in curly tail embryos cultured in the presence of myo- and D-chiro-inositol

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Conc. μg/ml</th>
<th>No. of embryos</th>
<th>Somite numbera</th>
<th>Crown–rump lengthb</th>
<th>PNP lengthc</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>5</td>
<td>15</td>
<td>30.6 ± 0.13</td>
<td>3.50 ± 0.10</td>
<td>0.62 ± 0.11</td>
</tr>
<tr>
<td>PBS – 5</td>
<td>10</td>
<td>15</td>
<td>30.5 ± 0.13</td>
<td>3.39 ± 0.10</td>
<td>0.55 ± 0.11</td>
</tr>
<tr>
<td>PBS – 20</td>
<td>20</td>
<td>18</td>
<td>30.6 ± 0.16</td>
<td>3.55 ± 0.10</td>
<td>0.09 ± 0.11*</td>
</tr>
<tr>
<td>PBS – 50</td>
<td>50</td>
<td>16</td>
<td>30.3 ± 0.16</td>
<td>3.49 ± 0.08</td>
<td>0.07 ± 0.03*</td>
</tr>
<tr>
<td>Myo-inositol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– 20</td>
<td>20</td>
<td>16</td>
<td>30.5 ± 0.12</td>
<td>3.50 ± 0.12</td>
<td>0.62 ± 0.06</td>
</tr>
<tr>
<td>– 50</td>
<td>50</td>
<td>16</td>
<td>30.5 ± 0.14</td>
<td>3.57 ± 0.07</td>
<td>0.06 ± 0.03*</td>
</tr>
<tr>
<td>D-chiro-inositol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– 5</td>
<td>5</td>
<td>15</td>
<td>30.3 ± 0.15</td>
<td>3.56 ± 0.10</td>
<td>0.59 ± 0.13</td>
</tr>
<tr>
<td>– 20</td>
<td>10</td>
<td>15</td>
<td>30.5 ± 0.12</td>
<td>3.50 ± 0.12</td>
<td>0.62 ± 0.06</td>
</tr>
<tr>
<td>– 50</td>
<td>20</td>
<td>18</td>
<td>30.5 ± 0.14</td>
<td>3.57 ± 0.07</td>
<td>0.06 ± 0.03*</td>
</tr>
<tr>
<td>– 50</td>
<td>50</td>
<td>16</td>
<td>30.5 ± 0.16</td>
<td>3.50 ± 0.10</td>
<td>0.62 ± 0.06</td>
</tr>
</tbody>
</table>

Values are mean ± SEM. Statistical analysis: somite number and crown–rump length do not differ significantly, whereas posterior neuropore (PNP) length varies significantly between treatment groups (P < 0.0001). Ordinal regression analysis indicates that PNP length is significantly reduced (marked with asterisk) in embryos treated with myo-inositol (50 μg/ml) and D-chiro-inositol (20 and 50 μg/ml) compared with those exposed to phosphate-buffered saline (PBS) alone (P < 0.05), whereas PNP length in other inositol-treated groups does not differ significantly from the PBS control group.
Inositol and prevention of neural tube defects

Reasons for the differing potency of myo- and D-chiro-inositol in preventing NTD

It was shown previously that the protective effect of myo-inositol is mediated via the phosphoinositide cycle (Greene and Copp, 1997), which generates the second messengers inositol triphosphate and diacylglycerol (DAG) (Majerus, 1992). Among the downstream events of this signalling pathway, activation of protein kinase C (PKC) by DAG appears critical for normalization of neuropore closure in curly tail embryos. For instance, activation of PKC by phorbol esters mimics the effect of inositol supplementation, whereas PKC inhibitors abrogate the protective effect (Greene and Copp, 1997).

It is possible that D-chiro-inositol also acts through a PKC-dependent pathway, in which case the greater preventive effect of D-chiro-inositol may result from its differential incorporation and metabolism within the phosphoinositide cycle. Insulin stimulation of rat fibroblasts expressing the human insulin receptor leads to a significant increase in the incorporation of D-chiro-inositol into phospholipids, whereas the effect on myo-inositol incorporation is only marginal (Pak et al., 1993). Moreover, D-chiro-inositol induces a much larger reduction in plasma glucose level in rats rendered diabetic by streptozotocin administration compared with exogenous myo-inositol (Ortmeyer et al., 1993). In humans, D-chiro-inositol can increase the action of insulin in patients with polycystic ovarian syndrome, improving ovulatory function, reducing blood pressure, and decreasing blood androgen and triglyceride concentrations (Nestler et al., 1999). These findings suggest an inherently greater potency or bioactivity of D-chiro-inositol than myo-inositol, perhaps as a result of incorporation into different phosphatidylinositol species (Pak and Lamer, 1992).

It is striking, however, that these differences of in-vivo potency are maintained in the face of the demonstrated interconversion of the two inositol isomers (Pak et al., 1992). Perhaps the rate of interconversion is too low to obscure the inherently greater potency of D-chiro-inositol in short-term effects on embryonic development.

How does inositol normalize neural tube closure in curly tail mice?

Although the causative gene responsible for the curly tail defect is unknown (Van Straaten and Copp, 2001), the primary cellular abnormality leading to the development of spina bifida has been identified as a reduced rate of cell proliferation in the hindgut endoderm and notochord (Copp et al., 1988). The resultant growth imbalance between dorsal and ventral tissues causes excessive ventral curvature of the caudal embryonic region, which mechanically opposes closure of the posterior neuropore (Brook et al., 1991). Exogenous inositol treatment may correct the underlying cell proliferation defect in curly tail embryos. In support of this idea, inositol metabolism is known to be intimately involved with cell cycle progression in a variety of cell types. For instance, a nuclear polyphosphoinositide cycle exists in which phosphatidylinositol-specific

model was evaluated. Maternal inositol administration significantly reduced the frequency of spina bifida in curly tail mice and normalized closure of the posterior neuropore in whole cultured embryos. A striking finding was the increased potency of D-chiro-inositol compared with myo-inositol—two closely related enantiomers that differ only in the orientation of the carbon-two hydroxyl group (C2-OH) relative to the plane of the six carbon ring. At identical dosage levels, s.c. administered D-chiro-inositol caused a consistently greater reduction in frequency of spina bifida than myo-inositol. Moreover, in vitro, D-chiro-inositol was effective in normaliz-
P.Cogram et al.

Table II. Frequency of neural tube and tail defects among curly tail fetuses treated in utero with myo- and D-chiro-inositol

<table>
<thead>
<tr>
<th>Dose route</th>
<th>Treatment</th>
<th>Inositol dose</th>
<th>No. of fetuses</th>
<th>Phenotype of fetuses&lt;sup&gt;b,c&lt;/sup&gt;</th>
<th>Spina bifida&lt;sup&gt;±&lt;/sup&gt;</th>
<th>Curly tail</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>s.c.</td>
<td>PBS</td>
<td>–</td>
<td>25</td>
<td></td>
<td>6 (24.0)</td>
<td>14 (56.0)</td>
<td>5 (20.0)</td>
</tr>
<tr>
<td></td>
<td>myo</td>
<td>29</td>
<td>29</td>
<td></td>
<td>6 (20.7)</td>
<td>12 (41.4)</td>
<td>11 (37.9)</td>
</tr>
<tr>
<td></td>
<td>D-chiro</td>
<td>29</td>
<td>26</td>
<td></td>
<td>3 (11.5)</td>
<td>17 (65.4)</td>
<td>6 (23.1)</td>
</tr>
<tr>
<td>PBS</td>
<td>–</td>
<td>104</td>
<td></td>
<td></td>
<td>14 (13.5)</td>
<td>63 (60.6)</td>
<td>27 (25.9)</td>
</tr>
<tr>
<td>myo</td>
<td>72</td>
<td>67</td>
<td></td>
<td></td>
<td>4 (6.0)</td>
<td>37 (55.2)</td>
<td>26 (38.8)</td>
</tr>
<tr>
<td>D-chiro</td>
<td>72</td>
<td>86</td>
<td></td>
<td></td>
<td>2 (2.3)</td>
<td>39 (45.4)</td>
<td>45 (52.3)</td>
</tr>
<tr>
<td>PBS</td>
<td>–</td>
<td>102</td>
<td></td>
<td></td>
<td>19 (18.6)</td>
<td>49 (48.0)</td>
<td>34 (33.3)</td>
</tr>
<tr>
<td>myo</td>
<td>144</td>
<td>94</td>
<td></td>
<td></td>
<td>8 (8.5)</td>
<td>52 (55.3)</td>
<td>34 (36.2)</td>
</tr>
<tr>
<td>D-chiro</td>
<td>144</td>
<td>99</td>
<td></td>
<td></td>
<td>5 (5.0)</td>
<td>46 (46.5)</td>
<td>48 (48.5)</td>
</tr>
<tr>
<td>Oral</td>
<td>PBS</td>
<td>–</td>
<td>44</td>
<td></td>
<td>8 (18.2)</td>
<td>21 (47.7)</td>
<td>15 (34.1)</td>
</tr>
<tr>
<td></td>
<td>myo</td>
<td>800</td>
<td>35</td>
<td></td>
<td>3 (8.6)</td>
<td>15 (42.9)</td>
<td>17 (48.6)</td>
</tr>
<tr>
<td></td>
<td>D-chiro</td>
<td>800</td>
<td>39</td>
<td></td>
<td>1 (2.6)</td>
<td>12 (30.8)</td>
<td>26 (66.7)</td>
</tr>
</tbody>
</table>

<sup>a</sup>μg inositol/g body weight per day.

<sup>b</sup>Phenotype frequencies expressed as number of fetuses (% of total for treatment group).

<sup>c</sup>Statistical analysis: distribution of embryos among the three phenotype categories varies significantly with treatment group at 72, 144 and 800 μg inositol/g body weight per day (χ^2-tests, P = 0.0005, 0.0051 and 0.026 respectively) but not at 29 μg inositol/g body weight per day (P = not significant).

PBS = phosphate-buffered saline.

Table III. Survival of embryos and fetuses among curly tail litters treated in utero with myo- and D-chiro-inositol

<table>
<thead>
<tr>
<th>Dose route</th>
<th>Treatment</th>
<th>Inositol dose</th>
<th>No. of litters</th>
<th>No. of viable fetuses</th>
<th>Mean fetal crown—rump length&lt;sup&gt;b&lt;/sup&gt;</th>
<th>No. of uterine resorptions&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Mean litter size&lt;sup&gt;d&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>s.c.</td>
<td>PBS</td>
<td>–</td>
<td>4</td>
<td>25</td>
<td>22.3 ± 0.3</td>
<td>3 (10.7)</td>
<td>6.3 ± 1.0</td>
</tr>
<tr>
<td></td>
<td>myo</td>
<td>29</td>
<td>4</td>
<td>29</td>
<td>21.8 ± 0.3</td>
<td>2 (6.5)</td>
<td>7.3 ± 1.8</td>
</tr>
<tr>
<td></td>
<td>D-chiro</td>
<td>29</td>
<td>3</td>
<td>26</td>
<td>22.0 ± 0.3</td>
<td>1 (3.7)</td>
<td>8.7 ± 1.8</td>
</tr>
<tr>
<td>PBS</td>
<td>–</td>
<td>12</td>
<td>104</td>
<td></td>
<td>21.4 ± 0.6</td>
<td>10 (8.8)</td>
<td>8.7 ± 0.5</td>
</tr>
<tr>
<td>myo</td>
<td>72</td>
<td>8</td>
<td>67</td>
<td></td>
<td>21.9 ± 0.2</td>
<td>7 (9.5)</td>
<td>8.4 ± 0.8</td>
</tr>
<tr>
<td>D-chiro</td>
<td>72</td>
<td>12</td>
<td>86</td>
<td></td>
<td>21.8 ± 0.2</td>
<td>8 (8.5)</td>
<td>7.2 ± 0.9</td>
</tr>
<tr>
<td>PBS</td>
<td>–</td>
<td>12</td>
<td>102</td>
<td></td>
<td>20.9 ± 0.3</td>
<td>9 (8.1)</td>
<td>8.5 ± 0.8</td>
</tr>
<tr>
<td>myo</td>
<td>144</td>
<td>12</td>
<td>94</td>
<td></td>
<td>21.4 ± 0.5</td>
<td>9 (8.7)</td>
<td>7.8 ± 0.4</td>
</tr>
<tr>
<td>D-chiro</td>
<td>144</td>
<td>14</td>
<td>99</td>
<td></td>
<td>21.6 ± 0.4</td>
<td>6 (5.7)</td>
<td>7.1 ± 0.8</td>
</tr>
<tr>
<td>Oral</td>
<td>PBS</td>
<td>–</td>
<td>7</td>
<td>44</td>
<td>22.3 ± 0.4</td>
<td>5 (10.2)</td>
<td>6.3 ± 0.4</td>
</tr>
<tr>
<td></td>
<td>myo</td>
<td>800</td>
<td>6</td>
<td>35</td>
<td>22.0 ± 0.3</td>
<td>3 (7.9)</td>
<td>5.8 ± 0.5</td>
</tr>
<tr>
<td></td>
<td>D-chiro</td>
<td>800</td>
<td>6</td>
<td>39</td>
<td>21.7 ± 0.2</td>
<td>3 (7.1)</td>
<td>6.5 ± 1.1</td>
</tr>
</tbody>
</table>

<sup>a</sup>μg inositol/g body weight per day.

<sup>b</sup>Crown-rump length (mm; mean ± SEM) measured on a subset of fetuses (n = 6-9 per group). Values do not differ significantly between treatments or dose levels.

<sup>c</sup>Values in parentheses are resorptions as % of total number of implantations (i.e. viable fetuses + resorptions). Logistic regression analysis: the proportion of resorptions does not differ significantly between myo-inositol and PBS litters, between D-chiro-inositol and PBS litters, or between inositol dose levels.

<sup>d</sup>Litter size (mean no. of viable fetuses per litter ± SEM) does not vary significantly with treatment group or inositol dose level. Although not statistically significant, litters treated with oral inositol contain an average of 1.6 (95% confidence intervals: 0.4-2.8) fewer fetuses than litters treated with s.c. inositol.

phospholipase C generates elevated levels of nuclear DAG specifically during G2 phase of the cell cycle (Sun et al., 1997). This DAG production is required for the G2/M transition, perhaps by attracting specific activated PKC isozymes to the nucleus, where they are stabilized by binding to nuclear proteins including lamins A, B and C. The elevation of DAG levels is transient, as DAG is rapidly converted to phosphatidic acid by nuclear DAG kinases, enzymes that are also induced by growth-promoting agents (Martelli et al., 2000). It is possible that inositol treatment of curly tail embryos stimulates this nuclear DAG cycle leading, via the activation of specific PKC isozymes, to the increased proliferation of hindgut and notochordal cells, so normalizing neural tube closure.

Relevance of the findings for clinical application of inositol therapy

In order for these experimental findings to be translated into a clinical application, inositol supplementation must be not only effective in preventing NTDs, but also safe for use during human pregnancy. The current demonstration of a protective
effect of inositol by s.c. and oral administration is supported by the results of previous studies in which myo-inositol was injected i.p. (Greene and Copp, 1997). Further support for the effectiveness of oral supplementation with myo-inositol comes from the finding of a reduction in the incidence of diabetes-induced abnormalities in rats by oral administration of myo-inositol (Khandelwal et al., 1998). The efficacy of inositol in preventing human NTDs has not yet been tested in a clinical trial. Nevertheless, a recent case study has documented inositol supplementation in association with a normal outcome in the third pregnancy of a woman who had two previous consecutive NTD pregnancies at risk of ‘folate-resistant’ NTDs is needed, to test the idea that inositol may be as effective in humans as in mice.

With regard to the safety of inositol therapy during pregnancy, the present pathological study revealed no major defects, apart from NTDs, and no increase in the frequency of embryonic or fetal loss in utero in inositol-treated mice. The present study was limited, however, and in particular the effects of inositol administration during the periconceptional period—when inositol would be taken during a clinical trial—were not assessed. The reproductive toxicology of D-chiro-inositol has been the subject of studies in rats and rabbits, with more extensive administration at doses up to 2000 mg/kg per day, and no adverse effects on mating, fertility or embryo/fetal development have been found (Insmed Inc., data on file). There is much less information available on the safety of inositol therapy in human pregnancy. In the case of the mother who took inositol in her third pregnancy following two apparently ‘folate-resistant’ NTD pregnancies, a dose of 0.5 g inositol per day was used, with no known side-effects for either mother or baby (Cavalli and Copp, 2002). In particular, there was no evidence of abnormal uterine contractions, such as have been suggested as a possible adverse effect of inositol therapy (Colodny and Hoffman, 1998). Myo-inositol has also been tested in adults for prevention of depression, panic disorder and obsessive compulsive disorder (Benjamin et al., 1995; Levine et al., 1995; Fux et al., 1996) and in children for treatment of autism (Levine et al., 1997). No significant side-effects were reported in these studies, which employed relatively high inositol doses of up to 18 g per day in adults and 200 mg/kg in children.

In conclusion, D-chiro-inositol has been shown to be highly effective in preventing folate-resistant mouse NTDs. A clinical trial could next evaluate the effectiveness of peri-conceptional inositol supplementation, as an adjunct to folic acid therapy, in preventing human NTDs. If folate-resistant NTDs can be prevented, in addition to those cases already prevented by folic acid, this could lead to a significant further reduction in the frequency of this birth defect.

### Table IV. Pathological analysis of curly tail fetuses treated in utero with myo- and D-chiro-inositol

<table>
<thead>
<tr>
<th>Pathology</th>
<th>PBSb</th>
<th>myo</th>
<th>D-chiro</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>72</td>
<td>144</td>
<td>72</td>
</tr>
<tr>
<td>No. of fetuses examined</td>
<td>27</td>
<td>17</td>
<td>11</td>
</tr>
<tr>
<td>Exencephaly = open eye</td>
<td>1 (3.7)</td>
<td>2 (11.8)</td>
<td>–</td>
</tr>
<tr>
<td>Hydrocephaly</td>
<td>1 (3.7)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Haemorrhage in/around brain</td>
<td>–</td>
<td>2 (11.8)</td>
<td>–</td>
</tr>
<tr>
<td>Microphthalmia/macrophthalmia</td>
<td>1 (3.7)</td>
<td>1 (5.9)</td>
<td>–</td>
</tr>
<tr>
<td>Bleeding in thorax/abdomen</td>
<td>6 (22.2)</td>
<td>4 (23.6)</td>
<td>2 (18.2)</td>
</tr>
<tr>
<td>Thyroid lobe reduction</td>
<td>1 (3.7)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Intrahepatic bleeding</td>
<td>–</td>
<td>1 (5.9)</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>Small additional liver lobe</td>
<td>9 (33.3)</td>
<td>4 (23.5)</td>
<td>6 (54.5)</td>
</tr>
<tr>
<td>Fissure in liver lobe</td>
<td>–</td>
<td>2 (11.8)</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>Renal pelvis/ureter enlarged</td>
<td>1 (3.7)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Skeletal analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of fetuses examined</td>
<td>29</td>
<td>18</td>
<td>16</td>
</tr>
<tr>
<td>Exencephaly</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Bony plaque in frontonasal suture</td>
<td>1 (3.4)</td>
<td>–</td>
<td>1 (6.3)</td>
</tr>
<tr>
<td>Anomalous cervical vertebra(e)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Rudimentary ribs on 7th cervical vertebra</td>
<td>4 (13.8)</td>
<td>2 (11.1)</td>
<td>1 (6.3)</td>
</tr>
<tr>
<td>Anomalous thoracic vertebrae and/or ribs</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Rudimentary 14th ribs</td>
<td>–</td>
<td>1 (5.6)</td>
<td>–</td>
</tr>
<tr>
<td>Sternal fusions</td>
<td>1 (3.4)</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

aSummary of most prevalent findings only are listed. A single fetus may have more than one morphological finding. Values are number of fetuses with defect (% of total for treatment group). A dash (–) indicates that no fetuses exhibited that finding.
bPBS dose levels 72 and 144 refer to saline controls performed contemporaneously with the stated dose levels of myo- and D-chiro-inositol.
cProportion with defect does not differ significantly between fetuses treated with D-chiro-inositol and PBS controls (144 µg/g body weight per day; Fisher’s exact test; P > 0.05).
Acknowledgements
The authors thank Katie Gardner for valuable technical assistance. This study was supported by Wellbeing. Insmed Incorporated and the Wellcome Trust.

References

Submitted on February 25, 2002: accepted on May 10, 2002
SPECIAL NOTE

ITEM SCANNED AS SUPPLIED
PAGINATION IS AS SEEN
Specific isoforms of protein kinase C are essential for prevention of folate-resistant neural tube defects by inositol

Patricia Cogram, Andrew Hynes, Louisa P.E. Dunlevy, Nicholas D.E. Greene and Andrew J. Copp*

1 Neural Development Unit, Institute of Child Health, University College London, London WC1N 1EH, UK

Received July 8, 2003; Revised and Accepted October 27, 2003

A proportion of neural tube defects (NTDs) can be prevented by maternal folic acid supplementation, although some cases are unresponsive. The curly tail mutant mouse provides a model of folate-resistant NTDs, in which defects can be prevented by inositol therapy in early pregnancy. Hence, inositol represents a possible novel adjunct therapy to prevent human NTDs. The present study investigated the molecular mechanism by which inositol prevents mouse NTDs. Activation of protein kinase C (PKC) is known to be essential, and we examined neurulation-stage embryos for PKC expression and applied PKC inhibitors to curly tail embryos developing in culture. Although all known PKC isoforms were detected in the closing neural tube, use of chemical PKC inhibitors identified a particular requirement for 'conventional' PKC isoforms. Peptide inhibitors offer selective inhibition of individual PKCs, and we demonstrated isoform-specific inhibition of PKC in embryonic cell cultures. Application of peptide inhibitors to neurulation-stage embryos revealed an absolute dependence on the activity of PKC\(\text{\textit{\textbeta}}}\) and \(\gamma\) for prevention of NTDs by inositol, and partial dependence on PKC\(\text{\textdelta}\), whereas other PKCs (\(\alpha\), \(\beta\), \(\delta\), and \(\epsilon\)) were dispensable. To investigate the cellular action of inositol and PKCs in NTD prevention, we examined cell proliferation in curly tail embryos. Defective proliferation of hindgut cells is a key component of the pathogenic sequence leading to NTDs in curly tail. Hindgut cell proliferation was stimulated specifically by inositol, an effect that required activation of PKC\(\text{\textit{\textbeta}}}\). Our findings reveal an essential role of specific PKC isoforms in mediating the prevention of mouse NTDs by inositol.

INTRODUCTION

Neural tube defects (NTDs) are common, severe birth defects with a multifactorial aetiology involving both genetic and environmental factors. In a proportion of cases, NTDs can be prevented by maternal peri-conceptional supplementation with folic acid (1,2). Around 30% of NTDs appear unresponsive to folic acid, however, and there is currently no preventive therapy available for these ‘folate-resistant’ defects. A large number of mouse genetic mutants exhibit NTDs and, as in humans, some of these are responsive to folic acid treatment whereas others are not (3,4). Mice homozygous for the curly tail mutation develop spina bifida that exhibits many similarities to the corresponding human NTD (5). NTDs in curly tail mice are folate-resistant (6), but we showed that the majority of NTDs in curly tail mice can be prevented by both myo-inositol and its D-chiro- enantiomer, either administered to pregnant females or directly to embryos \textit{in vitro} (7,8). Our findings raise the possibility of developing a novel clinical therapy based on inositol. The recent observation that inositol therapy is well tolerated during human pregnancy at high risk of NTD recurrence (9), encourages progress towards a clinical trial of inositol.

The mechanism of action of inositol in preventing NTDs in curly tail mice involves activation of PKC, a family of serine/threonine kinases (7). The effect of inositol can be mimicked by brief treatment of embryos with TPA (12-O-tetradecanoyl-phorbol-13-acetate), an agonist of PKC. Moreover, the effect of inositol is blocked by co-administration of a broad-spectrum chemical inhibitor of PKC (7). At least 10 isoforms of PKC are known, grouped according to their dependence on diacylglycerol (DAG) and Ca\(^{2+}\) for activation (10). Conventional PKCs

*To whom correspondence should be addressed at: Neural Development Unit, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK. Tel: +44 2078298893; Fax: +44 2078314366; Email: a.copp@ich.ucl.ac.uk

Present address:
Etiologies Limited, Harwell, Oxfordshire OX11 0RD, UK.
(cPKCs; α, βI, βII, γ) require DAG and Ca$^{2+}$, novel PKCs (nPKCs; δ, ε, η, θ) are DAG-sensitive but Ca$^{2+}$-insensitive, and atypical PKCs (aPKCs; α, λ and the related PKCμ) are activated by neither DAG or Ca$^{2+}$ (10).

To elucidate the molecular mechanism by which inositol normalizes neural tube closure, we determined which of the PKC isoforms mediate this effect. All known PKC isoforms could be detected during mouse neural tube closure, but culture of intact curly tail embryos in the presence of isoform-specific PKC inhibitors identified PKCβI and γ as essential for the normalizing action of inositol. Other PKC isoforms were not required. At the cellular level, inositol treatment was found to correct the deficit of cell proliferation that underlies NTD development in curly tail embryos (11), an effect that is blocked by inhibition of PKCβI. Moreover, treatment of cultured cells with either the PKC activator TPA or inositol itself, could induce translocation of PKC isoforms, including PKCβI and γ to the nucleus. We conclude that PKCβI and γ are essential components of the molecular mechanism underlying the preventive effect of inositol on mouse NTDs.

RESULTS

PKC isoform expression during mouse embryogenesis

In order to identify the isoforms that might play a role in prevention of NTD, we initially determined which PKC isoforms are expressed in mouse embryos undergoing organogenesis (E9.5 to E16.5). Western blot analysis of cytoplasmic (C), membrane-associated (Ps) and insoluble (Pi) fractions of embryonic cell extracts indicated the degree to which PKC isoforms are activated (i.e. associated with membrane or insoluble cellular compartments). All PKC isoforms could be detected, but their relative abundance varied with stage and cellular fraction (Fig. 1). cPKCs (α, β, γ) were weak or undetectable in the cytoplasmic fraction at E9.5 and E10.5, although expression increased from E11.5 onwards. Among the cPKCs, only PKCγ was present in the Ps fraction from E11.5 and in the Pi fraction at the latest stages. nPKCs (δ, ε, θ, η) were expressed throughout the developmental period in both C and Ps fractions, whereas expression in the Pi fraction was more variable. aPKCs (α, λ and the related PKCμ) were abundant from E9.5 onwards in all cellular fractions, with a fairly constant level of expression. All PKC isoforms were also detected in mutant curly tail embryos with no consistent differences in abundance compared with non-mutant CD1 mice (data not shown). Hence, the DAG-responsive cPKCs and nPKCs, which are likely to mediate the normalizing effect of inositol (6), exhibit evidence of stage-dependent activation unlike the aPKCs which appear ubiquitous and constitutively activated, as also described in other systems (12).

Western blot analysis was insufficiently sensitive to detect PKC isoform expression in specific embryonic regions, such as the posterior neuropore (PNP), the site of spinal neurulation (13). We performed immunohistochemistry on histological sections through the PNP region, and detected expression of PKCs α, βI, βII, γ and ε in the closing neural tube, hindgut, notochord and presomitic mesoderm, at both E9.5 and E10.5 (Fig. 2). We conclude that although cPKCs, in particular, are variably expressed in whole neurulation-stage embryos by immunoblotting, they can be detected in all tissues of the PNP region by immunohistochemistry and, therefore, are candidates for a role in mediating the preventive effect of inositol on NTDs. Immunostaining was not carried out for the remaining isoforms as they were clearly detectable by western blot (Fig. 1).

Chemical PKC inhibitors block the protective effect of inositol on NTDs

We used PKC inhibitors to block the effect of inositol on neural tube closure. Curly tail embryos were cultured from E9.5 to E10.5, and the length of unclosed neural folds at the PNP was then measured to indicate predisposition to spina bifida (13). Embryos exposed to PBS (vehicle) alone had enlarged PNPs (Fig. 3A), reflecting the in vivo development of spinal NTDs by 50-60% of curly tail embryos (5), whereas treatment with myo-inositol decreased PNP length significantly (first grey bar, Fig. 3A), to a value characteristic of normally developing embryos (5). Hence, inositol normalizes PNP closure in vitro, confirming previous findings (7,8). Curly tail embryos were exposed in culture to chemical inhibitors that block different combinations of PKC isoforms. Bisindolylmaleimide I (BisI) inhibits PKCα, βI, βII, γ and ε (14), Go6976 inhibits solely cPKCs (15), HBDDE inhibits PKCα and γ in vitro (16) and LY294002 is an inhibitor of phosphatidylinositol-3-kinase (17), an activator of PKCγ (18). When added alone, none of the inhibitors significantly altered PNP length (white bars, Fig. 3A). Moreover, BisI, an inactive control, did not prevent the reduction in PNP length caused by co-administration of inositol (second grey bar, Fig. 3A). In contrast, BisI, Go6976, HBDDE and LY294002 all partially blocked the normalizing effect of inositol, such that PNP length was reduced to a significantly lesser degree than in the presence of inositol alone (black bars, Fig. 3A). Hence, use of chemical inhibitors highlights the...
Figure 2. Ubiquitous expression of PKC isoforms during mouse spinal neurulation, detected by immunohistochemistry. Transverse histological sections through the posterior neuropore region of curly tail mouse embryos at E9.5 (A, D, G, J, M) and E10.5 (B, E, H, K, N) stained with antibodies specific for PKCα, βI, βII, γ and ε. All PKCs exhibit ubiquitous expression in the neural plate, notochord, hindgut and presomitic mesoderm of the posterior neuropore region. Sections of adult mouse cerebellum (C, F, I, L, O) provide a positive control for the isoform-specific PKC antibodies: anti-PKCα, γ and ε stain only Purkinje cells, whereas anti-PKCβI and βII stain only granule cells, as described previously for the rat cerebellum (46). Abbreviations: G, granule cells; H, hindgut; M, presomitic mesoderm; N, notochord; Np, neural plate; P, Purkinje cells. Scale bar represents 20 μm.

Peptide inhibitors identify a critical role for PKCβI, γ and ε in the inositol effect

Because of the relatively broad spectrum activity of chemical PKC inhibitors, we next applied isoform-specific peptide PKC inhibitors to cultured curly tail embryos, to more precisely define the PKC isoform requirement for the inositol effect. Each peptide inhibitor was designed to the amino acid sequence corresponding to the isoform-specific RACK (receptor for activated C kinase) binding site on PKC. Inhibitors of this type prevent PKC translocation and/or activation in an isoform-specific manner (19,20). Peptide inhibitors were coupled to a sequence derived from the Drosophila Antennapedia homeodomain, ensuring cell permeability.

As with the chemical inhibitors, peptide PKC inhibitors alone had no significant effect on PNP length. Moreover,
the normalizing effect of inositol on PNP length persisted in the presence of inhibitors for PKCα, βII, δ and ε, as well as an inactive peptide (Fig. 3B). Strikingly, however, the co-addition with inositol of inhibitors for PKCβI or γ largely abolished the normalizing effect of inositol (black bars in Fig. 3B). Inhibition of PKCε also partially blocked the normalizing action of inositol. These findings are consistent with the results from use of the chemical inhibitors, and indicate that the cPKCs, βI and γ, and additionally PKCε, are critical for mediating the preventive effect of inositol.

Activation of PKC isoforms in embryonic mouse cells is blocked by peptide inhibitors

One possible explanation for the apparently isoform-specific PKC requirement for inositol action is that βI, γ and ε are the only isoforms whose activation is blocked by peptide inhibitors in curly tail embryonic cells. To test this idea, primary fibroblastic cell cultures, prepared from caudal regions of E9.5 curly tail embryos were serum-starved and then treated with the PKC agonist, TPA, in the presence or absence of peptide PKC inhibitors. Prior to TPA treatment, each PKC isoform exhibited cytoplasmic localization (Fig. 4A, D, G, J and M) but, following TPA treatment, all isoforms translocated to the nucleus (Fig. 4B, E, H, K and N), indicative of activation. In every case, addition of the appropriate peptide inhibitor blocked this TPA-induced translocation indicating that PKC activation had been prevented (Fig. 4C, F, I, L and O). Closely similar results were obtained with the mouse 3T3 cell line (data not shown).

In view of the close relationship between PKCβI and its alternatively spliced variant PKCβIII, we tested whether abrogation of the inositol effect by the PKCβI inhibitor might have resulted from antagonism of both PKCβI and βII activation. PKCβIII translocated to the nucleus following TPA stimulation, and this translocation was blocked by the βI inhibitor, but not by the βII inhibitor (Fig. 5A–C). Conversely, translocation of PKCβIII was blocked by the βII inhibitor but not the βI inhibitor (Fig. 5D–F). This finding confirms that the peptide inhibitors of PKCβI and βII are indeed isoform-specific and suggests separate roles for these splice variants. We conclude that the requirement for specific PKC isoforms is unlikely to reflect differential activity of the peptide inhibitors, but may reflect a difference in participation of PKC isoforms in the action of inositol in preventing mouse NTDs.

To determine whether the PKC stimulation observed after TPA treatment also follows inositol administration, we studied PKC localization after inositol treatment. Inositol treatment was capable of inducing the translocation of PKCα from the cytoplasm, as in serum-starved cells, to the nucleus (Fig. 5G and H). Similarly, PKCβI and γ, isoforms whose activity is essential for prevention of NTD, were also found to exhibit nuclear localization in inositol-treated but not in untreated cells (data not shown). No difference in the localization of PKCε could be detected after 6 h inositol treatment (50 μM), but we cannot rule out the possibility that PKCε is activated at a different dose or at a different time point. This observation suggests that PKCα, βI and γ can be activated by inositol treatment. However, PKCα is not required for prevention of NTD whereas PKCβI and γ are essential.

Figure 4. Inhibition of PKC isoform translocation by peptide inhibitors in TPA-treated mouse embryonic cells. Immunocytochemistry using isoform-specific antibodies to PKC (as in Fig. 2) in curly tail primary embryonic cell cultures. Cells cultured for 18 h in growth medium containing 1% FCS were either fixed with no additional treatment ('serum starved': A. D. G. J. M), exposed to 100 nM TPA for 10 min prior to fixation (+TPA: B. E. H. K. N), or exposed to 1 μM isoform-specific PKC inhibitor for 20 min and to TPA for 10 min prior to fixation (TPA + Inhib: C. F. I. L. O). PKCs are uniformly located in the cytoplasm of serum-starved cells whereas a 10 min treatment with TPA induces translocation to the nucleus in all cases. Pre-treatment with isoform-specific PKC inhibitors prevents TPA-induced translocation and all PKC isoforms exhibit cytoplasmic staining. Inset in (O) shows same field stained with DAPI to demonstrate nuclei. Scale bar represents 20 μm.

Embryonic cell proliferation is stimulated by inositol, in a PKCβI-sensitive manner

Delayed closure of the PNP in curly tail embryos results from a reduced rate of cell proliferation, specifically in the embryonic hindgut, within the caudal region (3,11,21,22). The resulting proliferation imbalance causes ventral curvature of the caudal region, counteracting the apposition of the neural folds, and leading to spina bifida (23,24). The effect of inositol on cell proliferation was examined by immunohistochemistry for PCNA (proliferating cell nuclear antigen) and phospho-histone H3, markers of S-phase and M-phase of the cell cycle respectively. A significant stimulatory effect of inositol on
Figure 5. Inositol stimulates PKC translocation, whereas peptide inhibitors to PKCβII and βI exhibit isoform-specificity in blocking translocation. PKC isoforms were localized by immunocytochemistry on primary cell cultures established from curly tail mouse embryos. Serum starved cells exhibit PKCβII and βI immunoreactivity in the cytoplasm. TPA-induced translocation to the nucleus of PKCβII can be blocked by the βI inhibitor (B) but not by the βII inhibitor (C). Conversely, translocation to the nucleus of PKCβII can be blocked by the inhibitor to βII (E) but not by the inhibitor to βI (F). Addition of 50 μg/ml myo-inositol to serum starved cells 6 h prior to fixation induces translocation of PKCa to the nucleus (H), whereas PKCa is cytoplasmic in untreated cells (G). This effect of inositol is not unique to curly tail cells as similar results were obtained in 3T3 cells. Scale bar represents 20 μm.

Figure 6. Inositol stimulates hindgut cell proliferation during NTD prevention, an effect requiring activation of PKCβII but not PKCa. Cell proliferation was measured in tissues of the posterior neuropore region of cultured curly tail embryos by (A) PCNA labelling, a measure of cells in S-phase and (B) phospho-histone H3 labelling, a marker of mitotic cells. Cell proliferation is most rapid in neuroepithelium, less intense in hindgut endoderm and slowest in notochord, as described previously (11). Inositol significantly stimulates PCNA labelling (P < 0.005) and histone H3 labelling (P < 0.02) in hindgut endoderm, whereas inositol has no significant effect on PCNA or histone H3 labelling in either neuroepithelium or notochord (P > 0.05). In hindgut endoderm, inhibition of PKCβII significantly reduces histone H3 labelling compared with inositol alone (P < 0.05), whereas inhibition of PKCa has no significant effect (P > 0.05). Blocking PKCβII or βI has no significant effect on histone H3 labelling in neuroepithelium or notochord (P > 0.05). No cells were positive for histone H3 in the presence of inositol and the PKCβII inhibitor (Fig. 6B; notochord data, bar 5). Labelling indices are mean ± SEM of at least 10 embryos per treatment.

DISCUSSION

Inositol normalizes neural tube closure in the spinal region of curly tail mouse embryos destined to develop spina bifida (7), whereas folic acid has no preventive effect (6). Brief treatment with the PKC agonist TPA mimics the inositol effect, whereas the PKC inhibitor BisI abrogates inositol-mediated prevention (7). Here, we used other chemical PKC inhibitors, with reportedly narrower spectra of action, and showed that these are also able to block the inositol effect. However, the precise specificity of chemical PKC inhibitors may vary between cell types. For example, HBDDE is specific for PKCa and γ in vitro (16), but acts on other molecular targets in cerebellar granule neurons (25). This prompted the use of peptide PKC inhibitors which were able to block the translocation of specific PKC isoforms. Isoform-by-isoform analysis using these inhibitors revealed a requirement for PKCβII, γ and μ, but not other PKCs in the normalization of neural tube closure in curly tail embryos.
Developmental regulation of PKC isoform expression

We detected all PKC isoforms, during mouse development from E9.5 to E17.5, in agreement with previous analysis of PKCs in E15–17 fetuses (26). Our findings contrast with a study of E10.5 embryos that detected PKC\(\alpha\), \(\delta\) and \(\zeta\), but not \(\beta\), \(\beta\)l, \(\gamma\) and \(\epsilon\) (27). This difference may reflect the low abundance of cPKCs on western blot, at early stages (E9.5–11.5) in particular, although all isoforms were clearly detectable in the PNP region by immunohistochemistry. Each PKC isoform exhibited a distinct distribution between sub-cellular fractions, which likely reflects the degree of activation. For instance, cPKCs were confined to the cytoplasmic fraction, suggesting minimal activation during undisturbed development, whereas aPKCs were present in membrane-associated and insoluble fractions throughout development, suggesting constitutive activation, as described in other systems (12). This finding is consistent with a role for the cPKCs, \(\beta\)l and \(\gamma\), in mediating the preventive effect of inositol, since activation of these isoforms may be limiting in the absence of inositol, providing capacity for activation after treatment.

PKC isoforms and cell cycle regulation

We have demonstrated that inositol stimulates cell proliferation in the hindgut of curly tail embryos, reversing the imbalance of cell proliferation that is known to lead, via enhanced ventral curvature of the caudal region, to delay or failure of PNP closure (11,23,24,28). Moreover, PKC\(\beta\)l but not PKC\(\epsilon\) is required for this stimulation of cell proliferation. PKC\(\beta\)l has been previously associated with increased cell cycle entry. Its over-expression leads to increased proliferation of aortic endothelial cells, in contrast to PKC\(\alpha\) which has an inhibitory effect (29). Similarly, proliferation of vascular smooth muscle cells is stimulated by PKC\(\beta\)l, through increased S-phase entry, but inhibited by PKC\(\epsilon\), through extension of S-phase (30). S-phase entry/progression has been suggested to be defective in hindgut cells of curly tail embryos (11), raising the possibility that activation of PKC\(\beta\)l may reverse this defect, leading to 'rescue' of the mutant phenotype. Interestingly, inositol treatment of cells for 6h resulted in nuclear translocation of PKC\(\beta\)l and \(\gamma\) in some cells, as observed for short-term exposure to TPA. This nuclear localization suggests that a role of PKC\(\beta\)l in cell cycle regulation is plausible. PKC\(\alpha\) also exhibits nuclear translocation in inositol-treated cells (both curly tail and non-mutant), but does not play an essential role in the prevention of NTD.

Molecular basis of the requirement for PKC\(\zeta\) and PI3-kinase

The normalizing effect of inositol on PNP closure was partially blocked by inhibition of PKC\(\zeta\) or PI3-kinase. The requirement for PKC\(\zeta\) may reflect a role in regulating other PKC isoforms (31). PKC\(\zeta\) is activated downstream of PI3-kinase (18), whose activity in turn depends on availability of phosphatidylinositol species. Hence, inositol administration may activate both PI3-kinase and PKC\(\zeta\), by increasing flux through intracellular phosphoinositide metabolism. Indeed, inhibition of the inositol phosphate cycle by lithium blocks the preventive effect of inositol (7). The requirement for PI3-kinase may also be explained by its participation, with 3-phosphoinositide-dependent protein kinase-1 (PDK1) (32), in phosphorylation of the T-loop of the kinase domain, a requirement for activity of PKCs (33). Although we detected nuclear translocation of PKC\(\alpha\), \(\beta\)l and \(\gamma\) following treatment of cells with inositol for 6h, altered localization of PKC\(\zeta\) was not detected. This could be simply due to suboptimal dose or period of treatment (activation could be short-lived), but it is also likely that PKC\(\zeta\) activation occurs by a different mechanism to the classical isoforms as PKC\(\zeta\) is not diacylglycerol-responsive. Moreover, the partial requirement for PKC\(\zeta\) in the protective effect of inositol may reflect a permissive role for PKC\(\zeta\) activity that does not involve translocation to the nucleus.

Is PKC implicated in the mechanism of neural tube closure?

Several lines of evidence suggest that spinal neurulation per se does not depend on PKC activation and that defective closure in curly tail embryos is unlikely to result from an intrinsic deficiency in specific PKC isoforms. First, exposure of curly tail embryos to PKC inhibitors, in the absence of inositol, did not affect PNP closure. Similar findings were obtained with non-mutant CD1 embryos (data not shown). Second, there is no difference in abundance of PKC isoforms between affected and unaffected curly tail embryos (data not shown). Third, uptake and incorporation of \(^{3}H\)-inositol occurs similarly in cultured curly tail and non-mutant embryos, while inositol deficiency in vitro does not increase the penetrance of spinal NTDs in curly tail embryos (7). Finally, mice with targeted inactivation of the genes encoding PKC\(\alpha\), \(\beta\), \(\gamma\), \(\delta\), \(\varepsilon\) and \(\zeta\) do not exhibit neurulation defects (34–39). We suggest, therefore, that prevention of NTDs in curly tail mice by exogenous inositol operates via stimulation of the cell cycle in the embryonic hindgut, an effect that requires activation of specific PKC isoforms. Inositol is also reported to prevent NTDs in animal models of diabetes (40), whereas inositol deficiency causes cranial NTD, even in non-mutant mice (41). It remains to be determined whether the protective action of inositol also involves stimulation of cell proliferation in these cases.

MATERIALS AND METHODS

Mouse strains and embryo culture

Curly tail mice were maintained as described (5). Non-mutant random-bred CD1 mice were purchased from Charles River, UK. Mice were paired overnight and females checked for copulation plugs the following morning, designated embryonic day (E) 0.5. Embryos were explanted at E9.5 and those with 17–19 somites were cultured for 24h in rat serum (6). Embryos were randomly allocated to treatment groups to minimize the effect of litter-to-litter variation. Cultures were supplemented with 1% (v/v) additions of phosphate buffer saline (PBS) or mvo-inositol (50 \(\mu\)g/ml, final concentration). PKC inhibitors were added as 1% (v/v) additions. Bisindolylmaleimide (Bis) I and V, Go6976, HBDDE and LY294002 (all from Calbiochem) were diluted in minimal volumes of DMSO, further diluted in...
PBS, and added to cultures at final concentrations corresponding to their IC\textsubscript{50} values (14–17): 10 \mu M (BisI, BisV, Go6976), 50 \mu M (HBDE) or 1.4 \mu M (LY294002). DMSO diluted in PBS was added to control cultures. Peptide PKC inhibitors (supplied by Dr D. Moehly-Rosen) were added to embryo cultures to final concentrations of 1 \mu M: PKC\alpha\textsubscript{2-4}, PKC\beta\textsubscript{IV-5-3}, PKC\beta\textsubscript{IV-5-3}, PKC\gamma\textsubscript{2-4}, PKC\delta\textsubscript{V-1-1}; PKC\epsilon\textsubscript{V-1-2} and PKC\zeta\textsuperscript{+} (pseudosubstrate region) (19,42–45). An Antennapedia peptide dimer served as an inactive control.

**Statistical analysis**

Comparison of multiple experimental groups was carried out by one way analysis of variance or by Kruskal–Wallis test (for data that were not normally distributed). Where significant variation was detected, multiple pairwise comparisons were performed by Tukey \textit{t}-test or by Dunn’s test. A value of \( P < 0.05 \) was considered significant where the power of the test exceeded 0.8. Statistical tests were computed using SigmaStat 2.03 software.

**Western blot of PKC isoforms**

Embryos were homogenized in ice cold buffer (60 mM Tris/ HCl, pH 7.5, 0.25 M sucrose, 10 mM EGTA, 5 mM EDTA, 500 \mu M leupeptin, 1 mM PMSF, 1 mM dithiothreitol, 100 \mu M sodium orthovanadate, 50 \mu M sodium fluoride) and prepared as sub-cellular fractions: centrifugation at 100 000 \times g for 30 min yielded a supernatant (C fraction). The pellet was resuspended in homogenization buffer containing 1% Triton X-100, and spun at 40 000 \times g for 15 min., yielding a second supernatant (P\textsubscript{s}-fraction) and a pellet (P\textsubscript{i}-fraction). Samples were western blotted with mouse monoclonal IgGs for specific PKC isoforms (Transduction Laboratories), diluted as: \( \alpha, 1:1000; \beta, 1:250; \gamma, 1:5000; \delta, 1:500; \epsilon, 1:1000; \eta/\zeta, 1:250; \mu, 1:250; \theta, 1:250; \psi, 1:1000, \) or rabbit polyclonal anti-PKC \eta (1:2000, Sigma). Constant protein loading was confirmed in parallel blots probed with rabbit anti-\beta-actin (1:5000; Sigma). Blots were exposed to horseradish peroxidase-linked rabbit secondary antibodies and visualized by ECL detection system (Amersham Bioscience). Positive controls were C\textsubscript{\textsuperscript{\textfrac{1}{2}}} fraction from adult male CD\textsubscript{1} mouse brain or spleen.

**Immunohistochemistry**

E9.5–10.5 embryos were fixed in 4% paraformaldehyde (PFA), embedded in paraffin wax and sectioned at 6 \mu m. Sections were re-fixed in 4% PFA then exposed to rabbit IgG primary antibodies to PKCa, \beta, \betaI, \gamma or \epsilon (1:200; Santa Cruz Biototechnology), anti-PCNA (1:100; Santa Cruz Biototechnology) or anti-phospho-histone H3 (1:100; Upstate Biototechnology). After washing in PBS, 0.1% BSA, 0.05% Triton X-100, sections were exposed to FITC-linked secondary antibodies (1:40; Jackson Immuno Research). Controls included non-specific rabbit IgG [R&D Systems, 1:100 dilution in 10% foetal calf serum (FCS) in PBS] in place of primary antibody or pre-absorption of primary antibody with blocking peptides. Both yielded no signal. Labelling indices (number of labelled cells total cell number \times 100) were obtained from alternate transverse sections through the rostral end of the PNP (i.e. the region of maximal neural fold elevation) stained for PCNA or histone H3. Experiments were carried out in triplicate by an observer blinded to treatment type.

**Primary embryonic cell cultures**

The trunk distal to the forelimb bud was removed from 15 \textit{curly tail} embryos (average stage: 27 somites), disrupted mechanically and dissociated by 20 min incubation at room temperature in F10 medium containing 0.12% w/v sodium bicarbonate, 10 mM HEPES, pH 7.4, 1 mg/ml trypsin, 1.5 mg/ml collagenase. After trituration, the suspension was passed through a Nitex filter and centrifuged for 5 min at 1000g. Pelleted cells were resuspended in 5 ml growth medium (Dulbecco’s Modified Eagle’s Medium, 100 units/ml penicillin, 100 \mu g/ml streptomycin) containing 10% FCS, then seeded onto tissue culture dishes and cultured at 37°C in 5% CO\textsubscript{2}. For experiments, 10\textsuperscript{4} cells (passage 5) were seeded onto glass cover slips coated with poly-l-lysine and fibronectin, cultured for 5 h in growth medium containing 10% FCS, and transferred to growth medium containing 1% FCS for 18 h (‘serum starvation’). Cells received either: (i) 100 mM TPA, 10 min prior to fixation in 4% PFA; (ii) 100 mM isoform-specific peptide PKC inhibitor, 20 min prior to fixation, then 100mM TPA, 10 min prior to fixation; (iii) 50 \mu g/ml myo-inositol, 6 h prior to fixation; or (iv) no treatment. For analysis of the effect of inositol, parallel experiments were carried using 3T3 cells. Cells were processed for immunohistochemistry as above and analysed in triplicate by an observer blinded to treatment type.

**ACKNOWLEDGEMENTS**

We thank Dr Peter Parker and Dr Radu Aricescu for advice and assistance during the study, and Dr Daria Moehly-Rosen for generously providing the PKC peptide inhibitors. This work was supported by the Wellcome Trust, Wellbeing and Birth Defects Foundation.

**REFERENCES**


